var title_f21_44_22208="LA ablation map";
var content_f21_44_22208=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Image fusion with an advanced mapping system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 417px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown is a three dimensional reconstruction of the left atrium and pulmonary veins obtained from a multislice computed tomography scan. The image is merged with an electroanatomic map that was acquired during a left atrial catheter ablation procedure for atrial fibrillation. Each red dot depicts a site where radiofrequency ablation was performed to create a wide area circumferential confluent lesion around the left and right pulmonary vein pairs. The view is left anterior oblique with the mitral annulus and left atrial appendage facing forward.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bradley Knight MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_44_22208=[""].join("\n");
var outline_f21_44_22208=null;
var title_f21_44_22209="Thyroid ultrasound papillary thyroid carcinoma";
var content_f21_44_22209=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F61668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F61668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thyroid ultrasound of a nonpalpable recurrent papillary thyroid carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 263px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sonogram of the right thyroid lobe in the longitudinal plane from a patient who had had a left lobectomy for papillary thyroid carcinoma. Although the physical examination was normal, the sonogram shows a 8.6 mm hypoechogenic nodule (arrow) that represented tumor.",
"    <div class=\"footnotes\">",
"     L: thyroid lobe.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Manfred Blum, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_44_22209=[""].join("\n");
var outline_f21_44_22209=null;
var title_f21_44_22210="Patient information: Starting treatment for HIV (The Basics)";
var content_f21_44_22210=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?21/25/21907\">",
"         Patient information: HIV/AIDS (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/35/31282\">",
"         Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/13/10451\">",
"         Patient information: Tests to monitor HIV (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/41/36498\">",
"         Patient information: Vaccines for people with HIV (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/29/7635\">",
"         Patient information: HIV and pregnancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/31/15861\">",
"         Patient information: Initial treatment of HIV (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/56/2946\">",
"         Patient information: Tips for taking HIV medications (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Starting treatment for HIV (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/starting-treatment-for-hiv-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H4957509\">",
"      <span class=\"h1\">",
"       What is HIV?",
"      </span>",
"      &nbsp;&mdash;&nbsp;HIV is the name of a virus that affects the body&rsquo;s infection-fighting system. Another name for the infection-fighting system is the immune system. People with HIV can get sick more easily than people without HIV. That&rsquo;s because their immune system doesn&rsquo;t work as well to fight off infections or cancer.",
"     </p>",
"     <p>",
"      One type of cell in the immune system that helps keep you from getting sick is the &ldquo;T cell.&rdquo; HIV lowers the number of T cells in your body. When you have lower numbers of T cells, you have a higher chance of getting a serious infection.",
"     </p>",
"     <p>",
"      The last stage of HIV infection, when the immune system is at its weakest, is called AIDS.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4957516\">",
"      <span class=\"h1\">",
"       How is HIV treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors treat HIV with medicines called &ldquo;antiretroviral&rdquo; medicines. There are different types of antiretroviral medicines that work in different ways. Most people take a combination of 3 different medicines each day. Sometimes, the different medicines are combined into 1 or 2 pills. That way, people don&rsquo;t need to take as many pills each day.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4957523\">",
"      <span class=\"h1\">",
"       Do I need to take medicines if I have HIV but feel fine?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You might. That&rsquo;s because HIV can attack your immune system without you knowing it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4957530\">",
"      <span class=\"h1\">",
"       How can HIV medicines help me?",
"      </span>",
"      &nbsp;&mdash;&nbsp;HIV medicines help keep the HIV virus in your body under control. When you take your medicines every day, your T cell count will go up, and the amount of virus in your body (called the &ldquo;viral load&rdquo;) will go down. That way, your immune system can work better, and you can stay healthy for many years.",
"     </p>",
"     <p>",
"      HIV attacks other parts of the body, too, such as the kidneys. HIV medicines can help the kidneys become healthy again.",
"     </p>",
"     <p>",
"      HIV medicines can also help when women are pregnant. Pregnant women with HIV can spread the virus to their baby. The medicines lower a woman&rsquo;s chance of spreading HIV to her baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4957537\">",
"      <span class=\"h1\">",
"       When should I start treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You and your doctor will decide when you should start treatment.",
"     </p>",
"     <p>",
"      Before you start treatment, your doctor will order blood tests to check your T cell count and viral load. Your doctor might recommend that you start treatment to increase your T cells and lower your viral load. It is especially important to start treatment if your T cell count is low, but your doctor might suggest treatment even if your T cell count is high.",
"     </p>",
"     <p>",
"      When you start treatment, your doctor will work with you to find the combination of medicines that is right for you. This will depend on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your blood test results",
"       </li>",
"       <li>",
"        Your medical conditions",
"       </li>",
"       <li>",
"        The other medicines you take, including over-the-counter medicines",
"       </li>",
"       <li>",
"        How many pills you want to take each day",
"       </li>",
"       <li>",
"        Whether you are thinking about getting pregnant",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4957544\">",
"      <span class=\"h1\">",
"       What else should I know before I start treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should know that:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Treatment is life-long. Once you start treatment, you need to take your medicines every day for the rest of your life. That&rsquo;s because your HIV can get worse if you skip doses or stop taking your medicines.",
"       </li>",
"       <li>",
"        The medicines can have short-term and long-term side effects. Let your doctor know if you have any problems or side effects from your medicines.",
"       </li>",
"       <li>",
"        You need to keep track of when and how to take your medicines. It&rsquo;s important to follow all of your doctor&rsquo;s instructions about treatment. If you take a lot of medicines, you can use a pill box to help you organize your medicines.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4957551\">",
"      <span class=\"h1\">",
"       What is a clinical trial?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A clinical trial is a scientific study that tests new medicines or new combinations of medicines to see how well they work. There are clinical trials for HIV all over the world. To find out more about being in a clinical trial, talk with your doctor.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4957558\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=see_link\">",
"       Patient information: HIV/AIDS (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/13/10451?source=see_link\">",
"       Patient information: Tests to monitor HIV (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/41/36498?source=see_link\">",
"       Patient information: Vaccines for people with HIV (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/35/31282?source=see_link\">",
"       Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/31/15861?source=see_link\">",
"       Patient information: Initial treatment of HIV (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/56/2946?source=see_link\">",
"       Patient information: Tips for taking HIV medications (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/29/7635?source=see_link\">",
"       Patient information: HIV and pregnancy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?21/44/22210?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16165 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-66B715A8D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_44_22210=[""].join("\n");
var outline_f21_44_22210=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4957509\">",
"      What is HIV?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4957516\">",
"      How is HIV treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4957523\">",
"      Do I need to take medicines if I have HIV but feel fine?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4957530\">",
"      How can HIV medicines help me?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4957537\">",
"      When should I start treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4957544\">",
"      What else should I know before I start treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4957551\">",
"      What is a clinical trial?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4957558\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/29/7635?source=related_link\">",
"      Patient information: HIV and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=related_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/31/15861?source=related_link\">",
"      Patient information: Initial treatment of HIV (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/35/31282?source=related_link\">",
"      Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/13/10451?source=related_link\">",
"      Patient information: Tests to monitor HIV (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/56/2946?source=related_link\">",
"      Patient information: Tips for taking HIV medications (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/41/36498?source=related_link\">",
"      Patient information: Vaccines for people with HIV (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_44_22211="Sodium citrate and potassium citrate: Drug information";
var content_f21_44_22211=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium citrate and potassium citrate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/24/7556?source=see_link\">",
"    see \"Sodium citrate and potassium citrate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/53/4948?source=see_link\">",
"    see \"Sodium citrate and potassium citrate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cytra-3;",
"     </li>",
"     <li>",
"      Tricitrates",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F221776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkalinizing Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F221770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alkalinizing agent/bicarbonate precursor/potassium supplement: Oral: 15-30 mL diluted in water after meals and at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F221773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/53/4948?source=see_link\">",
"      see \"Sodium citrate and potassium citrate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alkalinizing agent/bicarbonate precursor/potassium supplement: Oral: Children: 5-15 mL diluted in water after meals and at bedtime",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F221771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cytra-3: Citric acid 334 mg, sodium citrate 500 mg, and potassium citrate 550 mg per 5 mL (480 mL [DSC]) [equivalent to potassium 1 mEq, sodium 1 mEq, and bicarbonate 2 mEq per 1 mL; alcohol free, sugar free; contains sodium benzoate and propylene glycol; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tricitrates: Citric acid 334 mg, sodium citrate 500 mg, and potassium citrate 550 mg per 5 mL (480 mL) [equivalent to potassium 1 mEq, sodium 1 mEq, and bicarbonate 2 mEq per 1 mL; alcohol free; contains sodium benzoate; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tricitrates: Citric acid 334 mg, sodium citrate 500 mg, and potassium citrate 550 mg per 5 mL (15 mL [DSC]; 30 mL [DSC]; 480 mL [DSC]) [equivalent to potassium 1 mEq, sodium 1 mEq, and bicarbonate 2 mEq per 1 mL; alcohol free, sugar free; contains sodiuim benzoate and propylene glycol; raspberry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9460504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer after meals. Dilute with water prior to administration. Chilling solution prior to dosing helps to enhance palatability. May follow dose with additional water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F221762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Conditions where long-term maintenance of an alkaline urine is desirable as in control and dissolution of uric acid and cystine calculi of the urinary tract",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Polycitra may be confused with Bicitra",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F221774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac abnormalities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Metabolic alkalosis, calcium levels, hyperkalemia, hypernatremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tetany",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11507109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe renal impairment with oliguria or azotemia; untreated Addison&rsquo;s disease; severe myocardial damage.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6061584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with heart failure or hypertension; contains sodium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Edema: Use with caution in patients with peripheral or pulmonary edema; contains sodium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Citrate is converted to bicarbonate in the liver; this conversion may be blocked in patients in hepatic failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; contains sodium. Contraindicated in patients with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Severely ill: Use with caution in patients who are severely ill; conversion to bicarbonate may be impaired.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Shock: Use with caution in patients who are in shock; conversion to bicarbonate may be impaired.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Digitalis: Use with caution in digitalized patients; may be more susceptible to potentially life-threatening cardiac effects with rapid changes in serum potassium concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Potassium-altering therapies: Use with caution in patients receiving concomitant medications or therapies that increase potassium (eg, ACEI, potassium-sparing diuretics, potassium containing salt substitutes).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F221757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium Salts may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Citric Acid Derivatives may increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F221758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not established (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11507149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution with toxemia of pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F221765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken after meals to avoid GI upset or laxative effect.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F221764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Cytra-3 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     550-500-334 mg/5 mL (473 mL): $16.95",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F11507152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium, sodium, and bicarbonate; urinary pH",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F13246568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Reference ranges may vary depending on the laboratory",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Urinary pH: 4.6-8.0",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9911 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-FDE34C00CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_44_22211=[""].join("\n");
var outline_f21_44_22211=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221767\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221776\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221770\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221773\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221771\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221761\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221751\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9460504\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221762\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914135\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221774\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11507109\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6061584\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299053\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221757\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221758\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11507149\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221765\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221764\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11507152\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13246568\">",
"      Reference Range",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9911\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9911|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/24/7556?source=related_link\">",
"      Sodium citrate and potassium citrate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/53/4948?source=related_link\">",
"      Sodium citrate and potassium citrate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_44_22212="Promethazine and phenylephrine: Drug information";
var content_f21_44_22212=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Promethazine and phenylephrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/21/14677?source=see_link\">",
"    see \"Promethazine and phenylephrine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/44/19139?source=see_link\">",
"    see \"Promethazine and phenylephrine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13715219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Promethazine VC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F214209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha-Adrenergic Agonist;",
"     </li>",
"     <li>",
"      Decongestant;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"     <li>",
"      Phenothiazine Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F214200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Upper respiratory symptoms: Oral: 5 mL every 4-6 hours, not to exceed 30 mL in 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F214206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/44/19139?source=see_link\">",
"      see \"Promethazine and phenylephrine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Upper respiratory symptoms: Oral: Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2 years: Use of promethazine is contraindicated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2-6 years: 1.25-2.5 mL every 4-6 hours, not to exceed 7.5 mL in 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     6-12 years: 2.5-5 mL every 4-6 hours, not to exceed 30 mL in 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F214201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to dosing in individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F214192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Syrup, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Promethazine VC: Promethazine hydrochloride 6.25 mg and phenylephrine hydrochloride 5 mg per 5 mL (118 mL, 473 mL) [contains ethanol 7%, menthol, propylene glycol, sodium benzoate; apricot-peach flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F214182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F214194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of upper respiratory symptoms associated with allergy or the common cold",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13899035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2934878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to promethazine, phenylephrine, or any component of the formulation (cross-reactivity between phenothiazines may occur;) treatment of lower respiratory tract symptoms, including asthma; hypertension; ventricular tachycardia; peripheral vascular insufficiency; use with or within 14 days of MAO inhibitor therapy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2934879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: May alter cardiac conduction (life-threatening arrhythmias have occurred with therapeutic doses of phenothiazines).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: Phenothiazines may cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); therefore, they should be used with caution in patients with decreased gastrointestinal motility, urinary retention, BPH, xerostomia, or visual problems.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms: May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): Use may be associated with NMS; monitor for mental status changes, fever, muscle rigidity and/or autonomic instability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May be sedating, use with caution in disorders where CNS depression is a feature; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Use with caution in patients with bone marrow suppression; leukopenia and agranulocytosis have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use phenylephrine with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma and/or increased intraocular pressure; condition may be exacerbated by cholinergic blockade. Screening is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use phenylephrine with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use with caution in patients with parkinson's disease; may have increased risk of tardive dyskinesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia: Use phenylephrine with caution in patients with prostatic hyperplasia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with severe respiratory disease (asthma, COPD, sleep apnea); may lead to potentially fatal respiratory depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiemetic effects: May mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reye's syndrome, brain tumor) due to antiemetic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use phenylephrine with caution in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics:",
"     <b>",
"      [U.S. Boxed Warning]: Safety and efficacy of this combination have not been established in children &lt;2 years of age (use of promethazine is contraindicated). In children &ge;2 years, use the lowest possible dose; other drugs with respiratory depressant effects should be avoided.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F214207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F214187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha1-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha1-Agonists may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Phenylephrine (Systemic). Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of phenylephrine.  Use of hyaluronidase for other purposes in patients receiving phenylephrine may be considered as clinically indicated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2934922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression). Avoid ephedra, yohimbe (may cause CNS stimulation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F214188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F214197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted with this combination. Refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F214203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F214198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increase dietary intake of riboflavin.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Promethazine-Phenylephrine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.25-5 mg/5 mL (118 mL): $14.64",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F214196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10072 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-4554544F47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_44_22212=[""].join("\n");
var outline_f21_44_22212=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709343\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13715219\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214209\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214200\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214206\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214201\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214192\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214182\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214194\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13899035\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934878\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934879\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214207\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214187\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934922\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214188\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214197\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214203\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214198\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323731\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214196\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10072\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10072|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/21/14677?source=related_link\">",
"      Promethazine and phenylephrine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/44/19139?source=related_link\">",
"      Promethazine and phenylephrine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_44_22213="Coronary artery anatomy";
var content_f21_44_22213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Coronary artery anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 466px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_44_22213=[""].join("\n");
var outline_f21_44_22213=null;
var title_f21_44_22214="Inverse pityriasis rosea";
var content_f21_44_22214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atypical (inverse) pityriasis rosea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 326px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFGAY8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDWjfVLR9/loY0bdnIAJP1qvdzyLclLi3RZJRkqwG0cZBB7H+daBiUykA3EUZIUIRuDepGauQWtvKkqxEm0cAMrr6Z5I7EeoriSbPq+e3vMyYJJZbaNpRaJcoo2nnEhOflz/nmrWnBoIIWEYhJUnyS5zLznAbkGopLaNbtWtPmCjJXy920fXv35qnbXOwxSQTMYVLnaV4X1UZ/Op5rbltcy0OjtVa4dVUmUqpYBs7Ys9cE9evasjWtNb7TGyAIyjeAFABz39607CSQxlJEaaRgSuxsgE9OKjWFYxDEZxLIv3wpGDweWJ5H0onG6MVdSOU1C2zK8iONg4O3jdWJfRJIu4KQw5DKOtdhqCRIxYyDzO6pyuevJx9KxZ4gszRzfu8A545XuOD15Nc7jYtx5keV+MdCSWL7XAo80feVeCw9a4eFpYm3QvtIGTg4r3nU7COaNkUhhk4OenH6fSvMPFPhwwPJdWqEhSTJGOOPUV00KtvclsePi8LKP7yBm2Xia8t12sd4rYg8ZgcSK2O3HSuYZbR/9Wrsz/dAYAA++enepl0eSS0S5VJUt2lMKyOvyyN6KRwTzyBnH41u4R9Dkhi6kep21p40tx0kK5GMHvWpD4wi+X99wOcBugrzr+xSEgR/MiuiCJEcqNpz8vfOCKtXvg7VLSNHkWL5m2/fAH4E4B/ClyrpI6oZlVXQ9In8aRt5YFwAD1BPBqlqXjO2gWN1mTzBxgdMH2HavO7Lw3qd0JWt0UwIu55Q/yAf1+la0PhLUf7IhN07RW9w/mRhbUuSwyPvcY9xnFJpdZGv9p1mrRRFrPiC/1icC3bEbZQEsF3Y5zjqBU1v4fjgEVxc3tneXE/ym3STc0TY+82DjHOBz9RTbfwZqE5lNtBdBNxXOBllA+YdsnPYe1aWiaD/Y5jlvdNkuXlHyK8eTuHVCvUfhzzRzRS0OGp7WtK82Q2Wmfa7vyJ4LlLVZNu+deI8dmCcdeAccelWBJewfaJIIi1jN5YMJhUIzKTsJPXPJ5HPODXSfZbySJ/sU17BpjxCOaNrdTNC2eYyewwMeZ17YrrtJ+H62VtBfabLHKkKAFbeQHcz9MFs/MF5x2I5xWVm9jRQS3OW0a61e2smv9OlWC4jZbcwOZDIxI6jjaMepP0p+n6DfalrG24t7m4vVGZJHfhG9XHUYH1/GvTtO8PpHZJNPPPLcOw+03Esn7th08vBxvHA5PvVefV1TXbX/AIQ7Tg91KhjnZBmBmC/IcnuCT17Gm6e12bKBJ4KtDpc041KMYdxsiELlC3cHdhsHrhevpiuiup9OuhDCJ45grGQLbR7DuH+2TkYPp0q1a2d3Bbg6zLsiYFmitASJOBku332PbsMD0rSjksLpyltHEkUCBt3ljbu/uj6flmtVHoP2b3OXuPD940t693cS+VMFYxxgHchIyG4yAAD065q4bGa3mF1NK9lb3H7uOK2wHaPOEzjpn355q7reumKVLPTCZrlxkhx1Qnkn19vXtXPrZ6oNUX7VeJEwxJGACXjblcMx6DbnA9jRbXQqz5dS/A1yLEyrbxxxBEkCyckfNg5J+YkcgDgfgK4nULG71XxJKN4a2t3Lt9oZlefPIQZ7+9dZpmgXOmYFxcObeZz5Mnllsg9NgJ6ZLdcDv0raj0LT9PW9ka3H2oIZfMlcMwAXueg5FDTaIpz5WzG0HTSRHqVxcKjSqFVIosqqL02q3Uf7RH0rqLayjG2edmWfGVKxnITHJ5zj0+lZumWP/HtO0ZjiihVMcAFupPHUc4FXry/May+d5cQMf7oEkkj2B7mmaSv0G63qEEGlpHtURswMSodzy+g6YXPvXMTozxma4kCs4REdMyGBlY45A65/iAx+FaUoup51u1kDRxqTCMhcOGwSfXHbHYfng6vKtjO4CTGSdPni2llbcSTxnk47+ufpTHCNnpuN0rUmtrS4a6inmEmIkkDjarkfdDdSpHYdDmp217+x9SsINShjs4MCSJI23LkqSDyee44454zWZPP9lEaGQNDNGIfLV+TnhCR2wxAzwBzUmn6W+qa1Peap+8s7OCK0XA83hk3M3zc5yR8x6Cpd9kXVcUei6Mw8mOSZUmlu5QZFiYjYcfLz14xVnUEMcl5O5Z4QiKEZQAVUnbknkAk1ji2tLOL7BJbRrMc+TtjO11x94sM/dBGe/SsDUodZWKdG2y2QkVSskrLLKoXA3Hptzn0zVmMFzO9zR1i4g1WI21qod4gcSxNud1yMMW52pnsOeOwrPSCOJbm3C7Jyy/axCOuT99eeMdOvQ9zSQzzQpdWzwQRSqAZSU+5GAuBngEjJOOpxUeqNbS2olna5muhHvZXKoCoPTAx1z064+ho06msY62Lt9DarZ3CxSFgczRyucsVboq+oHTJrMa6aa0+ziLZGJFRrYEgyYAwUGOM5x+tNuLGZorGRbiCwfZ86Ft+xsnCtzjGACMY681Z05JZNQhMbWkk1wTEbg5OQp46njpjg46UW1L5Uo3NfQ9JlvMyySPa23RYw37we+48dR05+tbK28VpfJ5YZ2cGNZJJCWB7KVzxkZ+b1qW1im2mFTCUQjkuSy+oHb1q/eJbJZ/vWjTsoZiM+mOM5zVpI5ZzuzNvJYomaM2swlchVG7IGe+ew4pUNxdfKERI2OF2x4Ge7AnoPw5qa4tBNIsyyJbykDktlcdvoasxn7HaljLhs7WO/Jye/rT3CNkQ29ha2kk0oeZ3ZE/eMc5wTxk9evSpp9Xd5fsELx7xnzJM8xrjr6E9gKakc1ysj3SqkSg+XGQQSuB0HrUtha7YFjEKjzD5rjOCfb37c0BKz+Is2xhjMY3FGRdiBFOFHoPf3ouHlYom1FZmyELYx9fX6CobqZiJIbdJMKPncEgJ6DPrWZMLm5IubcSIEGdzElgeQwC9/bNCFy9S88jPiQoMr867TyTnqc+o7VYa5jJEZdCyjJB5OOx4rMmim8hoTe3AdkAdxgBQeg4GMn9KsafZpZwhUddjcljyc+/8AjVbEs8VlmurW8by0S4gUgLglcHqcDvWnBqksNkpmjjSQHMc0Lhg/qCO/0qMxSLmRwpDP5gdItw9/pWLqs8UUixFFt2L/ADyQ5UsM9x0NedzOJ7V07JmnawzpHJOj4nl+YpG+Ao5J4PYVT1KJ3liNwoa3lTYWj5BOOcnsen1rRtREEhIx5LY2yDgr3+Yd19/zq21jHOZDahIhIM7QTjaOCShzwfb8Klq+hSqWdyLTb5YrWNE+RUCqCCQMD0461qi3iLu0aGMlctlMZUd/fr3rlIIPsc0ayyl41BYAseAejZ7jPT0roNLuQ08BMSTSxEFfly8eRgk+xxz9KalciemqLkkLPbsDFZhSdrEE4Ue+eCa5e9ke6u5rS4BXdKFOF4QDnBPbr2rr/s1vc28BZHhie4Mixs20MP4yeox36dKz7rT0jM7B9yCQOZCpDsckAAdCoFVKDsKE1cwPs68QJGHyeJABycYPI61z2t6UVDH7pGcHtzXf3EECXYijdAByCOdwxnGPr6cis3XbViVJjO443c8c+v8AOspQsWmpaHgniPw8qXHnQqsQJ/eqckA/3hjt7Vv3HhhtK02we48RWF7FFu8i3trwymPccttQj5STg9Oe9dVf2BlL+YoPsOD0rln0t9MvvMS5S1t5VZvMIVcnrtLYJye1aRqNx5WeNjML7OXPHY6OI6bjSVt7C8kY2ys6FURi5HzSBuSVOOrD1xWlb6LfapZOmppAlvKC9tbzKz+a23aJMkcADOT09c8Vl+C3t0ZYZZrFRL8yTPdlD0IByG6YJHOOSecHFatxd2lq6GW5mlgjHziG5bMakgYCjIKnj1GMVS11Zz00kdPb22k6JpcEV1bW80lunmBpQH6nbsOwDGAc5/2al0pJrqeS2nt727820Xy5pkaKGILuDc8nJGDwOSK4S2a712+SYiVLCGMrJ57J5jLu4YjOSecDjn0NbmuTmK4gtZb+51GFGIe3BeNGQfdB6MeTkg4z3xV81zTl6oilnjTXhZ3k9qn2TyhauXZSQD85woba3JPP1+mzYalpH2Z5ruWO51CaQ4lupSVwDkfNt6cL8p5I7V5n4z1KPTb9fKtxiIhRbLN+5Rj94uR1z6A/ia5W81mbUrmN7pJLl1bCRwxKIlwDkAdT9TQrmcqltEd9q3i67F9bvGLOK7h5hhEYk3I645J4JweuM9uMVa0i/wDEUzTTxfZ990FQhY4vmUDbwirxheM9a5DTNMu9ZtDMPJjCqI1iAUFmxwuOAOO5rNntb2xjWaxumhmjyY5IZNrqfTcvOfXtUXd9RKV99T3XRvD2oSyz3GvRWkNushjSz89lGQANowWJ+nB56iuh0vwnLbzi+0+Y2/m7StpDGxWLg5IJyPxINVPhxO0ujWl1dXk9zLAoeSSd8MXZR8vJzkc4I65xXbpdRNKI4J5rldxVVi3MM98nt+NbRijeNRsygmo2lgZ7FhatHGBI7wF2YLnPHXceOnJps/8AaFtHDF9itmvGfy7bz42eV2I5IXdhRxkkk8DmtZvtESyJHC4Yj5ZLrL4LHHAA6DniskMk+s6jc+XLNcQoIIxhgERiQxwDnJI7AcCmac72EtdGuLG4uJpdZubi9kPLSbTuY8EKBz6DOeO3SnNJZSoLGFYmndt91tUNg9vm7kEcY9KiuDdjfFC0MMco8p73aC0YwTiNM43EdznrzUdsby1WMW7yh5A6jKBEALDnnBOP0pIVm9Taea5RHZ0SVwnzrKCiRgDgZGcjPbGa5XVL7WZXaGK3t9l1hHEhbDr94qhI9BjketdBaTTQNCGjtrkq2/5HMYXj/azk9eTVN2u4ZZLu/ENqGwQxczBFGeTnABOabuxLRj/tpEKq0zx3HCLvtzETnoF3dQPUY61gXl1Z22q+Soklu5YWdiCJCcHjceRjr9Per2oa3p6gyTxSXCKwBZE3q3HRd3TtwcfjWRALSTz5WS38x3P7wx7cnoVU8AD3P4Ci50U7ItSXEsnkQXM88iMPlVHESeUeSCeuT0zx0qR7i3e6cKWlS4JVRDLmUFeAC38IA9OSBTYoLSB2a3RPOBAdyu8ovQZ4HHPGOvUVakihsLUTX8ltayKRPjzMyKgydqryfXPqadyaklbQyLyJINJuBdwravIjfuzh1wepyvLN6E1N4Bv47k6mFt8XMs6xhWcrGqiNeSeeuM9Mkn6VWudRi1dWD6e0GNoxNuGc/wAR9eMnPpitHwslhFpzrCIkujK6swX5toPUcZ6YIJOeeKFdsznF2u9zetbK9WwxNf3CtJJsfeA0ZxwFUH5hxySevWn3lxb26tfQtLO1q4jeS5B2lMDAHqQSD0PeszxFHqC+TLHNMx38LIAAEHXcepz1zwe3PWsPUtYgJned538mdZhAMlpiVIAwT8w4H+eKplxpykk0ad8Fj0+SdtrZlVp2GW+YnkAHp2GD2q3rOqS3Fnc2lpDbSTKpSSZz8nmcDrjjuO/PtXLNqUstvcD7NM9vbsoknbbG7KWAUMfbdgcfnW5bXL3CxQIkIkRQnnSgEZyWwoHA9M0r9jZRa3I9KuoYb0QXB3XPBPnKAnU8KRxnnoOPeurtre3urryQkW1YCqlnG77wyVAHB9x3rn2sml1cuSVGzPlIB93OB0JI711NtbSWltF9mj2NH8qu6fNgnofXFNE1mklylhQYDcrJG0iKFx5T/M35+9aVnDyQ6pkfNs7jPbn+dQIZxLh5Iw7KRh144PX3p2ySYfu542kBAZkUnHHXNWjkepaLBFZIk+Y87euT/WqtxZrtDzxqzuQowMY/EY61Ih+zkGY53HmQ8EkevpUrs1xF+7KIuQwdhn5gc9KLFLQSMSZZRH/qxt49celMe4bdCqb1MyncxAwnT8jwRUomRpNsUT+YwJDNnH596qS21xJOd24ocbSRgKw5GB379elAb7kiyGF5C21LdGwFHVjt5+nOOanmjWFZlQ7MrvGB0Ht/jQEb5xN3wQw5JHao51RhGA7KEBPHUk9h6jPaglla2AW1kZAWyQcdzngD3qxPLFDEyqA7AhQOlVHtrkyqYLjAVF+Vk++RzjnkfWrUIWaCCWLCjYDg5JGeuffIpi31PFbydo7YuhWaDjdtIOc9eP6Vx+t3KX1i72+15osmNkH8XbOa7C8sLe4lMLQBZD0MK7cfj269K5vWfCLbnuLSeeF2OCVbcMe4I5rzWexNaaDtB1sX+lQOpUSKxIcDBU9GHHrW/Z6nKD5JYs2epGWUjt+I6gV5ZYrf+HddKXjBra6fKSKNoD4xgj3/AJ13emXiRXQkGShXBUHkg9PyPeh7mdOd1ZrU6aSS2uIyyswUnesYUnafTjkjOaljHlSK0YlfcMqAMggZ5z6896zluAfJkiRgrYyRwRz1x2I/lWhZyLJGrEIhSXLfMdpUjknFEdymtC+lzD5cEhmZo0dVbJ4B/hAx0Gc5FW0ElvZSM4aO5wJUjAEmSuRwc+hHFYkZ3aefJcXBQ5VH4UFTk4/lmrMJa3uI2lV2+dgqFz8pIyc46nBHNbcxFrEusWFhd6qqsUS4iRXuRygx03Z/vZFR3SPchFQMHG9drEZJ/vfSughe6+zzw3bJfTMFIEDbWClfuv0/TrWbNZRi7C3DJFtxEkSOdxJHU+g696UoroVCfTscfqFjvUvFtyCQcdOP6ZrJuraK90t7eUAOOVzzgjr+FdtqVmFVxAqkK/y5GFGD0Ht1rEnsTE6yb8MwyAB2yQf61jazNJpVI6nOWXiV7eNNPtoYbafd5l681nHLEcd4wFygI688GsnUvENrLfqlqHMMbHzBbxrGD2ALdCcFup/irY8WWFxptvJe2ACrJGYpVlTeoRuN2PUZJB7UzTPD+7RGu49UgE1i2T9ntwoXL8fKfvgr82eOMc1ouZ6Hjunyyt0KUGo20BuLSJXFvGqsse5l3MedoZRjg5+YntS6W51Dak8FxJIj8YGYMbRn93GMs3uT25rtNLezvtQUTXP9o3MzG3WaQnh0IRWVTkLwSc4PYV1Vhoq6BAkVkbVbZAzzLFGvAyTuHUnOOR171cYX16Dtfc881TwjYX1hbXGn2l1f3EBMjRTW5hQAZyMAZI9M9PevDtW026sr+5gktntFjk5jlDAr15PGfzFfbNhDOyI0flm2lhwqFAmSehC9hjPXmuK8T+DF1LUruWZHacEEyyws4TPQKy53DqMHtWlrbESgnufOvhS9ntSyzSwyWrDa77RJ5P8AtAflzXQTWX2m2T7QGZpnEpn89CrA8E9tufbP0Fdh4h8A3ug69Bc6Naxv5yb4xBMSVPAwSOQO3zfnxWMnnw3CWWp6HHFdMQGGChlOSOR+XbqM1jJdyI09bo3/AIe65Lo5SBLSGK2mbbJPFF5jg5yvG7nuOBgg+tep23jHTr+aSSHUZFuBJsEdzA0cZUHaF+XHcH3ryzSNBtJtShfTLWaydDh4pcSsGP8AdXHTjqcDpXU6WyXOmsYbeS8VLho9vmMoXcd+Qg2/MPqcdq0jdKxoo9zrp9Z0+P7JIrSXUud/mq37sZBx1OQMjArn28Qm3M3mxxCVpQq2kMhkkbqSPkGM5OTz0qjcGW6N3p/m3VsVHmx+ZC8agdRIxfLnHPGeccdaS1luvOe4jtdQYJk+dHH5aGNQA+0kHBxzz06Zp3bNVGyuzZGq388dtN9ll0yBHBCTbjJJ2AVQD6ngcn1ApLdpzFLJelVVoyDumWNcAkFAPvH1+99K5u1vDc3TXBkjjhWRoh58m6SVSQR8x5P+6MfStloI45lMMNpJIyjf5iGQqCeeOdo6+v0FBdkakGqRlPIgRPMwQQMIYwBx8vYDjJ468ZqprspjW2nldissoyqPgnPRcnHHv261z15fxwzBpopTLDGRkRnamScMG3cYAHWm30sV4gaa6E8saYCnLZPdlAwTxxz9fencvkS1NCG8uPNluCYk8qM/Z4kywK85dD6Zz839K0Ir7y7OKSaWEtFEisEUliW42hvXjk+9YlgqQRh5A0obakwk4JiJBzGecOMGtTTdzzWkUbM6IjMg7nDEAvnn398ChEc0WT2Ekj3MyNMYVyXIcH5cjhc45Az0PHpiqslzNJYXTyRxF4lKPKrqd2f7xb24CDNVtR1SCJr4q2/I5IGFRmyMAdSx7E+tQ2No7R3ElsbjesbMYoTjC9cBMEk5OQ3XjFWkilFLUg823s7BLOR9lvDvMZwolBOQMt0CgZOAck8cU7wtdLYyXklrqs/mLI22RoyTMm3P3TlAc9zk0mgwC5e6eS6jjmmcCJ2jJV8pjYOccgk88+3FdYmnwnV2hPm6dJ5QU+VzHOikZOcfe525HPr607X1NGlJ6lO+1N5tNNrPJN9ocrskl8uMEjncuCCrY/qR6VzOLcalbWgnWIK8gmu3fCgYJBTI5znr0OelbXiE2139oaSR76+QEQpKxcovU7sYwcD143cnpilZaRa3E4ku4lMchKPEq4KnaOpAGcYU8d8EknNDTexrGKjErzazZRRy2FrLHgfMku/hyHyCx6nuO/bkVpeF7FZ5IhFJPJFKd5DgLGBk7hjOCd1X7Pw6pv1lREjP3VSQhgfViO3f863dA0KDSJBNMiPIxDAsgyBk5AHRSM9BSSd9TOdSME1Es2s1vZajkozyiModoGF5GADnGeea2TOykDBRz1TByfb/APX0p8i27yrtVCF5JwOSO3t60zfhtsah5m+ZV7kf0q0cUppu4xWmaf8AekMuzhkGQuTxkHrgDNWkhZNwilKxDkYCnJNUIXaMtLckuZCdgyTnnkgDp7fSp4U/eCZXkhjJ+SJhvBz3IPI/A0w63LsVqAEklJfHOG6E45OOlWV8uQM8ZQAcqQOuOpFZwcNbbbqU/OeQPQ9cevFWI5CDulBRVA2xDsB0pDd2X4EVAWY4ycj2FR3Dq0nlscZ+cnPYf5FCRtJtkmPG37oPfPrUFwjiUCPrggDrnvz+VMlLUmeVzCAArYILHpjNJBFmCNpQp3HcAe3+BonIEQj/AL3ysO5z1H1pSGNsikZITjaKBPYV2RMeXj1yx6/jVaSQWnmMgYl23FWQkDP0qSGOPeH8vkcfOfu+v0p8kZnbcDnH/LT09gOlAlZHktzDEm4TyTMWAIDfKRzg8ehqMNCm8LIGXGQuCM89ver86GSGa5g8p5ETIgAwXAHvznPHFV4JPNgVosuT8zFRgofQg+nrXE1Y9dSutTnPE2hW2pWkqOOXTkY5X0IPqMVwCvd6TfJZahhZ41zG46SIe4/qK9j8jfD8xdh3J4I47+tcb4z8Pf2hAEgYpNH+8hcn7rDt9PUVElfYTXVEFnco3PKIRkMxztPXH4Hp9a1bMbppGC9W2Min5DgcMB/WuL0fUhKfs9zG8NzF8ki45U+uO44/Kuu0tpY0kKorOSGIBxn/AOv/AI1FwUtDbRWgmCBg0cnzMik8NjHH6Vs2Fv5uyPCuM5diMiPjt79eawCXeWNncgKo6jGwnj8Sa0bC7GnxzIu7YuNqKuMkdyfQVaZMou2m5auo1tb77NBKwUEDaDkuvvjmtVkV4n8s4VgMndkH6t349KxJpvLnWWCQPO3zbjnP4+g+lTwSqUVTIiNndk5GPYdqtdiXfQdewmaUgneqsDjdgEjsKyb2LZcxRlwwU885PPIrU32/m28USqWIJLvkLt7sSeg7Vg64WSR5IkjmQLkNEwK8dge596Ul1Nqbb0LN7DFJbmCX58DaSen0rx7U9Mvra4u9OtljMKtvZWRkOxj3lHG0f3TXrADSW4lTBBz8jDn6e9ec+MdOuJr43UMkgPlBDGrEBwDnn+QpaJ3ZhiMO3BuO6LFiL61gia4tDGhUrC32oMyn+8ijGcEdDwa9U8D3F3Jpj3DRadAZHJCklR5x5/eZ4DHg4Ud+K4DwwbvUbCZI9J0uaO5PK3dyBLD/ALbY2g5OcAV0+kWN1pin7NqKJNtERe5iG5CrYIZcMPYEc/rW0YtHmxqXVrHdQarOttm9u4rQyAqyW0yyOcnDZDAbBnvyajXWbA6VJHdmW6ILIV+baU7HI746gc5NYWo21zIpa40yLWk3AeZDMUJIPICqu0+uSRitB2a9W3jito9LhK7XkWZppVx/BzwCM5zirTNGSXVzY3lkZo5NPsZcmKIxFvmdTlRkg5PJBHvVLUbRJLW4g1+W9lChblIPLZ0VTxhCgBAHP3+/Ss+az1SwmnuYLy2uQ7fvlltgzlf7xCkr05wPSrcEMVrK19CfKtZEVpEggdk6/K6KW568jjjmle4KHUyvsbpZyxaJbSpagCRlRivm4/vuWBIA5CjA9cmrWl6rfpeFbhbKzt5EDCeQqHGOhBzjkfN+FdAimUNPcy31wqsQsKosYCtjoVJxz3NcvrtrAjSfatOlBGDG0QaQxkAkEZzuPB5I4FF2EVzaGYviZV1BJzZG7mlkDia7Y4fYCA2MkbsY6ggD0rd02G/1lDd3ji3sWYDybeZ5QWHU8HA57nJHUYotdSnVZ31JHsTIRKjPbNgcDG1scEj1pRNo8sCzxjVLxyDjykeJeMnJwFH55oT8zXluR2+n2lvZvOYBbFpWJLH5mYHByOuD/Wo10bzJJLq3WKKFeB5+S8n+4c5X68/SoJrO4NwBBKQsmWaEqsmDxyzDr+f4Vavby+jdLaKFQWYcoSeM8kueQOKNGbapWTKL28Vncsq2HmXTxKXjlYuuecNk8d+/5VVmmfSys26I3EoO9EBYYwfu8dugHSugtj58zN+4jjT5gAzneSO+fvHj8qo6hIFdm2HZB82IwESIY4yepyf559qm1jGU7uxhS3moRLvkaK2IzhThXPHTn7p+g6VmSzXNtqwdpHnEyAMsbsofBJIyMEj2/WtMPHZxy3Orf6Teb2JbBYD0LnoBjr3wKgvLdtS0o3EjxpI8btbvbnCygMo3kH33Af8AAelHQm9tDSt5WuYVulaS3ieTbGkbqyY5xwc5/wDr/StBIpozuW4upJnK4SEEbXHUMvyvj1b7uPeq2l6DAYFWFiJjGC8gAk2EkgKoIz2/DNdHp9jb2azhYHd4kDktP+8YrkeWHBJA7nHfFaxvY2g1y6mHe2K2DXBhlSBpnWQwEho1jXJyQeWTG45yGUDjJqafxDHclIfICq0pKvIS6xjnpnswx83rUuo6j5F3ia3V7oq4AEYjEG9Rhmz1fIOQ3XjAHfC/s+G8iadora3xtDNCrCPaerEHBypB/h755od+holbVmzEJNRaOKAQRiEImACoZSCRtHUjgjJ5yPStvRrSOXU2WBZoIooVRmlPRgckE+p4OO/PpXL6Jp86wj7FYXUkUkvmx3KkCQqP4dvUjjIYYIORgg8dFo8Uc94bhVZ7JMtC7sW8rHDNgnJbdnqATzRcJt20OktpYYb+SFlP2hlb92rcnGCcn+EcjrWrdoJInefD4TKoBkdOh/xqpBGAI5IItxYZYphmc5P3j1pgkOXjUSCCMbsREbCx5wMnqPWmjilK+pQ1O+uBcRQWkZe4eTYUKB0i45y3A3Y5xmtDTLe8KBrmTIZjIxiOQ3YBu/Tt0qSxtA4UqgWJA20A5C7uv1PvVqGQaey25BdC2xB3Zj0H+P0pisMO2OYmNYsynAy2Pr9BS20jJLtmmiluG5Cx8kDPHFW8MyM0hwGPJPoP5CqhtD5+6HAYjLluMKBxk/yFNF3VtRlks+oSu28pHA21ZMd+uR/LPsav48mNWkdtwOAScg+/19qhSIqkNvBGyKkWWOOCM9PxOaqrHeHVdwRzCAVG8jD/AP1h60DSTNmOduEfG4dl53e4FP8AL8sq0hy7NhifQ8cUsUSxr5khBcjaWAwMeg9qmmiEkR2n5jgdKLmTZWuYpFdGY5CnPHVsD/PIobzFeNWRljVM4A5H4d6dfnaIlc/McFcHG7BGfxq2/wAuRnHY+oouK+hSBikdVG1nbleM5HuKV3dzshfknoVGBilSMM3mS/6xhk5647Uq7UkyGDLjIJOMfU0xXPIrVLqDIksztJJicBWKMR69h9KS3+z3EcCjUobHUApLJkEH/e4ySD2q3aTz2QjDFnEisrJCAQP9oKe4HoeahsnnE8EkS/aJg5CJJGFccgkjHAGO+cdK5ElseqmV4L65l85JoRKsJO9oxtMuc4fbngY9KkkAktyzAdmIHPynsferjPNLJMtrmR1O2ORVUKAxyQT04PX9Kjn02SGG2it2V5fNbh/4h3J9PYUpRKTWx5v4z0GXf/aNgD9phUMoUY81O6H19RnpTfDepLdWiMh+71UnBHrkevau+ktZGt2juI0jkXO4divY+2fSvOfEWk3Oi3smp2iFoGObiJV5H+2B/MfjWMkDjbVHc2EhltkVmJZvmJ6kHtV5W8hDHIVyM7ecDPvXJeHtXWS0di+5XIKspx8p9DXRLdRzylSSsUY5XHJb+poROrZdkSOeyfy1fzwVaSQAHcOnHp9PzqtPdNDdJaWkQmvGXcoz8iL/AHnPYfzpLmZrWPbAjyXUoxHGT3Izk/zJplgYNPspGaZS+5ZriWU4JJ/pjoK1SNFtqXNN06MzNPfXE1/cP8jY/wBUoHQBemMnv9aZrtiW/diLybdtrLlstjPoOBj0qhplxcXFw7SNJYWbOXRgv7yTB4wOi1s6zcxJawsSysxzJk7gzcd/8etPRxB80JogIjkiu0VdiiQbTnphecfjmsnVNMYIgZQ4Awxzj8avafOcwxbiZZAzlenJPNak8KjgrhTjIJ6+9FroabjoeY7YtD1KU3MSNp86nzlaEORxwcH9a6ezVpbK3ltpJHghwkU0xQbFIOGx1Kjrj0FM1zT/ADE8x+Sv3SemPSsLT9NRL5LSSTyo5SPKLtujJ7oQTgEjgcc0oN3sclehFPnW3U7S30+cWou5b1pbZJNpuI7jCISeVQA/XkcYrorfTNHDRxT2bEffE2+TZuHQ5Jzn8Kg0qURXjoiS3E8wDSNLKAWbHzHG0gZ9FAHHrWjMl/FGsc8EJiOWVpwGO0c8gYI4zyAcda3UbHNa7Kf9mafZSx+RMyKrHc4nkeRMrwcMeePT8jUY0+6t7e4+z3UtyWZdqXMYKOScD0O3HUdenSnLqklxK1vqEk8EIQMEjEcjNg/LgSLyO/AJ47UTy6S8cCPev9syUEqsI5kLHBVSFyxOMcDgU7FbbmY1ldxb4pbmeORyU22G5Rk9vnzgA9CMZ71k3OnRPdzPczahf3EZUKjTsFU4x8zLjtn3Fb0U5tZjBp8ti0UeYpRJLswd3Clzgkj2HfkVcVtRktWe8vrKKzDD95AcBOoIyTj9B7A1NjRNLU5eOAzW8Bms47W4jUJKrOoUkdCWZifTnirFrDeMCba4ZLMZcosgKqO5JOcKeSMfnW3ew2RFrhEuHJC+ZMdzSR4JZctwM8deKqzNavtkGGgiJ2FuF46gA8cD04FCQ4z5tLFGKHzJSkV0ZvK+Zj5XlxjnkA8HJ9uvNamn2wtLIyygbpGLPKwyxI4APUnA6Afj61VjnkvJGiiTaoYFmj43E44GfY9T04p08EbmGWYSNHAxWLc5AOGO5R7ZwSTye54oHPXQlnuB5QctiR1ykZP3VJ5/E1h3qbmjklb/AEP7SAvQBz1Y+4yMY6nr0q7qFysZ+zlgoZGdnPGwAE8n0PT6VieI76IrZ21xH5aRjMqMCvlfLhV4+6TgZ78gdaHqZcrRl6qX1Gd7d5ZUtHZcIW/1zDIB46gbiOPU1TsrdLDV7WC3UzxLIrCVx8ic4LkdRzgHtnnBqY6hcQT7oYjJcKvlyyEbNnYr6Ajngcc80yaUyXW+eMFXXzGUDO1QMJ06ccdjU26ltdjtvDSGfTy806rPPIyvGEMrKF6gkdcjGD71tzXdoptIfIYx3DsgCbY5UbbuXAOMEEcZ56V53pdxfaTC1/bKZbL7k8c8uZS+MHKqQ20MByParVtr14UWJLyBCgEhSMKdw3ZwjMN2Rk8cEZIq1LowjC+5u6/dLC8NhaQSFImaeOJFAaMFesh7HdyWOcde9W7PSZV2T3cSGWSQBIclEjJxncOy55wf1rnLQJBHBNPdQW6Rls7z+8OerEZ5PsfSug027SW6LWpM6QnO3f8ALuxwzADAHPTrmrWpvNWWhvyRkWqzWo/fM5RREdqOQxB2n0Hr6fWs3T5DaNZW7RGa4L/v2jPzMS2ASVPAGcYNTP8AapJSHN2nmKXmllKofL64QHO0YBP+NWfDTJ9h+zpsXzIhMkinGckk9R94Egc0eZzzlyxN428apBEkSosag5kYk+nKjsPQmp4bSEyjdGpYYZnKDAPoPwqCDUESPZd7RNGOAj7yTj+fbmr9svmMs9wyL8vyxZ6fX1NBzepct03I2wbU+v8AnFZd2FKS3IZkcoViwc4Xd1A9z/Sp72+lINvYDMpYLnbnb64H07nAHvXHeMPGmk+BrC1u/EN29zcTuIoYLYLuTBG4hcjhQcknqcD6G+g1pqzvQm8nznAVeNv8803ziuFA4fJbavbpj+VUra6j1Kyt5dLkLWU8KyrclSpdGUFdoIBBIOSSBj61cLpHMVCqyRADaO59/YcfjVDEMjRKyrgSld59QvQgVbtlwmXwuB07VUkgDujMpaY/OT7Dtj0qxEnmYdcbMA5XqfbnpQLQsbzMjbACNxUfXp/jU5Yoi/NzkdaqGTE4APCc/iR/hUiuGAAG7BzknpSJaHPGj4WRVbc211PIIwf1qIR7YmEjZ8sgbXOc46HNPuAdw2tz79M1WjU7zMCkhCgcgjjJ4PvQBXudQi3MiMglBx+8OB+HY1NHHBcJvcNL056j8qlD5jKoiEDKuueh64qJ0cSDESsrdRkbhx0B/wAabGeWWV3iURXaSI4QlH6L164H9DVT7WyyLBa7gQTiRydoA6gHpjoRn3rnNL1YwStE0rlY0KRuxyYx/Dle6+p/wraudUNtp8s0E0UzLGj+Tu4f+9g9R1PUVyLa56CNRLmCe3dLybZaqArhogvmY7AdPxq3p0DC4+y2MkjyEn55MEgZzjPrjOPWs2NY7pYEdGyAJGR3Uhiecgntg1cWFkik3SSLE58xIoflkJHAAbseO1O41axeMQihCyxvLu3KZd2SMc//AFqp3lgjI0U8ZclAd/TP+fUVtJDcMF8yUsir8qbRk55yx+p7USRPMx3AyEjK5ONo6MMdKJJDUzxPXtKm8MX5nhSQ6XI2XVeRC5HUf7J/Q/WrGkauY5YkVwYgPmz3PGBmvUNc0hZEe3mIZSMAYzuHoa8X8TaJP4Xn86NS+msc4GSYCDwP93+VYSTWwua2p6fZzxRLPdtJlJI9uHGdgA/SstJjdzreXMJ+woweCFkyJSONze2eQKwvDOow6hBCZW3wA/MuRtOOma7m5kN9bq4MSRIuOmASccY/wq1qjaLRQi1I3l4YgzxRg8SZ+bK9B+vNXbiRfIw0mIUGSSOSccE/4VzmpRDT7lRDnd1PoQTyRVh9RNwxit/3r8gzP/q19T7n0xVKfRhJLSxraLEz3zsQqxW4EZ7ne3YfzroLyFAxaSQ7Q25iwyMdsVzejzrbqkcbc7sgs2c9i34n+ldAr/aIlkmA254yOpxgfX2oTMm3e5Q1OJPKdMHafm3MOg9KyL7R4r7TjuG7PDAADoeo961fKmZ3t5crHH83mqcg5ONv/wBerREexxCQYi2MDkA09GavayOTtdQW1A0+5Jtrm2UyCZH278HiQE9Dg4KgHNdNp0+pRGGCWW0U8HzJWOHbHXcMZz07+lYniDTXmjS6tiBNCxKN0LZ6r+PStLw/fXV/pQntbC7ht0IUyvEcNJ0IVscnIPTp0NaQfRnJOkqbvfRmjFfaq8Uov0dIpVAmjsbPylyxIwzj537cggHNPtbqHTLKS2lur6Ly2VcpZPH5fPHPftnc30pYNcSeCF3vjbDesbq0TeaUI54JDA8dhU8gP24vNIbZ5B5gjnXaWbAwqKcncVwSdv0rRGbcUVYbQ3TMVtb+SdzsV7yVVSUElvlGSd3Y8Zp9vZOlrHJFY28IQbowXL7SP4iMAdv1oGoX13ZI1lcySReWQZ5ovKETH5TiQg8AZ5Ayfas24v4IGeNtShvFbICtcmT5h7KOf0qLhzN6MtvCZ7xbq7ubUwnISGKIb3BHHJ5C5A5HJ7Y61EGjRz5AXzYk2mRgXAyenXCgdcD0rMia5kLvbKzgHJRkUBz1IBcZU46cYz2qvLey3Qms4L9pCu2RjBKCIkJ5B3YwcdgBg0CV7m5bXC3F06AFUEjGZwAFjzzgc+wyex9TUGpXpiSd4LKWSEkKxL48tQRuIHoO/Tk4GScVHHNFYWriKPzQMhhAxx7DeefqcfzrMlu47i5S6uVIIKRQWwLNlxkZ4GeucDk7iepNBV76kVzO90itZXZdndjlFAfIOE+UnAOeck8Y54Fc/qDv9phexcyZuAFuFcvH5nORHnPmvlsmQgnJ+XHWp/El5bw28FsY9mZHlvVdy2WwNqEgdVXdkLxk854FRadPHPtulkjkuRGYrc7ipAI27wv3VXqPXuBnFLyJTvqWzCkcHkW0QeaIAPJIQqxjgEqoyMnn5jk56AVrrpFtAQ5cNKdsqZ3RLt6gyY5x2P1GO9XtA0eS0g8sxKFtVLSOQOWPOEHrjAOeB7mt6TTGi0mSzNxPcO+GWLJ53DJRfQdSc8AVpFaGt00ZkcVvJqBmkWadp28yG4liI2ITtmjO7G5C3JHQcYqvNosKTJNMlnNp7jNwCQoQ84Y+hA446jH1o09o7GXN9dhj5ZjinyxjjJYZz6KRwXOMnB4q7bzvJdNc3NsscJZVNqVD+VtC7WY92J3DPYD60JXCN72RTm8MQXF3Gh2wWW8bsR7pJMjPy55Ud8dT7Vrf2FbQyQtaJJEoIPkrwhIH3zz3GR06+1LJd20U7SmQyGZmxCvzlPfHY+3pW5psCXMMpRgIj8owMYXv9frVWSLc3FXbILHSUeJmvLSNo2YtFBu6L03MT1PXBPrV4rEJLa2hEkcO1gQrA5HUAHsMirpaMyNDEwRY9qyScZX0Ue+PypLgKbci0CoQcowHJb+vepZyTfM7shj01DL8yIka9EHPzdSTV5bJURdiqB0wOn59qSOWKCzZppUCIpkaR22ggDlmJ6ADk1W13XdM0LQJNY1C4iGlxRrM06nKyZHyBMfeLdsdaLGbZheKtb0XwR4TuNZ1GNVjLMIo4zh7qU7sKD+Zz2HPtXkPw28Ian8TPEknjnxfGkelRuPsdqU/dybThVVT/wAslPr95s5z81UNEstQ+M3jQ674iSW28I2UpSC2UkBuQfJQjqx4LsOfplRX0XGxkRbW0hjt7SLbGERAixqqgKgXsAO1VtoZq83d7Fu5mZleK3crgYMmeQSen1Pc9qmiSKIxRK4VBmV8H7xHc556motixBVUqcZC+mT/ABGrCKDM5A3uoCbmAyT1H880GreggXzZSzjauQo3HGeMn+dRQTMkwig/1TlmAP8AAe2B3BpQS0blZFbIIz2BzySaWIblUBeMDJPUKOn4mgF5kwA8kyAtkkn1B/2qnhV1IjLE5GRkevP51nfbRNqH2JQw2fM/HG0AcD6mr2TuDngDnJPPT/61MqUWtGLC+6aWGVtrbeMenqPeopC4YyQYLkYYdmYHkfWnybZA5Bw+75T3BxxRBJ5LtHJ/eyrY4Y45/HikSJJIHm8yMMr8KxUZBwe4qGXUIgzgyoTkNhxs/QirrL0YHO4feXj6fWlCBkRV2LJjLMOcfTNDJ0PlOER3cAnt3GwKH+XI79j6e1b+nz3ER8trQPLGrMsmMsUP+z6g/pUHjDw6/hW5/tDTgx0SdszRgcW7HuP9k/pSWl1i3hmjkPmwHMcnc/7J9frXElZnQpNHXaRq9q9vFGwgklQ4lBBAQjOST2Pt7V0UC288glRkBRjsbb8p4647nBrzjSHtobkXQtl89zhtr4XPfIPHP867CyLzW+52RXReAWz3OCfX6CqjK5rc1ri8jVo1lkIKnIKHO/25q9DcSZD+WxQ5KjPP1x6fWsGKKVt258yHAV3ALAkdQOgq3Lew2EwgjLXEuMNHGu8gerY71SZfLe0UX7txPGHC7HByBn/CsTW9LjvLUJKql2B3ZHHpyPpW6ftN3ZO0ca2xK/L5nLtx12jhR9eaoPG32d2nYx4BDbVzuPHVqGr6FRWljwnXfD134cvpbzSXK2n3pIWUsid/ujnH05HuK0rHx1K8SrdxFJio2tncjD+8CO1eiahbJJhUfecfxAcivM/EPhi4srh7vRgoZcO9qWwjZ64P8LfoazaaE4OGsTorHWYZoXeWZSX/AMOn0phDu6OsshhY/Iqg7m9Ao/OuU0q5tL2QqAbe5Q4kjZcOjehBrp7C42PjccnGWzyfXpyB+VTd7MqM76m7pltvfMjAswBZE52gdAT6fzrqLNmMapu2uWHToBjr9BXN208a2zJH/qhhieDzn+6K049R2qT8qHb94jOR6+9NOxTvLY2pI1MSxxKGeQhVAOAe5J/z60wi2Sd44YtsYy/mf3ye5HvVFdUSJQrN80gwFAwyqe/t9alnvba5jjeHCIq7cjo5/wBn1x3NaaDV+pfISe0EKKNo5Y5HB71wuqomharfSGw863uYdpYTOht2z9/A4Oe4/Gu2sZHWLeh3KVORjpVG7tkvCRjzDt5A649PyrTXdCcFNOMtjnWvLufSgjtJeRRIqbrCSRisIYZP7tGO1eoPHrVm1huXVEttUmgjcbzDasZyE5yAT8yjk5JP5Vzl5Zy6HeFkkmisZJFLyQu6tGM8n5WGV55Bz7d62769vRps+Lu1n0+X901xMiNM8RGOcbQ3GMHPXgnJpp82pw1YSpy5S7DHpa2cMN8zyNbl1HmXokWMFuOCSQPYKRUl/qXh37SYTqMaogDL8pwDgcY259RsAJ6VRto7iW6S2guJ5GVOIUiQKi9MvE/Yj+EE/lzVuW4s9PNrI0tlqUcUbpmPNsysTwxVQRjjaSowARTRmuZPQW41uP7NLFZXVwCVOwNamNic4AK7PlXJA65x1xmqenxNbxTNMS8btmSWSMxoHzycY9QegNXtTvdO1fTZrWOC6iV4iQBESC2OCspOAc8g45xWVaXGozWKjU5Y7tztW2hVgkjrjLSSISBGGG7jq46YXJNE8zNW4DfZHuY5FmRVVIEjQq87M4yxUHcQANoH1J9RiatLGl28CSltrukLRA/dI2llYdQM4yPoPUpfarCqmHTw0ZdlQB5NjFc56Z4AyflHH1rLkK3GpcBneGIxruOASMZYnoAAe+ckVMmjVLQbbRwKr2s0UQlR1CSPJ8qRkfM8mM4OACSeBgipfDtk0skNzpqKsDzuIC3DwyMwVZcdyATheilwf4az74v/AGisFuY2lljRZFjUgMWGREBjkKSGY9+O1dn4b0tLMXtssXmxThELHkc4ycjheeT6djzUJXFfsdBqM39m3U1kzbmjZZjFGoJYbQCAc8ZPPNbLTGC2kuZ5I3uNoykTZ2JnO0H/ADnvXHx3X2mxnWMytGvktPcj707k/Ko4+7xnHXp71tW+n+ZKk1/ehII+fKdT85z9fmx6VqnobX93Uy1nDLMRFDcqsBWeGUny5VHAbP8AEAOo7kn0qp4bmQyX2nzxs0exJ8SKNx4BA684BGAeTW5IGa5sihFsSv7lAgUDLA4JPDYODg9O2azFsI3uIbySSNr1ZjJ5LLyXUkK7nOcE4K/3ePWmlaxtCKtqamk2El9PC0JVLRE/1Z6g8ZBPGexJ59M8V1MVmHkmggdnTI5OcKR2UdAPr+tZelWd1b20LXk5luHBaTedvP8Aeftx0961hNMbNEkUqkqfME4yD05Hr7Y70N3MKknJ2WxYtyrlyqxeW2TubGc9D9fr0qxNvGxYx8xySS3A469O2ayf7Wtp/LUwlSo2KQoAAHVQT0HFWrK6ku7iSSUxxIuERM7vqff/AOtRYiVOSVzz749ayPD3wwu7dJCbrVHWxjct8zp96Rsem0bf+BV8xWWtz31vpOia/ql+PDdrc+Z5Uf7wwhiN5RSRzjOB0GTjqc+y/HLTte8efECHQtBspJLLSItss7nbEk0gDyFpDxwpQY68cCtbwn8DdL0N4J/EU8eq3hIKwjK24PXBX7z/AI4HtVJ2OV051p6HrWgDR/8AhHNKi8OGEaQ8QFoIckCJcktnrkt1zzuznnNY+i6nfW3iG4trqMGByzqI0PyoOAvvjA9eSa6mxtI7W3D28UcMIURpGqhFVP7qIPu/SqS3sSHakc7S+aWLsONvoD0xz9OKm9nc7KUlBNNX/Qu2DyQ2KtPbszEZLH5dozwPyp9q0jy3LXbARFlKLESTIMd/bIpkcyTuTalJUX7xDDB/GmK/74zRgRb+MRrlm47Y4x/Si5iy4oZ3CEBVjJ2xDsM5y3+FWA+0ERgeXnhugJx1+nvVZIp/mjLZGd21uCx/2jj9Kkhi83aH+VAQT/tn3z2poEixDFzvIHmMAN2Mf5709sfLzyB36ECmlmaVSo+7n8MDinD/AEhh5uAv86BPzGRLIJTvZRsAYLnuTTo1EjzI4OQgbA/HBBoRRI5kXlSuD6n3oGXm3bSq8Dk8kZ5z6CmDZYRmP7uTIYA5bGcj1oc4mKuuQw6/T/8AXUUmZoso5Vs7lPcHtT4pGk/dMqh8kPgngj09qRKRwOqyrcRS200avCAyMjgSbj7gZ4/xrxLX9Mu/CV2rQNIdIkbEbOctbk9FP+zzwfwr2y3LPCwtsQxofuKACfYMeMfhWT4hsluYmtbmCGVGX94DLnAPAzkcZrllG528ieiPMtPv5YS8quCMEkAZ3Z6g/Xmut0bUA0TxW8YVCxK7R8ygjJGe3ua8/wBa0y98LXMsiwyyaOrYLk7zAD0DHuvHB7d60vDutxxM8cbfunUFtpxn6HtWa03IjKzszvdRne8hVrR2ht0GJXHJOP7nqeuT2qTQdRjKtHHCI4R8wOSpZsnkt1P48VW0S9iuWjcruEZ2qir8uPX6VSvZWvZmt7NhFYpk3M2Oc/3FPXHritF3OpO65TrLLX5Jd2naOhvrrOJWclYYB33N3+gq3p1vcwDNwwuXcCR2I2pGSfuoo6njqa5C11H7HBbwWduoKZZQcIvI6AnqCB1rpdI1cXOnlrpy82Sd0fAUei5/n71cddyrWTsv8/6/rUp6ki+eHAkYBgpJXaDnrx68/pVC4t0dsMcmMrg44KkYwf51o6sse03DFwq42IpyDzg/XnFNt442ubqVxnAzhT9zYADg9DzmlJD5jz7xh4QW8ZLu0YW94AfLmQc8fwkfxD2NcjZ6vcabe/YtWh8u4HIAYhJAO6nuP1Fe7yWglt8YwoYAjHTcN36VxvjPwzZ6vAVkUebw2EyGHowPYis5RuZTp9Y7mRaalbv93KhgOnzY+g6CtCPVo5AUhEgI+bcRkk569PyArzK4+36DdLDqH7y3cgR3OMBvZh2P8637DVDGqsuVGc7d2D9azbcdGZqodM9/OjEBcNyG8wkl+Ohxyx9FH4mtvR47lLQz3KDYQFHmEY3Y44749BwMc5rhJ9VaSUyMVUhstztUH/Ppya3dP1e4ubaAXTOIkXbul4TnsF6t9O/enFps6acnLSx22kzKqyTNmRH6EtyxPAOOw449RU8bF52CqckrGDtwc9SMfQ/pWFYGbzVe6RoIAR5UTrtdv9o+nH+Na6SLvkKMqrgY2+3YZrqgzflSZLq+m+fZkquR0z1Jx3ri9PgmtNVXSQqm1uizxpI4T5gpJjDEEDccEZGMj3rt5NQ82JUXorHLE5Ncx4tsY7qxkUnrzlSPlJJ5oejujlqU/aLkZ2dvDFa6fGs2l3swlkG1IzHKFfGd2Vb5WJzyPxxWLr1yboSRajaxRJGrhGVfLkVgP7qEbvqCc46Y5rBXxNeagliun2UcOqNi2maPMKZBwTlRgA5B65GRgVYtLaFnf+12jkuJHxHvYqrt3Xr5hODwSeentWiblseXFTu11Mexs1bcdryXkTiRlkchEUkDcELYXjncQTnt3rpo76D7IplETea5ecwn95Iegy5GcAADAwD36VHcWs0EltHcMGh34EkjfvUA4yrD7w7YOPrWLrGpySMyFY41YncrOqJgYwzZGAoAySSRQrIpR7k/iWWKHzHRYra3UgMNgZwMgHJAyvOAD1Jb8K5e7m+x3PmyiUHyWYwzy7lPI+QjJyC2S4BP93PBAfqeqpqD3d9cSSicRb4yURSHA+/kdM9iACAfXmsW8KzLKzBYktCFcKh+QHGGxk5xnpnp7k1nJ31QXuaelSvLqv2pzLPOoAYucNlhksSpzuJ6k/w4B4rvrTz1keD9/LcxRNPI4wWkaUYZSQMYwFHGOO4rznw7dt/wkE11PIo3jzIpgOWxhDn8QCBznOK9E028f7ZfXdqIwsEh2yTfKyoigbSvYbcj25FEdgg03oaOjYn1W7kbbaRSr5e3bgKUjA3EdgBwPUnFdSkawwq0IZzkKC4yI0POB7nv+VcdeRPY2cAmbzpLpEeURDBRj8wAY54yRgdMnPatm1lki0iAlZBu/wBYuT+65wAy/eySQFUc9feqWiubpaKQmrrLPMggSRpYs+YVUZdc9Ez3+nQc0aVpt3beHZJrSaKL5POWR4/MYMGzgDoQeeufb1rQ0+2tt3n39wikggrkozKCPlOeQuR0zz344qDUNX2zGytiyWkkwBmxjaTx0PUN68AHrwRTeponKb5Ylm9mgtvOjMjPI8JldwdzlcdMnjbzjp1qvFfXA060Z5fLlnACrIrBmbHCj6Ac/SnRW8FtdCa5VZpSHZEcqd5TPI7AcjqRjPbiqlmt0yeXYu7XbOYkmRxsVeDgZ4GSD0PzDFVY1UYrRFlwIdpW5371Lb5FACnJywUckD/PBrJGpzBBcQbdspB3HjzAT0VR0/3untWjcwR6jqVvHNdtcsmTIYVx5eCfl2joCwJz2A96y7KB/tUI2edGxEYAPzKw5I9Dz3470zWFrO50mhLcXs012yMkUWI1yx9OdoPTk89yRW3LbySv5mBGVIVFCDcWOOSckk+1V4LgW6fu8CNhiKMD5Qen4nvV2WW3ghSe7feqg4CLye/AqDznJ3uV5YhGQJf31wxZlHGQM/TjmorhYlidpvmQpjYnKl8gDO3+uaW1dJd8t3bkyN/q7eIAfLn1P8PqfWrF2JQYzIkFuxO2NAdzc9go4HIoDqW1gAgVrpEjixkx4DZ92P8AQVaWIPGGkBCD5VUDbj3PuayLnUY7ZftN7P5Ygw7LjfkHgHA6+nHepLS5nu9s0imNWboWAOMdAD39/rTuJpluI4n8lsOxHA/idex/DpVpuwYFUX7/AKD2FUJLn5TGkIjcHG9GDsrf407ZmJPPd5EQ5LO+PzA7/SmSW3ZZmAG5YlO8dt3XimNKJcxwAszdefmGfX0FVkWVpCFRYkLBssNzY9x2+lWI1kiXEShyCRgjOR60CaLpZY48SEbVTP0wKjTZJOjIR5ezg9OnoPxqit1bi4KF08zJAVuox3x/Sp3mZZBlMoq8A8DH9TRYSRalfYQgDDgEf7X/AOr+tDps2sWyScEg4Ht/UVVEBZw0523CdDn7g9v60+NI5PluU3uvzEAZ46Aj2zTsPY8VutRsbERmC8lu75TlfMfzZN3oE6d629Eg1abfeajGlqm3zFi8vzZmB6MQDtB6gZPFefaR4uOhxRpp0FvbQFNsiKoLn6nr35rfsPEMV3D5kCHyyQzpvMe704GPrmuRNX3O1TurG/r0KyNIL6NmVyE2DBbbkdR0JJ7e9eV/EXwhceFNSmvtKjDWBZmltY+RDzk7P9kenavUNP1CNdUjuZ3UeWGChzndJj73PJA7/QVa1jytTQfvY2JAXDHIUdgePx/Km9UTUgpWPJtB8QvNZobW48pJBh2Vug74Pr2rZa7zBbWkCEQYOFQlS/PJJ9O5965fxj4WvNGvp9U0KEGDdvmtFHA/2lH4E49KraF4lhuQksJZbjowLDI+gqLaEU6/I+WR38FrMZEa7ljkjzuSPOQPXOeeM/StOErHIvlPHk5CvH8oI4+Xnp3zXP2WvwBC7uvQAhu49OfenNrx1ecxxxgHoVTgY9+1XodPtrnQyT3OoajCXl2QxDOckiQj0+nb1NauniLyVTeWiwI1X1Qd/fJrlrIyJOplGYRlQo4z9B3+vQV1OnOSBKFUyAhgeMZ9v9kdaVxc5tL/AKzyQWXzOW7jGKhaAThmZc7QOoxkE5H8s1Lbr5eCGeRXJI46egH16+1aAUB2R3yUwHUDHv8A5+lA1NHD+KvD1teWDJLCkm9eVxwR6GvEtRs7jw/etBOJHsXbEMjHOwnojH+R719P6jbxLGkpb5D0HofpXnXirTItUjIliV1dCHyMgj3FQ10ZlKHP7y3PObR9/lOiM7Lyu4BUU5689/etW01r+zbxHnCMxYfvGXeYxn+H/wCtXI6jYXnhuVmQvLpx5JB3PEue/qvvVC91UBAY5FIYcFWOf8anlkn7pMa3Lo9GeqzeLVvmYNnyGxt5JYH1qp/b8yLu3DZu2ox7Edc+/wDKvJoNRZGJDFF6eVGSSx9zW5osF/r2oC10yIyyDAI6rGPVj0A9utNxqN2NoYtJWPRNG1F5rhEWb5d2cs2Ac56mupijj8oCVxI7DCgHI9+ag0/4bWtlZRy6jqU88zDlY1Eajjp3rQ/4RwWUUj2dwxhK5EUnOCPRuMfQ11QozgryRpHEKq7owLS4udF1hzBK0djdsIpUIOwtjCMQOf8AZ9sg84p+s+KoQSVLLd7wrR7ylyCMfJ3QnuXUYwR9K0tYtYpbK7tp0eOVV2sHxuU4Hpx7gj2rkItekuoEknuoI5Gjd53CSeaxLbQm5lIVfcHk0J20TOPFpRkqi6k0mq3kxna6BaS6T5I44zJcIc5O0DAbgcsxAxzz0rndduZ2uHVYYmtUCeWr3BlDueQXfALEDGcADPAAFQ63KTObiTVDbRyklY2dmJAwMggfMT74rlbjW49NHkgyTuoYgiQqMn+HjsM9O+Md6Su2cE5W1Zs6hfQRRQxAiW5aTMsiBl3kksTznKgAD8sU+xaaO0nuC6MGyMzOWO5ucYxyQOp9SK5PSpXkuBM8yiVwN29WJJGSfbHIJPYHArrrFZbspY20g2vbsJJpQWO0/dCryR90gHv7Ypz00MYSbdyfSjJYMJkiENzZfIULFyJGOFzu4yDk54yW9AK9S0m1mtrC+W4Vdn2SVTHk5kfaFkPPLMd4P5jPNcF4MWGVIbpojKF8u4dWG4F9y5KjoMjaOTxtr0rUrhE06SWN5ZzsLgGNiA7MAwUY4LDB46lQKk6aOxsWVotw2mxSKXdojPKrD7z/AHY957cq5A/2cVciuEtp5Lpz5luXcq/HIXjzWHcFg5B7ZwOOa57SNX843vkqy3CRxQW8UmNynad0jgfdC8ceo96treW0rpbKHEgPlMzqG+dVUbTjsTxxj296Wp1Qi5aGpqesRNEsMlypilJdgW/5ZjB6jjnI49KUXv2dGmeASSl1aUSfKIyBuKHIyDt7djVLSoYhZXySgQXbXGZDGGXai5QBVPfAOW9SPSoYYJL6SSxsoXnt7WJkG+Qkbm+UlCem0bjk5JPPNa2sdUYK1kJpEd7aWc88ADqqMYd0QLiMc8ZznoOOcDHWrygXSRWqrK0YXzZ1MoGyTghG6ZycknsOKS/vYZdHukVxdkkQNbldskTgBcBh8oHy5H4nrmqIjlmTzfMUR3KmZY5AJJZznAPHfJ4zgDrQrLQpa7o0JpmijSWOSOB23eX5YAIwPmz2wc5+h4q9pGmK9yzzXIa4X5hs6knv9MZH5Vh/2aZ2KttlaNPL2RJw7gdznnpye59K7S0RIbRGWBvMdwvGMnHHPtntUtmVado2RoQvGY18pYwwGUTP+rHoff1qhJ5TvFLK7SySkLEidgTkj6cdfY1Z8yMgRMCJHcb1VDlm78dhxVK0kee7uJIowrQfuY5JDkJ3ZiB69AOvFI5EjQylsAqbFlkwv3cnA6YX09BUgQxKWuAyc72LHeT7k/0qIwRRWzGZiJ5RkyFfmz2OB1rO1MFpLS3kMkQeYyFS3zSqg3ct2yccDpQNIWXyJ9ShhCHNuuWCgfKvULn3659q1FgeX5ioRMcZ649PYVHaRRwzSrGitMMBgOmcZyfTr0q2Y5JSFmZ8/wB1Dgfif6UxtjLXyYVMccUZYnHTkn3qWOVMjzOFChiMZ256DH50rNFEgJQeoAHU5/xxVRiAzIgBmkkycHt7kdqZBaFwwdtsXzSKGbf8qjsMn9KZI8+/yg6KQcF057fdJ9Oe1OZEiT5pN7EklmOfqafZQFItyEAMS3lvzgn0/CnYTK+mW0EULERqXZiWZjuPp1/CrJRUZDGgV87cjsOhJoEbxO6IqJvOeuR/+umyMxeOKIIGLDLMefyo0AlmmU/LIoZR8pJ6Z9Pc/SmujCLziXUpjCt6dOcf5FTLEgZTgntn/CkPzCRQuQPl574xQI+ULW2isrlHuJMlCdoC4G715zzWtczxKGbT5YVUkkkptUH2B7+3avJ7DxA8sf8Apl6wfGCDH/XNdLpNxZ3DK1vd5cDqPnOffOAK45Jx0sVGvF7HYWv70pJcvlCOpPztn09B712OmOkwREGIVHCf3vx7D3/wri9LiRctP+87nz2JVvwHzN09hXW2d1bqFUYKEL3O6TB6ey89B1qLnSql9DpY7OOWCUOf3zJhWA4Yn+IZ+mPoPevOfHvwzttW33mjYtNTUcuPkSZsZ+Ydj7j8a9Csr1pcmZVSJc7vmz+AP4flitexVJGUh4iHZt2Wzg/5/OrTtqiJwUldnyPctqOgXzWWvwTQzKOBIuQQeQR6jmux0HUreWJGRiR2HXn19K9b8faFp+tRi3ubeO4XI4A+YdvlPVeteF+JvCWr+DpTc2jPd6dyc4+aMZ/iHp7jiqaUtVucjUoarY9K0zUYwrrINzEbjuGeAO/t04/Oup0fU7bEZkkJOc7lHB9vevF/D3imKWMJO+MdicfpXX6fra74lJBG35nPBP0HasrtPU2p1Uz1TT7su52tgMdynOCw9/Tt+VWbiaYyLHHlW6jjG7PU/wCfSuDg12Mf6tnRSASucgD696ux6wLhinnPtzgswPGe3H0FXzHTGWtzpNUvfMiZIiA4fGd3HHc+vrWZH5JsbiSVseXknPpjn+WahumiNvue5hLAcQqwww75PYep71WWdJA5QFldjgsMblHt2HOc0jem1JWRlX9nHdx5IUhxgc9QR/LmvLtW8FK/nNYN5NwrH92RlGGf/Ha9siCCPYeAo+bK8n0+mSelYN1ajz3Zht2nHpzV6rVHTLCQrR13PBhpz2uoi11RZIADlimCSueSvrxzX0J8Pzo+n6bHDZSwrAMEN0OfVj3NYWq6Rb3yKk8CSq5IKsueex9j1rlJNG1Hw+XmsS9zpyfeTJMkOPbuvuOnetqdbldzyKuHlSlZ7HtWr6/AzxxxNlVHLdmz6e1LJrkAte2Mc9uB615BY+IGliV1jeRG6MjBlH40+61tY1aW6lSBRlsOwHT1Hf6CtJV01oXGtGmrHa+NdatrW0kkDn/R7dIi2flO1OfxzxXldhdy2eiW1xeeZaxzptLOdo+8WVlRTufqcEjHJ+tYPibxGdYaOxgk8qxD5aRs5fn7xH5n1NIJ7GLc9rvkYxFGaIYGM8gqOSCMDBKjnqelZqLtdnBiMRzcsV0NXWdViurCAwOvlGVi8TKVQ8cNK5OXbOcL0UdBya5LUrtLgCONVYg7zLtwWJHP0A4wOn50Xt0siRjeZCSWKYwsfYKAMdgPaoLV/lki+QeZgbj1HtnsOc/hWiVtTmbbOiiWzjtY/JZ5kjXzlOzBRsgKrEZ9ckDqMdzXVRNdWViNPhIOoXozMrrs8pFjyGYDoqruIHfjPNYFlAsFrI1wgjkLLtkwfMYgrgIM/dGCee/0re02KW4iNze2xmMe4JGVzuDO2WLfxEk4DMegwOlYykVCNtDf8O2ywACGQRRSgM/OAyspQBVPJ9j24NdTC0gZXlZ1hsYkmaSN/wB60jK3lpt5AcLnn3zxWXbWOILSzQLNJcROLiZc5EaJmcJkZ53CME9ycdBXRaIYf7Ahu5IwkdxG6zuWyI3zwoX1AAXJ74x1qUuh1rTYo6JqCwW0k01m4uSW3BAW8tQOV9Rj5gx9u/FWdBjTypLyM/vJcMS0jSPhe+3I/hBIPHTHtWXLEq3UlgiALJNJdbGTh0flCMdRuG3Hsc1b0xLiC6eaRDGJVJlUDcsUQORn/a4GMcc1UND0cPpG/U34FQpI99LGqRglISdrcE43f3sq6428DnIyK2bFZBO0N8Gj09kaQq0hTfnJO7r368+2K5u3uQ9xJcgTvGXRolcENJ8wOXc8e+BxxW4dQlvbeR3jAsix8tTJjB4+foCxPOAfy71opI1V7WKet3Ze9WKC2jSy/wBcRE5WQk8MVAA+9gpj/ePHNWygvXkEltBb2u5RcwQn5t5x949DjuOnU1Wc3Sj7e+ReyMP3kp/5ZnJRMDoSBuIHU5rpNEsprW3jCxmO5nDTSTsgYqrHPyxjp14z+XFK45yhCF+po2FkmlxuryKisvBHJHXAHt6Ci3v4GV5pJhBFHgEYJc5AP8zTG/s+0uPKSUTTjlYyxeXPf5evAI7d6r3sstjibyVMgU4iCbmY9sr91cZPX9am55/xMnurp4bhRmOB5kYne3MC8Zdj9B07kiremRJHpyru2xg72YjlieSxz3rFg0nfDd3+oRtNdNGSschDbT9Omc8CtmS4DgHCCNWAO44wR15PGBTTHJdizHOJHMhQqoPG49fQfX/Go5k+1altGMQja5HQuR0GewHf3qomoR3Cn7ETdEHLTf8ALNcdcH+I+wpN0kVrDGYzJcynzGVnxgE8kkc4A6etUNI0LdILd5USMRliGPHP4/pz3q1PeQHP79Ag4J3dfYetUlR5pRG0yuyEeZJtAK5HQehP8quxpBHvlCpHjgMB8x9geuKdyJeZVdDcXXmy7gif6mM8YP8Aex3J7D0q3FB5MrXKrkn5CAOq+v1zmmeZ9njb5QpB4yCWcHpgfpzVSOW6lt4YmJgRlBPltlz65PYn2ouG5Yku4pL4wRuXbaAUHUDqT+oH51YiRhK7ScNgHbnOCf51UsYEtAAkcaySgS/KSWb19z25pzKXb55HLnIPlnhB7+pz2FBN+xNduBIsaud+DtReWJx2PaoIUuVnO90kPWRgdpTsB78ZOaWPyYUJiQtNuBw3Dke5PYDvVu3QeUmG3M53SEcfNjn9OMUDvYfHOfKRsKgJ7nOO3NS2w2wjBbd1Y92Of0phhUtjdjcAOTwaQThcMpfPRgvJB9cUC32PkLxt4S0y+V7zTnitbs5KqowsuD1IHC59vyrzu2um066MN3CI5UPLDr+nX611ba3LITlmZs85PPPfP9K1tJ8JN4qilkumS3s0/wCXgrli3ZU9T39B3rlhNzfI0TWpx+KJT0rWPNt/3cwLHoc8n6nrXVaTe7AjO3GRkjHf1NeeeJ/BOs+Fz9qh33FjnImjH3f94dqzbDxAY2xJvRSeRuyMe9OdCUXoRCq4aSPfodYj2Kd7Y4zh+vrmtu01pX4BBj/i2/Kc+mB1+leE2XiDOzEwAz1LZxXSaXrEDkCa68uMds4z7/SsbtbnQq0bHqEV/wDabqR1wdpBVuAoycD8fb2qPUHk1O8kt5UQLjEZiBZgoA3F/wAcgAdsVyUHiCPeywnzIxgZJ2qvvn6cYrWtdVDpsxGkIG5iTwScjp1wOeD16+lUnc1j7xxvjD4Z284kvNEZbK4AysefkkJ9P7p+nH0rzmS61nw7cC3v4nQ9mYZDD2PevoDT9Snuiqury71XapQ4EeSTI3bkdM1LqWlQ3tsrXdlE1rK7Bo5E3BscZGffIyK0Uk9HsRUwb3Wh4nZeLFmG2SQgnjaowDXQWGvxOyLJI2d2cI2Pz9aXxD8LIbi4mbQpjBKo3GGTLRjPYN1H615xf2eqaHeLaX0T28gPyZxtb3B6EfjQ6Sl8LOWTqUnaR7HBf+eyurB1wDjBA9j/AJ/D1q+mpeUAoWVpXbLbGwM8YwO315rybRdavoX2ywtMmQNyjKrnue1draahavGftbeXu65OS3qWI5x2wKzaadmdlCtc7G21NJGBLxgpuztYnnvn+f8AOrT3UNwDk5Y4BK8jj37964u61aybZDaTqyjDEAKq/hx+tU5tcjt0J87AVsbRycUc9tD0oYiK3Z3cN3BDIGYqyDJUnuKjhdJppTEAglYbMHGO/T8688j1qSX5lZvLHdj1zWxomrGSf/Rop7xlyGFsm8J7Z6CiE+ZmNSrCTuXvFPgazmSS4jieK4kyTLbttOQf4uxB9cda8b8R6O2k6vJbSTb4sB1lI5Kn1Hr2r6Hju7qSCGS4s5be0Y+UpkIBLdwOc9Ocde/SvL/ihYtNNp72MTTTmRo1VV3HaSNvH1P5muqLs9Dz8VSi4Oa3RwNlHbBR5jO7vwuEwEPqTgk464A5pk928cojRi0cUhOHOQ/PcdO1Qyb1eUySFZEYD5R1I46jjtWqnkjQL4tcC4vJpYAsYDBlCq7Ox9duFX05PpmtTyXoZDwyoQzIBkbu3TOOn4VtaMipqVoAsYXyvnJOzcTnncQehHbHTFY1q6xujqzLKpyOBjqO/wCf6V0EFwos5C6wuQnkq6EosZDhlbjjH3gR/tZ6ipk7FHRWUUc5hElusUoljEs7ZwFJYBiT1GRgg9D61tTyzIZ7WABGu5S2Q2WhCltoHvh1Bz0J7VzVvcXEt3CIxGtqIm3FCygxqQQec8qRkcdVB71eS+uvMS5lbffXjSyRnbtXBOMj0G4HjscVzs2TOrXVjO8sEKRxG2t1tcLwFUHdJgng5cDn06ciuiuFjk+1Q2kkUcm9NowCkqoFOSScBsoeRyAR3rjAq/YPsMOJJWLqHk+9hgNxI6DJOPXntWxoMsrXLxrGl1MsvzNE20mJcfKAeAMj6naRg5prbU6oqyNLU5riz8SWuqvBIPKz8sa8eUWOF2HJVeenOM9Sa1rDUo2giYtG0ux5JIJAcLtPWX32kAKCccGl1m6e+isykkO8/u1ZQdjqeduerAkD8QDWrpun2zz2jvMguUXbJvxuO3BLnPIPoeadmjq51GKKsNpc3JkFyXudOjCiNkUKgxztIPOB2IzycVvwtEulGS8xPcM/kxQQx7mXLbfpv2g+1aln5UshkU+Xbx42BGOCScZ+nQD1OaSGF5NUN7KZDDHvaKIctu5Xf+WRge/NUHt7qxOtlFDaPPfLtmLBnQOWER6qoPfHyjA6459KdbI8EVzLcsYHkYs5V8bX9m/u9PpWBrXiqJZjaWbGC3iXe8hTBGDjgH3P1JrUtoHktRqLoTcgMI0HKxEnAAB4J5ySfwqrWQ5U5wjzT6ly2nW6lkXS0CoeZrpRliSB8iZ5yO5PT60+OJbS6STKFIvkZWJ+8RneT3PQZPvWPcPFptxbaYk9yiIWUJAyqHwu4sw45J3Z5HXNL4a00avZrd6t5jxS7j5BkJVlbn5/Xt+VK2g5UuWHO9jRu76fUbfyLeMBZQA7tyAGJwQB/MmrKaXE0vnXLSSuo+VG4Ve2AB2rTRQP3G92jUfMwwMeikD2oE8MTf6OUkABO0HnAHPPf6mmjnv2ELypaj92tum4IqKBk+g9hmoowsFuFgIN3OSis+TnHO4+wHP5ConvpJlTEfBU7TuwAWIUc89ieangDGaa5bbHHjYoHJ2D0PTk8/lTJ1Gvst4xEqnDAjg8sx6/n1zSwvICp4zt2oRy2B1PpiiaZFgLAgRHv1Ljv+HrTJFM92QZHPyBmQEBAOuWI5P0oKfmPdx800wMciZAYtuIPc+/pRbNPHHIQokjYkmV8r9R+fPYVOFTKxxJ5h3gbvugDqTUl15i2MgVhGrAhVXr7cmmT5FSbzYYlkjaOO4kVcFyWGOhUe3t61NCpxCkbOnzmRw/DE9sj8ajgjjMyxKuJyMszDJyfc/Sp5lMswLfPGikEMeW6HGaAYMqgDYPlyE/3iev17VdjJEUXGZCOcHvVZpAka/udiKMgLjtTZpWRd4R924MRj7nYn6dfxp+orXLW0nJCqzochuuPWmySbGSSHaS4ztPAI7HPalllMeQGULyScgsMd6rQGN8lJUKZztznJx1JpDPiLQo1e9iW4gYpkEueBjsP517FbXcf2GKG3Ty7demAAPfIFeQX9r4o8EXDRa1pkghkXy/9IQtFIM8FXB5wQCOeK0tM8X2aeUtybi3nj4dG5XP1HP5ipguRXRz06iUrzPZLXVIZLfyJVO37vzHqP8ACuO8UfDjRNWtZL7TZ1srhjxswUYjJbK9uqjj34qK38X6AIVeW9nkb/nmiLEv4uxJx9FrC8SfEhDam20xvNbG0EJtUfj/AEH51Tm5GtapCa90811Oym0u/ltpivmRnG5DkH3FSWV+0R+bDEnJLnIq6tul7ma7yZZif3zZVd3cZ9F47Gs28tBbykQTpOFJyUB4AxyeOnP6UOKkrM472Oz0rxE0DKLjzG3DICLnPuB29M12OmaxaXKL9u8vykAIhUbVGCD8xAy7+56V49Dqc8cWxcLn7zLwxFW7bVHjGF27c8bjk/8A1z9a5pUZLY6aVblZ7jaa5FGGYz5M23lSV3gZAB9QOtaGr+KUufKitZw0SKEXd1wPb0z+teMWeoSXM2DMzMwznpuH9K6iydI0jcFN2Mncc4+lc7ck7Hp0qqm7s7u21SRomCyBGP8AFjPSsHVIbTVoZLS/EckbcgOeV9wexrS8I+G9Q8Ty/aA/2TTi2w3DL97HXYO+Oma7S28I6NYiRDC9y4YnzJ+SR7DoK6KVGclzdC5zpybilc8OvfAOt2tvIdHlh1C0KlvLY4cDH5H61wN2byyuHt75J4nXhonJXFfW+j6ZYi6ns7e3QTbGmVt237uOD7EcVynjfQNK1XM88MboyDGeCBjPB7Vty2ZxSwbbagfOL6hK5GCE+g/Wp7CctOiJG1zKT8sfQE+ppt5pE6anPa26FwjkBmIUY45JPA6imafdy6ZN50SpICB82DjpnGf89KpQi0ee6kotxe56p4R8FvqU8U+vTo8SEP8AY4/uYz/F3I/SvQILq2trhoEihiiQt8scYjVTn+6OBXk2m/ExreDZLaEOBgMh/wA/lVO88a3F4zmzjZWwWeR22gD1/wDrVpeMFaCNKdZRd5HsGq61A0NzaxyqgdUJBA+bD8Ak9BknnivHfHOvTtqkUNm6+aiyLmMcguNvy4PpnH1rPvfFQWwFnZxMxb95cXMj5aeXkA4xgRqpICepJJ7Dl2klklaQsxkPJas1FuV2FTEc8XFdS/fC5S7KX4UhvnKwbQrFQVyNo2nGDnHvzmktbiQ2TW0RB+dpAOR8xTHX2GfriqbwMG2hH3dRkYJHXp9Ka5O0MFwueo6ZAH61e5ycvQRFLyKFAOcDFdHauPIMEgEaqymRBtHA4wf8cZrAtlaaeJBu3bsAjk1s2YaOETKN0rpuKADpknJ46Ed6ioWjcnhjM8TQqYYMATIrExgNt2gE54zzn0Bq+LmSXUYpSN21m8iZ+AiKp4P4nJHfFY1g8l5PJFc85fdJEgAjJUhVUnrghWGOpz+Nal9GsXlRwNugYAuCpc4OASM8jJDA9eg9axtY0juXtLuQ5GCy3ErGQ/LywA+VR7k9q6vTW/s/aIBHtIw0hQZMg25KZ4PBHXsDXKsVIUxKsk0kuzzN2C/AUKPx9OO+a39WmEmIVffIGVZShBAULgqp6Zx+ePejY7Y2k0b1ncxxXYunjaRYLcvg8KrBTnDdCpYg8YPPFdVbzQyPEbGMzvbhBKzpwU2/Oik9GIOc9q5TS5Y4pEikdUgMJyzoWWM5H3QeqjIP19q7Kz1KysZYoBNGUYhchgXMh5AI6k+9Vc1lKJsxbLC3aSWRnii4ick7nJbhc92G4AH6nrUt2Ws9Hn+zEi4VNm7A4b2HYCsq0V9RnJd3jtcl40zgsd3P4ccVo3KCO3WKBBKk8uTCT8xcDJAPpgE89MUK5EbJ3ZyGnwnUvEsMGzzrWGJXkeTjaQxOM98sQce1eisrxWNxJIu1URnBDZCgc/mcVlaRZGOymkaGOGZpfN3pJvGAdoAOOePbvVy5v3RBC8LfaJZSRb9QAOfmfpgkAE/UVTZviK3tHpsiDUNOhuDun3G5nAijCnbsj6kn36k/gOa1bGF7dISq7YFQrtHGF7HHqBWZHYETtLqE7P5a7twJ2ruz8pH8j1qwt4JLWZ03xxLkbuVJA68dQOvWgylUk4pXuXhNsgaJSNxOXcHJLHkge+KuW6RAZ8tdpx7l/T/9VV9PRI4SYowE5wvp3OKppdG4vXgtmaKKBisk4G5Yz3VfftntQZN3LUsphuvJU75gPkQcKgJJxn/J4qWGIOq4ZtqdFxhSf93+tVnaJb5YUV5XVN+FTLEkHGSfWpUMtzjGIoQcMok5Y/3cjsPUU0C0K13uW/VnCskUIVY88M7HufYCrsBit1keRHeWXawA53HoMD1qndrK2p2pt4UMSgqByFJwMu3sDn69K0lSK3uFl8x5ZSvLEZJB6njoKY2x+yeTbJcfJ8+RFGeFGO57n8qjnkjEbDhVXjJHbPJq1dTB0CxnJGDuPQjvj1qhMqNewxkfK48/B5+4QAD/AN9Z/CgI9xbe4BVHwzKyFlIb7p6n6n3q1FIs9vlD83ZscZPXNUr9CCUtgZHAMhiHbGe/bvxVu1mSWCN3dEjaPcYkGOMe9CBj5zu+QBD9eR+NTCSOKE7iS8gG7ceTxUEAEBMtwFUle3QDsKZEVe73OHcovBwdvPp79s0wGznzIfJZFMzfKXdf4f6cVogKiBBtVVAHyjjp2FUJJlVGkZXZy2VXZ24AH86fE+0eYxI9B7dPyoQnsc4tnJqWnx22qQRPCsAt5ISvmISNuSVPGCeh5OMe9eVa78GNGvxcrAJtO1A7pEeNt8TDPTaeQRkA8jjB55r2S1nljVo2RDOpIZQwG4/XtkdAeOvNR6gqyQtviJB+WRem1jwOvftUsfInpY+UJvhZdpepbjU7cHdtcSRsrKcE49DnHGD1IrR034a6fbxme/1FbrAIaHBi2/KMMeScZOO1e9avbPLbwJd2yFrTG6ZVBzHz82OmSAePUH1FefXemvp2o3dusbPAZi8ZRCrAEA8KOSMFcDjIwabk0d1DA0KnQ8m1rwZeWkMt3pyCSzhQOYWlLSMNwViVABHbiuZinvFeSERNwrZiAZdo6ngEGvoQQi3ljlH335VJvU4Gdp53EHGT7+lbE2n6brlnJcX2nwzWzM0e64jDMuAdybsZzjkMMYpps5sRl1tYHywzLJtDYVUGAQoyfr0zUPQ17zrnwr0q3u2LCaKCUnyJI3Cq3AYAhsjdjdheM8Yya5vVPhVc+QradHMWAPJbO4AdSCBtPqOfx5wuddTz/YyuedQXtxZBVBA3KGHAOQfeun8IXJvr9TcyRuq8mI8fp3rH1nwprOjwebeWbmAcF4zuWNvRsdD7GsOOWSGRWRirL0Io5IvVCVSUND638PspsYkt7uS3YAGJjyPoAeB0xj+tad3cB71WXbvB+ZR0b3xXzLo3jjUbJAjymRCPu7znI7dOv+c11Vr45mniPkQ3UckgAMhjLjj3HpVyqM66eJS3Pa7S9t/t904YDy7Zg7D5duSCASehOOB3rA1+eOKwYyYR2H3Ce3b8B/SuQsfFotLKRnmlgd2EjtJIAxK+2cADJwOp46VwPi7xtLeJJbWUrMrZHmZ6D296jmudEcWopyMLXdR8/U9RNuzNbPIBKuQAyrgKQfXJP/16pXLx+STBua3LFU8wgEAD+IDvz19vwGchwwJHA5xVmO1ZpcOyLnkBjjPtVr3UePN80nJ9SJh8jsyAFjlSDgYz2HeoqvC2824KofkHO58AdRknHbn9RWymgSyNiKOIQICoklBG8Hqx5HIHQdOKlzihqL6I5+K0mltZblUP2eIhXk7AnOB9Tg/lWhothLJOkhyibtrf3tuMkrngnFbQ04Jck3U7yxblIQR+WeARuCAdAAM/XvVicrbyAFpESQZDMAMA8M2GHB/DGKznVvpE0hB7yMC7KRTXazSMGbjG0YbAAHHYDn6cVn3HmSyeXsCFeCoJALdzg9zxWrfxRK4eUGSMR7jyFPzH19clj+PSsqZoTHJHG8jHflXbADKAeo7H8aum9DKW4jlj5qpD5Y35AGTt9Rn/AD0rQgmRZY5Zi0jOC2xWwCOgUnt3rLgK7gJVLIeMA8j3rQtZUX91IHKMuzaeSMkE4HXPf04okgRp2V6qxzFioWVpCrNxn72D+BI57YrqTMl7d75GTMsYjZdpGQBxgHoOnT1rmbCDY9vNE0RMNyQkaKeMPyWz1HGQtdLiDzGaO4BeaRVViTuIK8k+o6kAemKzb7GiZWlS5hmjRD9oQFYoYCSZZGYggLjt06mt+2v/ACLaW8MUbOrrbgbuUbJJO3HDA5A9BVDRgjatOJUEyw7sNnAAOBkn0wpAHua0rVYpruaEMJFhdyzsBho2B2yEn2yDgEZGak3hLWzOq0KdIUhllVBN5TCGJSW83OAFX1HXJrW0nSpBdbZ5VYqfNlkhO05IIAX0wBjuRnisrQHtZbm2FvE4i8mT/SAdzTEEKUBzlcHIzwDuBHBzW5IFiO12QTSOsQRMlIkZMkAeoUHJ74NVY2vdnTadPCoWC2dVeM4cKMqMZGAe7cdM9qtyCGR5p5mXy4AI1dj93HJb254/CsG1ldLWBrYESznfDGj48uIEdvQ8Z+uKv2UjT2saSxI25pC7ORhSHI6dqZa7mhYTs75iRUjQ7ogW+6OQSccAj09D61ny6skV/MixPcXEX+tUfw8FyzY6KFAPr19Km1vUWsbaRLY5uQmSUA2xITgk574JwvevOLW5uZNdmFtKTdQyNMk4IASRlG9yxxxhQM/hRezOvC4f2rbex6fbTrPnUQXkjLhIcDCgnADhfXk8noPerVmIhbwRQBWhuFlUMX3Mz5xn34Bz9KwPD0MhhggZnW1twJA2Au9SSFJA6Z5JHvW+l5Z2eoPC0Ry53kRoMgYz9ffiqsZVadpNREOuRvo1sBMqXUv7shVIKMuQ5HHbBxWhp0aadpiqihIoV6kbQGPXA7nJ/wAmuVuruaLUCzbDHNNsid0IcDO+TA9MbeePWt7Ubow21orjzbm4kVLS1TqQOefXAGS3YfWl5mDVti0zb5/mUpuTe7Nxgf3R6Ejuen4ir+0eQWaLy4OAkYXBb0Hsvt+dZ9vbPujuLmchFOAsfWRz1bPcZ4FWR5UtxiRA21ckbs8nufw/nQSyQsiRALIoPGWBAyegx7CmxOJZXVCy8ASkcBuOAPbvx2qaWSOOEzMRHBGM8LjPYcf5zVISzb4tiklslwRgqD3b2HTHWqSEloaJCsBGCOMDGOAv0/pVSdHW3jDMwkBMZbGSmeM/UcGraLFB8/meYw+Y55/KoLwh5ooJSB52ZHCnGEAIP8wPxpiTKcKTOzhpDHboQGAILy4Axz6HqfernkBQFVP3LNuzxkEntnoKhkRLKESqHDHjCdce49fep3lE1u4kbdt/hIx07kflRZDk+wZM9xGFCiEZbGOSB0P+fSpdggEwGSCgIPccnmmWk5ePzyuxCOhHKn0P407G9JfMX+HCnOMEjNMHdaEUiEtD87AyHkAVYjODlzuWMYUMcfiKrb/OW28jCkAbmJ6H+7Vl3UbHPmJKO5PIH+FAr3OVjvNktra6hKjtcKyLJkKWDE7cnuRtOO5/Or8qOYlE5Wfbwu0/NxwCCev0rPit7a5WK3uI4r3MyYk/jcAEbiOMEAHp0OTxSTtcWt3G7zXP2ZN6nzEDDafmBYdSOuee355o1T1EulWWBpIAvClVyCqucYKH27dMg81xj2YuJpGjll2TBY4sYCoqkAcZyNoyeOflxzXZtNAHkdJYxOpHmRByUcDjJHUA9m7cZrHubSO7gW7sRuimkz5bjGBu5Oc5BU5BxVI78PNLQ5uO0nlxNcbJC5ZTLHJxJjHBDYI6HBHcnvkU955PNU2B8p3iYOquPL25IbOecEbRtGfX2qo7XKlYPLWRfMMZUuzYbIO31IPOCPX6VBb+Ubi5e7WORApUKR0ORhuuTzwM8cHrSuzvdFNbm7MpuPssuqS211phXzobfyN+1sg+ZsyN6jkYGMDketXLSK3+xCC1v4ZIMZyrseQxOVGexHTOfeo3dzpEJtI0mjKiErvAPPAAJ45IAz7Vhw6vLDKojiVlmYLImMFGAJ4Hpjj0JA70rJHAsIpJkuv6HfPp080SIYtjDagIZ0bHBRT8w+vOOM8V5h4l8C2s0klzYOYEeRiVeBo1jGegGSVyc8N2GeK9hu9XFzYTPZIm1EO5WOdgGBz/AJ7Vytix2u8xZLjb5kMm7IJzyWyB9SD+HpUbbGE8E5RbaPBNU0q502d4Z0O+PlipyMZ4P0PUHvkVVWSeJFKvKiN0IJANe4w29qmpR301gVikfY8bwFkCHjIHrnseOccVF4m8IWF5DLcxaQykP1X5DgnqTn8MEcZq41e55ksM72R4nc+crlLgvuHZzmrM1uJLmSK1WTyE+ZGeMb9pxgtj2rtJPDn2CCZG3SWAkR3Uxh3jI79BuUZAKhgeQRmqgsbuPT9kUoeFGUOIFwWZc7ecZOQ3Gf7vtVOouhKw8r+8YsmmS2YhZ4lcn5DE8fzHjPTrnkd81JZ6V50kEkSCFHC/fkGDjqc445HTtXRwWriTbepvO0IGVief73PSr9vcpZbLXTtiq5BJbDEdeT6EVk5tnUsMraGbY29uLh/PIIBV42CZyoPQHoBwTW1Ld2C3Ny5KvIZvlKn7/wAoIwB270y9kjiiCxzLBcYCK7RHK4PJbBx0/PNY8bRyQl5GE07xqu5lIKKuFCgD06e9ZW0NadFbGhP593NuYvEUb5Ythb16844yaw76CSOWQRoJAqHjHOMEbfoSc/hXQR3MCwSSPKtrFFuAjjckDn7oJ6/mc4zWNeXv2pblrRg6PtXBUg8rjrTtbUyrU+XU5+78pyUQSMWCbNrDaPXHrk+prHmjeJ2R1KspKkN1BHUVevG2SsJCd27buUY6Afrn+VVBM0dysyY8xWDjIBGc56GumGxwS8iJGZDlSQfatnSVWRmTaJCVLFSc8AA8/wCc1jq4DMWRWyCMHIxnv+FXoFaJYjC7CR1ypzgN2I+vanNaCRtWMhhQp5jeUG2nJDbSBkbQOnJ61sWzSfaTLGhETy+V8y/LHI+SOe2cdPSsGyuGlDvtC+WxkUehOPbParkLGS6gIYjLlw2OenBHvmsGtSjXinX+1pT0hGGkdcAshAIODno2Rge3etDUZIIGs4J1M8sjSNPHvy5jVgu08grzlgDxtAP8VY8N4ot4o9qyFIQGQkffC4zn3UEfUA8VLpZN5qFy5ZSzqgZyedhXDAZ9SOcU1YuD1Ousp79Yop2uEEfl9FG15BvVuc9DjuMHC8114lMq2sEaHe6MZCwxHHuUqGY9y2eAOeM1ycwE8kagxqsLDnsG9AOpB9fwrc0y8BszMyNvh3OQw53g4HHodvH1p+p2qScNNzsLBktLYBiv71fmLEBm98f0HFJHdM97dJCcwgCQsrcR4++o/vHdjnoN1Yen3gKW1heKGvZsSSv1BT72M9R/dx6VN4rvTFERvgS4GUYHCgIccgZyecVWxVLWSTOhsb63ubaZbKAyMHVRFj/WZHUv3BOeeelYkWlQDWtW+0SIyRTozw26lkkOA/zeoBI46ZGcUeHmhggaSaRY2cbYkyeCTjgfT16V0VnPHYvNsVczxI8aBe4+UKPbpRu0bTlySfs9jTgkBTyraLy0d9rbgNyjAPQeuf61nJbC3unQRLdXjzCGMM+G8o/NuY+nH41SutdS1u5YYZYnKHAC/TDfVuwHfHvUsWppdbp7Zkiii3JLO7cyKq/Mcjoq4wOpJ4GOtMSpyiuYuiJVS+ur+ZPMRhczv/Eo4JGOgHygY71W0a4UT3GpSEu7ERxKrZWCE/dQH1O4FsfSqkMNjeaxbNdNI8DqJI7ZeFj2Y2hh0ZmBySScYx1rZiSK0tVs28xtjjbGjZ4PO9vb1PQUtzFu25rLeItsbydJPLC7IUK7AF6ZwenTP0o0oyzIbmeIRbmMp3DaD74+nc/lVTTonluI57uR2dcGNWPC4H8I7/U1cvjACsRYmXepcn5mAznHoCaaM79Clqt/BFJO86PdXSgDyY/uQKRxuPQZ9evpWrpRllQz3JWJ5AGZYj1GPlG70A44x3rP1HT1bT0MmzeZEJJPH3h19cdKs2YaG2WOZyrdOSPlA9/U1SNW4OFluahw8UkVsQvBG4DIB+lYmozyLf2jBiYirMTGOoABQH2JB6VpXE6W9oSgAwCAAcHpn86yrC4K3ONhluVDssQOFXJGFz6Bf50WMlpqaBuIpYUaAF4WOGyDlvYDrn/Jq0FMkpSYhmUByueFPYfzNMjjw/mSNvnblQgGF9wP6mnxlVm2KytuwSASSMcZp2IcghTy2O0DJPB7fl0z70yRvOeIOMhJt54784/SpZXO0IONnJyMbh7VXtYSluwZ3Z4mYuQOA34/WkLmuJDEYGkw4MRdi2RjDEkk/Q5FOluEIfG7YMY2jOfU1Ju3MY9yNIi4Pf8AGo7WziAmQq3zsC7L1PpR5FHMTSt50Fy8MTSxfLGjcb2b5dzMOMAE45z19asrHIxna9gZEwqq1sxlQnk7iMZB5x6U+Zor61BscwzFQW+QFc+jY9+Mjr2p0N8huUtLrdaXrjdhQSkuAMlG6c9gRn8qg11RmxyLeW/lrdJJe25KwTPHtwPXOO4BBHPI+lUbbzQwtI4ZIUbBkbOcsckMh6c45yPpV3WbCNJ7N5Y94WUF4o4gEKlsgP3PoPfntVjUrsWjQT6fOLiVwzLbNlndCMnaeoxjIByMjHFJNo1jNx2PP9aM4uPs08UwkckbriQRsWGSDu99p/yazLpUkvAJGOyM8PHIJA8ZOCSy5xyOg/rXoWoWjal5V3DIlxC0YMLHgsDyHzjhsmuP1eGe2miijRoZpnZChGAPuk7B0J4GTnkUep6+HrKaT6k1rqZiV7Se4Wa1TGFljPAz/eAxtBHfGM9ahvdHFx9oubcRJGJFyGyCcNnDMCQCAODgDkDmqs8VzI2WhWLzVzI6MRjjPT0JHTiuostIY2Vu814PtEeN0aRAwjHIDhuXPucY7UnqTin7O0odTmUd4onDfIkzZEMuNxOcAlQMscc5wPyxStZ3IvI5J3WKYMpihlG/zSTjdj/ZzuK9eAa6oTxuj2MiBZEP3wuF6j5v1/xqtcWW+aa4XaEjUsJGUASSgcYHYDngdd1T0PPlWk36mRfaXcWttJ9okfkgMyc7ccg8nr1ORT7iwv4I8m/+02T5Db4g5I9iDzV/WLaWCKUwv5o2nCvgkAdcE/8A6+lLbwje8sUTo7KVIXCqW9xwOT3oMn3OH1OHzFeSKOKZz91QcgMeMqp68DPcjFctEqi4kcu8UkgH3RtDAdOvGCDn+XWu91iIm3jijRnlClHLEKNuRyrAknuOgrkLqxa0y8pjifcSuWZt3sAeAe/NS2bR5XH3mFvA2d6zyKRkIoYAjOflA981HEba2mWRNzKqKGXbnc3dc5y3GOfrUBdAjCIH7PnAkA5J9yOo4/SmTQOVj8wsgDEgIMbucnHPv1P4Ur9jZWtoXLqCK+tBPdKscSyYjhBIb1zz9axrmFre7V9OiDnbziPad3Rsg54I5J9K27CWGRZJYEjVYsRO5+Ypuzj8Tg0+5jjeaJAr+e0YCom4tgjO7j27mkcjlytpnK26gTuI0Tzo+Cy5ySSMdelOCou5EULCmQ7nkkknJGO3862PsDY2BWSFDufcQWZsdCRVPUIjHIUPG1c9cjJ9PXijU56rcjkdVG5mHzFixJHt2x+v4mshiSxJ65rZ15PKI3BQ7kk/NyuMVik5Oa6qexwz3BcZ55q9azI1o8MuWZTlAeRjnOP0P51Qp6NtIOSDjjFW1dEJ2NayllSVULowHAKtzzjGD064rRdIrh0DqxjC5YNjG8HjHfGCaxIY5BGpKkxy5KHkBiBg4461saaSYg5QspXovy5XH4/l7e9Yy01LWpetHkVXTYdsUhVcADA2/LkdMdRmtlDCrvNsQq6B4uCcPgBlwcYzgEHsaybO7Ec0LSBQHTZhucNjPP8ALFbUKb7MQ71MYG0Z5IU5yR68f54rJlrQ6bSWSJmQgvIkofB7ZPKsR0IOcDvWwscMqPb7NwMrNvZiFjDLwD/wI9B61z2kXcdsiRw27EgbVjTGH91P4dTWxpLrcQRTyJtaJUaLJyXYgAknuSTz7DirRtE1dLtri207z4mWJfLJ2xg72bb0ZjzjjHSrP2W0jkgMoi3qiTvKPn8w8Eqc8kZJIHTj2qnqFyunqEvGmlNyQAN3+rIxmRV6FcduvA9TVq2vo90JhZZmncyFkG7YuMtgenPHbn2qtDZN7nWWrhJoo4Y2f7PGXbaeFJ4XJ9Tzgdaxdcu1Z1g8xvtSAm3AP3Qu4s36hR9CagfU20po7KHfD+6adJTHlmRc/Mf+BEdaW20ZbzTxKcq6HzRIX+YjuM+vX8eO1D1Ki0n7xjpcgajHbJI8VqiSTEBNoEe3djpyWbaN3OBnNb/h3Tlvrq3CqHERS8dSirHvIwowB1/2R0xWXbaUsl9IYnZrW28tSTx5e5dzEDsTnrXY4h0wQNb/ACoPNWYK3RSfl5PAIKjk+tM68RiE0uVlnUZUtrZVnlja6hxiJUPzEnCnHfPTnvVa8l1GW3ldHhtbjyyCrfPtTIyM9AAac0sckdvIyTSFX83CDBGPTPPJPfr2FWlsHuGeMblklQ+ZFb/JGM8YZupwOMCixwb7lSCSa3uhYwN50zzPI0Qky0QOOpH8JySBx0xXQ3H2WwsHjVJDIqggsm5pDxyT6msO0sLyS6j/AHkVjHEhRpo4hmRS2Aq+n3Rkn8K247FbVZDANrMcNKXzk496BPViswv1dZNiRnhVbqO+T2Hbion1CC0bzHwztyzxruyccYA6en9aI3mR5gHVgv8ArcjOWwOSR/IevNPjElw1uAiq8hyckkLgHAH+fWquNJEd1frNKIkAa4eJm8x+IlGR1PfnHHermmQxRL9pQtNPcEvvIwWHb6Cs/UNOjF1GUaXy3cLK6vtBGfu/59KtIpKt87/LvZm+hxjI9f8AGgTRY0qRpVnPJbzXjyOiqD0B9PfvVtsRoHIIyOSKisNhtlEZUIflXbwMAdhT5TGtlJISSkaHkDuB1FMjqRTM09nKy4AkQsN3oD/9aoJZVDzJBFlSAJASSAxHGAOvHJ/CneWFWIOreZ9wR7iABgZU49v1qLR5USzlL7l8t2jJ28gBiM/UjFIvlsLpl3DJbiSSQFiSSiIVBbOOc9+K0cv5bMCuTg9MD8KhjjWdxlc27sXAHY/T9amYgTKkSvlgThuAAO5z0ouU9ziLgzwXWHDQ4lOZEfacHBwWAwfmP4960XhjvLNZ3ZZQ20sRllyDw3HOQR35+lSlLWUT2zqhuNnmOBxvLA5Ydj0A/KsCErpdzKBMFhMjbGBxuHAJOcjrnJ6jOTxU2HZtFyO81DzhFILa7j3blnicgSrnGORgMPc8/hzZsJIoDIJJvMhL/LDnLo3HyMDyec47DP41X1ewmWFJUudjo33/ACiGwcDBwecZzz6U2PS1nd/IkliLbkUJICvYH7wz1z37UMfQnsYms5GtEQRRsWm2v80agklgDkHAJ69Oa5bXbu5WaSZ0T7oEIRS2wDqQpGcnJP0FX7u71ELZtIUktskmQREhztOQ6KAVxtB4yD14FVJmtb6znf7VHmKaRSsgUYOePw7cUl5HbhpKMryONu9Qkju4wtzcuVyqQoNuD2688D/INa9h4m1DfHG9kJAWKqQTz8v3j7dz0qndG3Z5Hitow8m5cbTtHAGAW75OMAD8ay/tUcWft8scgBI6fIBgDGPbgGou09z15wjNao6qxD3yCfUYmuIDIsgFqSYmOMZOO2MYGavlgbaFrSF38tgo3IG3AEjoTwOPrmsjw3re6G5B+0yLuVfMdSrFyOevBHTn6etaX9pNGBtgMcS7gyMQcEnlecE/Si3Y8fEU3CTshlzczG2CXbKzF1aROQsnJOeOxwB+FVGgD7SYY0wSDtOPvdz3P1qMTXJl3y207KWOFcKu1cfKFHr7fgKjuJC0YkVUYH7p+6FHP/1+aDG9iveQlU22DTMY+CzSZRvbisR7XcH2mKJmf5w5YnOM9fStSQq0pCfPk7FCKQCeOh6Z6VgXdvKJdyMFMpEeMsrbsnk9+P8APWokLyTIk02ZFd5biG3SXIVXAVMeoyQBzWBfBjDIoLeWd+GjQqG28cA9Rk/SupvbJxlSmyZxgN0bHoo7fUmssxlJfKhQooPzSMNwIHRefSpsClKJm6PuRWLWr8MU2rgcZ7frzW5bo3kyu5khjdjuRgAwBA/LPP4UkAhs4XNwXfahVUiG5mHPGPxrGdY54lOzMX3xGjHKnPf8h+Rp7EvX3pGrqWsw2GmyGJdzXGApXpj29DXPNcfaZ2ui/mwFQI+xHX/69Qa87qIRG0wiVyTKrBeCMbR7nnmufu7141W3V28iPjA6gjvx/nitIxuRVmrFXVb17meTJ+QHAA6YGf8AGqFKxySSSfrSV0pWVjzZPmdwpyDcwBIGTjJ7U2lycY7daYiwkrIqooRWRyQ4HPOOM9xx0q/aTvAiBVVS6lSwcAAev1/wrOjZCQCSuSOR/CfWr9gy78Y2oVySeSD06+hOaznsNG5ayw3BUxkBiAGcrzgL16d8dfatyKNnWIJtBdsrtAyARXO2K7ZVISSAtjOAW3YGQSOmK3PPWO3ZpA67fnUKcH/JzWDNEaGjh4ZohmTCoFB+UBTjoT+H61uaRqQtpILe4LRohVEVH3NI38MY98Fu3GB9a562ju2XddJbtuk3PFGxLYI5IOeSMDNWtHeK1mkZUE8skAkjIxhtwPBz6EEE9elCdjWL7naWImvoriW4lURbvLRc73IHUZ6ZPUkD+Wam0q+NpDGoX7RNua3jWM7twAwgLAYHJPJ96ydD1K3u9scgkklwkRYxn72AcAHoBk5xjPGa1NNlnupQdNjAS3ndomkGSwzh2Ve56dferN3poxmoLqLzWU0irABA6TySnzcs2RvGBgYOAoJIAA712OhPbx5+SQyptTM5Gcqo5JGRjJOMVgXmqQJPFb2CS3t7LG1tLufOwgg5LdOuQMADmq9hYXscJW5ngAlTJjMmI844ZuDnAyDjk88d6FpsTe5sWknkXt3BDEGS9xOrMdscZKjcN35Y/LitSGJAs/8AaMjGORpJBECCpYDLKQCSW4Bz6HjFZVhprXCW093iVQ0aAbQkSooAOyMHHXufQVNNHa2d1JLbPmPBMMG4lpJNvJPocEAdvWqS0KjFyehtwWzNi/1EyMF+fYGw2WHO736AdeOmK03LtFtRZEIACq0hxg8ZIGPwHU47VlQ2ZvYLWV7mV7iVkKlZMxRLjPAxyf1J9BWjfWXmWskaTzyMUIXdJtBwM5bHvinawTVnY0YlhiYRKFITdHIR1U+2fbHPvUkoErbMhVXGTk/KMcD/AHj+lZVoY7a2WTI2smZkIC4PU5+nOfanLclLdSZ0RJAHJkPJB/ix+gHWixD0LiGIT5Mnk2sCeYBn5Sc4yfz/AD96ZZSSCZpbheS5ECMSOB0x7nHINRwR3V5dCZm+z2kahYomAy5z99vy4X8e9WrJWbEjvGQq7WZxhsc5x/d5/GhMd0TXztPYzqm2Ofb8oByUbHBNU45Uk0vEe8Q7Uj565ycgsffNX5kDRjLLDAvZRgkdTnPb261iLZSXF2zJj7CdksaEY3FeNx9hkEKfqaYo7Gqt0rxxQwpvBcqChx/Cef5/Wn6nNiKOJVZY5JY0APAxnn+VZlvKIRNI21JIyF6bfM28dfU5x+FaN/cRvcWKB8+SxlKggk8FQPzb9KPMel9CzKjbhlhvCkLxjJJyT/Km6YhTziM4+0O4I/iB/iqK6dlnREQbmboTn5cdPrUlrPH5e5GAjGGIY4IJ9vXNA7aFm7mQOI8MGI+UjjH49uOaS3LbFLbm9GAyce4qva3Mdy0gTG7d+8/2AMcfyFWbc5Z9uAoP3mGM0h7HFz6g1nbiXY8yFfPIVgTtOMgEDpjI/mO9PvdTtJdOljS2a7idiAoQFsnPBGeDgmqC6NqEdgRbXIRVkcNE67g3zHaMHjoQelZ01jPukknL2dyUOZIsGF1BGQyjlcHHt7UW7DjoUrHWr1rS8sprpJIYI3iUFyJCnYBscYHGevSumtNUs5rcBNtvtLDDEhTub+FuQfz7/WuGe1u5NcvktY47a5FvFM+zYxlHmFSy5+gz36e1dNayjTYds7I0A4ZNu459VHr+GPfmkr9TapKMtYm39rSGTYiidwP3JDBtx6Ee23FZl8tm96I7Vo5LiOPMylB1Jz8xx3wTVPULSyvIt8dmPLZci5glRZfqB06+vvxWTp8UGk3k/m+dlx524qY92RtUdODk84OOlJ9i4KHK23qa+uaTcvbySoIkhaMlirncykDKkkYrhrnT5BO8cgKsUXKSgKzElchSMjOO5/rXRazry2s0FutyghQqG25fAyPvjuBgnPFZ+m6rbXibPJaJ5t24vIAH57g9D2xxSlFM66VWpThfoZKRzfbHBR0kO0AXMXy8g8EKxAx1z39ARittdTFk/wDxMcfu9qh42BHP8Sg4OAMe5p/25IPK37HudpGHUHcA2AS4xnH51zfia+nmSSOFBCpKtIrNviU9Awx1Pzcj3qG+UtSVeSU9jo/7WTVZnSyYI+CpMueOcZUdSeOvbNVo4pVdi8luWib5A5xk7R07ZBOB161ytrPPZytNZbRMnJkkOV2kYAO0Dj2FblnFMIfLublpI3BfCKPmbPJ7kd/y9KL3ObE0FDWOw9ZFBkjuCVJbJixnJGcnPqMdqFms7a2klhV5ZyDxtwB/sjI5Hr+tIrj7K/2WF42YARh4wgfnoWzngcjvUEl3KIiuoRRtHtIG1tpU8jI98460I56dubUw5tcn2JH5UKQu/wA4D5DHngHH61NNcfbYwkYjACBiiAjaeec/SsS+R8vjAJfYG5w2fYf/AK8mr1pHJBbGNyfMOM7SCMA9D/ntUJt7m2IcPs7kV75nlb1uCsYGWU5BJPoP602yt85VRtySCT/EO1OljBcSPwiZdckY49B3P61SkvpPLd3yh24j77SeAT/hQjjbXUp+JLdWKRxyAOuS53cLzjOB6e1cVcFt7phsKec9scdq0tXunaRfMQHYVC/NkAADp35OSTWS7BmYj5QTkLnOK6qascted9EMooorQ5wooooAcEYqWAO0EAnsM1NExRij8AHPBxyPQ1CoycZH48Vb0yEXDSRB8MVyBxzj+velLYFuWYrm4tpXlilLuvIOdwHHU9uma6SS/S90iSYxosZQqwP3j8vX25rjhhZfvBSOcc4z9atW5Z4FVWQsGJ2keo6g5/H61nJaFp9DtNPcXEEcj3BVRgmInAx/e4xnB9OK0tFlH2wu0TkbnUScbQvUj1wRg9O9YOlQpBBE0i5iYkF5Wzxnp9O9bEmTcObF8y7dxKjoFHft/hz9KytqNMtW89vDqEhlmJFuxil2nGyM4IbPvwO5xXSpqX9oKsem7YIxEEWZhtccZyg7dhzXFWFs634lMaAqT5zxkliQcjcTwB1/Suo0y4gMqGBmWHYY2HZTkHnv0IH1oRupN7nQxQo9iCbmDDqAPs7BWZB2PfryfrWlaahBaKkdzDHJz/rVQlGc8+nHtnpisXSbmO2trSJIss5xK+3GRksTk/QCuhRkeQJKVIjbCIhyS57/AOTWiKTXUS7kBkeysEl82dw6wo52BW53E9ByDjHesVR9nDahPqCR3Lq0kKsS0ly27CkYyFzgjB/u56VoaqYba3juIYI5riNvMKElmkU9uOuBnj9awtIkR7q332UaStEYZJgRnhiRtXohIOMjHA96HvY7MNoro9E0S1udOgRzO5R/n8ravysxzge2TzWjaTSG2uJuGkkZ40KggkL9eB35qlZqY0jjDvvRcBMZCjr36fjRoTGe/wBQAXzPLmKoGb5EUjPzH354HqKpmNSd22y5qcqwwrEbi2M1xubZt35AUnjJ6cD696rXk9r9stxc2/nzqysJHO44PGUHUnJHQVYuJPs+Edy07EIxjUBmDKcIg7YHJ9BzUKQm+eNGIgMZxLcISX6fdU+vUEnoOnWkKDSd5GlYSGW3Pk5iiUBNwwcsOMIPXPU1Z0sPLCHuGV9rc4GEjYHnH95uOtQWNvHCn2ZSVt0LeUA3RTyQe3U8CoTdfZYmaKaMW8as5LHagOePbjGcCj1M730Rt/u7hhuOVzwD3PqT6Vl6vfPbRNNbhXRCMYP38nBOPTn8cVm28l3qNiPLnMW5CUd1/wBa3UMQMYXPbqe/pUer3ax2SWSGOS8eNpbhsYClU+8e+M9BQtBcttDYsoIptLSK6XzolTkN/E3/AOs1DAjQwzTSJuum2+WoHViMqvtgdT2wTSaTMYrK0xmV1jRmDgckjOOO+e3tzU2l20qyu93MzTbmLhDhYwT8qD1OBye/0quok2iWLzIniWKTfcl97ErgBiMMTn26D0GKsvEkdxE08nmlEPbIz94YX1IBNIULNKLRfnQgAEYDcdz6jgZqqswbzJmVmcswAA5+6VOPf+lIpO5e0+MgiM/JCYgflPJJPJJ/z0qy00e5lBAjQ4JZsAn3qDTwY7Yzn/WOiKobnGFHH50ssUbMttG24xnJB9eckn8aNCrpsxLeSR/MaK4iyX3eU5DYGMbscEE4PHbmqd7fAlmlt2ikVOWilGQCeMZAGOpwc03ULyGWaBpLJo2fKu8+0DBzjDex5/GovLs0KhpYmD/cQD5WOOAD378Z6UDRhXIacm8EMX9pRSFzIjhi6DgR4A5yO4J5yMDIrSttWttVZUtZvLuivKMm18d9oAGR3JGetaC31g8MUYx+8x5Z659ME8g/XHSuc1nQV1KOYxzIBuDpGJNpV/72cjaenck561Oq2K63G2cL215vS0IAlxJlCVU56qORkevAOao+JPEtub5LdysgV96bcYkYZGwdgT6GnW0101w1pqkU9rNECXkM/wB8A43LxgDkZAJ9ehps+h217OhjjEbZ4lXbgjOM/KcY46DFJttaHTCpBybmijrlhFd2iFIkwwHkunJjzyBIxHPbBxx+tZmj2ElgshMfmOpYPGoWQjseRwx68966qxaSx04wvHa7cHBYHbL+WccY4waQkGGCAwAiMYUhjuDdQc8H369KXLrclYicVypaFHTLaNYTNLtlXd0VAxVuflweh5H4ik1O1iuGSLaxQt5jJkAAj179+RV54Zo1Hz7SrDDMQGXGeGIGCOe4z79arLI8kfnLDtG0oIzg7WHBBPpn0FDREZu90c5qWlxJcqRGjL2BycAD25p0MR2orZIkG0RY2gdAPx46VcvZw9y32qExsw++5yoz644/lVP729oIsQbBnL4BPfb3wfX8qiyLlVk1ZsdiOVzIGhAVcgeYoZu3HPOegA549KyryFpVkVY7nB5A8/Yp/wCA8jp3IzVxZcTE4CqFCqoHDE98/pVa/dgVEbBDxkAc/T8gaTMXKxmra7UJWQ+aMbeMhP8AE1ChMaRwxDc0Y2KBj5c9Se+avSuZY8r5Ua4Kh0jxn1JJJ+meMVX097cSCNWDBeflXIPvmixN7kN/C6Rpgts24IK9/aud1B2kITl0Rs4JwD61s69rpE0ltBEHycbR3GB19s+lc3fysyuFQYAILE+3+eaLa6GdVcjszDv1zKCAFByVTOdq9qpHHarF6cyd+QD6Y4qtXVHY45O7CiiiqJCiiigAqWKRoJY5YyVdTkGoqUkkAEkgdKALUkqySSSJwhxlPQen0q3brG9u/wC4aQtkKxGeQRz+vSqEcDGEzg/u1cKxAyVz0NW7NDI3kK37tjuAXPJGf15qJbDTL1nKken3KPIYbj5nCjA384K4x/hWpaaiLu3Uys6lVbKIxCD2J78Z4FY3kMJtx3ecoD4ZchwPp7VLDFFsYRxILiQL5aqNzKc4OSeh578fSs3qWnZHVQ3ai5SM8AAbljDHgkY5P19OlaWiSxfaVEYjy+I/MfsST06D/IrC0wmNbVFkJdtyPlQdvJHI7qePfrx3OsIDI8iTRglxlAsQVGIIO0MTgDv64rO2padztNOuks77y5V+1Xaq7qZW2pjaFAb0APpkmtSOPMccTzSXMgKsxIIRc9wv1PAJJPeuIeGa1sSy7XlH3SA2VRcbgevHPfrWhBe3TWE8UZggBQGQxcP04GSTg8cnjA+tWn3LWp2pESqyu6RW0IbzJSRmVs7ccdFHT1J4HQ1V8NrNNfNKq+XETwzAbtn3QyL6n+8fw5qjo6vPcQzXCBz9/OcjcTncexPJOPXtXQ6bIiMEkuY4DgiQ9Xbk8Edv51ZXM1oamomzsLEWtiqhZX2yNu3EkDJ56sx49TV6GVLOK+leIwx5WTyf4iDhVAHqdvT1Nc4s8kHkXFtZtL5oK7ljZQmQcbS3f6dT61LO9xrF7HPqMscUEMckTwRE4jI2n5ieSd2OPTpRe2w/U27KZpjLJCq/aJJHEsuMCJRgEKT7d/xqPS4bYx287Tva2iORFHn/AFhPGfU5POOpPPSkGZ2RIx5P2yTHlKfmVNmHz+XQdMirtrChmeVFUi2KxpJnhOOT+Xf60FdBby5+0x3CTeZ9nibcypGVZsjhT7VQjtluL4yXUDtb2p2oJ33KSeS+0cDBA4z2/CpEWU2INq/mkKSEZdqHn7xPXjHHX6GprSYbrgS8COU78IcZIGcewGP500u5n6EllHPqSJFJK/2YE+c8ShTIM8LnkqDzk8HA7VR10iG8jttLiWNQrCR1UeXEjAAFv7xBBIA98mmxahayXTGRVaV0TFvtySV3A7sdv8k+jdXvofIKWsxDRx+ZKwO7aewJAwWIJwBwMYpNlLc2bdY7WN5rYmW5YBpWl5ABxhjjuePlH0rTtFZYHHmBpHy7NnOOxwPqPyrDhlEcJW6Wa0hGViRhv3dMsxAwD0wO3rUtjq2ZWhYiNEy6yMMF16jHqB0p2E0bMNwEhCQkbn3Pnuq5PzH+lVJnMUCwoozPkoh6Me5PuOTVWxuUEsyrLEzYzwcv5e4kHGMk5JGKv28bSSrKVk8wLiJOyL3PuTwD6CmK4lk73NoskcrsZUUYzgAYGTx6/wCe9W7R47ZQZOMfKR16Hj69+azbGRERoYypt4HMTMg5kfJ6ew6H/wDXV4xM9yuQBt5Az0JHf8P50D5rnOxsZsxBtsXXlAI5Rn723kBh3+UYJzVPUFmaKSOMPGkYzIURJAcf3VxkN3qkBJqECpEDZzw3TxNHLhfMVTwzY9AMZ9u9INSktboxXCbCWy8MsoYZ/hETYwwOM889qehotSk0txbwvBJbyTKAZJCxznkf6xOMtng4Gehwa27O6tpSvkwNGWyVWMgqB32jgEevcdwKzLq8iuHjmkRxHk5uArLv4+6D7HGT6iqzG3aTOn3aS+fgMjIMtIDgEHghx69/epasDk+ppX1obgh7K5RZoWLKnygA4wQwHTNc899AjSWsSC1u2J86JG+VRjmRDgg9+B+PIBp7XTRXckVzEjEkLuVAGz/dc9AeevQj0p62aRzTTJBCpEO3y4/mWQ53FiCPp7ipt2KXmSTxiG6jS/ZLKGNR9nnABRxzgMT0A7ZGecip7W5Vi8fkosYY+Zh+VYHnPseOfeuRvbP7dcp9iklWSIqjo3MbHJ/h6gYxwcVW1DUZdHNtbTurJKBbhkOSqk8kjOeCeM9jjsKSfc64UYySszrNS1uMbltjtuIyAyOCAufU8/XvXP3WpXRnazFs0ayMcllyOgH3u3PauZuSy30ubh9yAkLg5PHCnkZUnqfT16Vc0vVWaecXRe5cL5kZ3bXZh1BI/Dmp5r6bHTKiqcbRNmUFbb533lAOHYOM98Ht3/IVTM5jmcRurknkjGEGMkY9M8+1WUiiazDyOgdwWZcABc9fbFUZ0hZVhjO1M4cY25PYfT+dJnmtkdpIxt5ZJN3zuWjDDoM8fpzj3qjcTlcBChLZAbbuAGecg96uTMWkxK4kk2g8t1Pv2FV5if33AAb7pXqozx9fxpWM2zNuELuu+R5gi7in/LNQO+0cfnmoRqO4ktvkH8IC5BOO5NWG3+Y4EsjSMNrjfgOufunHUcDj6VQu3XnYvIyCOgz60hcziY16jROGCqJJMfNw23/6/t2rN1BiX2vIXwoJ54HHAP8AWtW7G6VQQWbptBxx3GawdQk2SEBkckEHb0B9M960gjnqSvqyg/XvTaUnI9/WkroMAooooAKKKKACiiigCSPOxznCdDUiEDPyqxI6AH/PvVepkKkH5T06g8j3pMEa0UiFoN4kJQAnOTjIwRz0x16eta0eyeBcoGkTBRFbGe2fTBrFgb/RoJIJnWZNwKqxyvHB47fT3rSscPMfK3FQAflOQ2eozz0OMVjIpDYMRXjthxIPMcRsD1HUcdsfWuthLSCIWE92UfBRHZQp9scnj8OtY8axNdIHTcjMSC0RBBx0/HmtOytxbiOGOWdQF3ICR83bgn8PcVJaRo22kzz3cseo3qxwMm4KuOWOOABnI4HXIzUErQabdLHErg+UQ0RAJOM7ehx7446Gn2kguZZWEq79xUKWxv77gB1H+TUbaV9puj5d6UbASOJ9rAjbyNvuSeAe+aGuxd7HT2zXc0EMstyjCMB/JX5Y0U9SzA8H2UZPbPWuzsruG1njWJwySsTE3l+UoYgZ68n9feuL0WziWxXEG0xceVI3Afjt3zW0+rLAI4mjmvL5gvlQo3O7PCjg7R6n+daR7ls3bi9jlS2jlkDyQgeVGxwPOGACc+hyfovam2CibUYbpJ51lEeFZFGzGeWCtywPryeewrjz9qh1W5uL+5ErT7YgmPlSQg8c87RntycGt278mHSo5WcvMcRvIrbWxwGCdy2OOBzu46U731BGnfXDz6ojtd28MEC/elfcCWzlQFx8hxzjrxzxVjRb03d3I7TyzhU8wboSiuhP3lHoDxk5PTHrWZLaJJBaMx2RkfaDAF++Ac7T3J6DB9D61djv0uI3vZNpvJDsigReVPOB/tHuecc0WsNvQ6S/uxa6XL56CNXUyeWvLru74/xPWuSb7frarDYXc8MVzEDPJHGXWLkjg9Nx+YcdhnPSpria8Vp98AjhgTzmLNh2JBwT2HTA/SotK8q2ilWBWG54me7yVAYpyQe4wCPQetK19CbWWhqadZDT7aU2cPlKo2kM4LvJ93G4ZzkYPzH8BWrZwuVllkgmnmfcrFuEx93aPQDFBktr+1SK3MZyufu43kEcY7dOp/WrVpdG1DRTPvfllYYO5Ox9uTg5p26Di2V4rUXjeXnD8eYq8JsPY55I4xjpx0pJ7XaqqY2cnlFiIUAD2546Zzx7VahBg3zeaqu43MxbO0ntx1HNRS3U0cjExxtJ/E5c4wCAAAAe5yfpQaK/QhWOWCZJCPPvZY9qtu2lR/dAI+UDv1qYSXjobSWNrdsfPJG+6Taf4VOMDP5+1XPtEdsyGVkNzcZVSwxzjJ/AAE1C8xhTdC+7cN5Zvfj6k8/nTJ3G28ckBUx7IolJWKAgcgHGfoOfqTWrMVjg8y7Jfbjar8Ak98cc4zVGOE+bGH3F4137skcdOo79eKls41nd5HZshztJycDA559f5fWgld2cLBLe6eIEu7YXNvtKwzu250VgTk4+Z84479hnpTLhbGQwm8kWYuQOYgEIbpjPBbPOOCMVVkuraMSpA0guTuzFw0Eg4y+equDyduDxn1qvLGhDKyGS7upBvu45cB8dNwYdRggA8UykXIr0RXrx30jyZTajXSsu2Mf3gB8xzyccnHtUMUMEzvJa+aI5G/eiAtiRNuRz0+8AfXFMAv7VWt0vC9qcHyjgyxndyVcDjkjr61OLqxhink8j94AZCqpkHGMg/wBzPOc4HfNJ+ZVtShPF5S+bAHVRiJw6/KqkY4x16+nTPNUXtblYxFCxjRThcSE85zj1Pvjt9K6hoUePEqIYnwcrjBGeAAOp/So799OZYzGiIzZKFl2nPXIPWpaNE2YloUlvIHhUQsEYM6HLhuOpGOOT1qjqehy3sSyRyySxKmMyOAAMjkN2AIBzS6nZwmZ5dMvVieLmWGNv9YvUfiOefrVOTVbyJZLfy98bDO3H3hznA7Ke/wCNQ7bM1jLl2ZzurxlbtbhS4J4KSHBwM9QfTd19+OtR6batJeiYIUnLsQg4woG0DmtU2vmW5tpImlu8YWSRhgKV4BOM4479e1WLLTiBHLG0cZTKs5J2q2R1BPIzk9OalJtmrxCa5UasYljCAHEQ+8O5wOazNR3ZQeYqlufu9f8ACqsl5NdQrHBdYd2OQikbueSO/Y81XhkVipMrzSEE7ipJbOOgxjHX8qbfY558seuoOzRopHAIwfUmqv2l2LfNu2Agnr8x7e/FPvnCNvlkBdif3e1sjn1Ix27dqrRSndiPBOMgbcYWkzBsY8DbZFkclMj5iefcVl3tx5ZSBfmcEjaBzj3/AJ1rSK6whUChiRjnOKwtTKIsiwFiScMw4+vNKxm9jKurlTIxGHkzhdwIAHc5rHmky7lQq5OeBir926CRzuxyPnAzisuQ7nY5JyScnqa3gtDnkxtFFFaEhRRRQAUUUUAFFFFABUkT7GJzjg//AFxUdFAFiKXYGAIGeOR2+tXIrtssPMyxURne2OOnBHbGKzSpU4YEHrzVywdlkyu0MRt6gcEflUyQ0dGn76NPLkeMBgQ0TMcEegNaKyK8LreieaJn3K7liM5/Q9axAImcMhzkbSrD5sHHU9ePX8K0reRkjWKPec4y/m4QcYGc81iWmb+l6japDH5SIJV+SQ7dzYDHOSen1rXn1BIrqRljVU2hSirg5/hJI4PU85rnoblLVmjkgjaJmyArFtjnggcenY1p215fTzx2sILoinG8g/J35IIIHqORQaLsapvTFKZI4/KWO3aQTNyUcAjocZzjt0PPNT2s8scNo9qVCogmE8ifNll6jB6AE8k1V0hIGWZ9ReO5nlBVXkl44yAB6nBHU5+lVYbmaDUILBxHE7FY3DqWUKPusF6cgjr3FNNrc0gnJ2RvWirLI2pXTT+UsYESJiMHIzuA6nPAGfTPFGlWV8bkzW5EnlRqEUyFvLLk5AbBy30GPTirGp6fAgUXkkty7L5UbHHbnAAxt44x7VesLpba4UWEUrxiMK4Vsg8/yAJzjsfWrtqC0EuUvpPIvJ9NSUQZLH7QCrJ/EOw9D7kd6fps93d3Mk7Wq2rSAw25YbmA/i2qAB65JPArTu7uQqkZWKeXzFHlQ5O1cjIPZccck0+wmGnWvmansjiDEMqnCgk5CjuQeoA6nNOxLYt3biSZhI8t5BcMiurncFIBG7A+8Rx7AY6VpW2ZrWK8MarMigLEWyPlPfsT976ZqSK4aa0iiiEcEyLlVySEHYsB/IGqXnRWe23aESXMh8yTJGWxgb/oTjt9AafkTc0rxLRITcTQMwC/NgjJzxgdwRx+NVToqkfanBS4chXiBJTGeV9zjvSTyoGBnkxJjCADK5YHr7gfoc1aL3bG1H2mFEyX5ByAq9TzjqR/+upsUnYt2ZaSzE/3eCy+YMAAZxkVDpluY3CyM3y75GOeZGzkHB9uce4qW0AWELM4YxtkR4+UZwVAH+TVS9v4rG+tGndkikdVO4Hk4IAyfUkfpR6midyzqLzM0EUnzmQkpuQHHI/pn86uxpA5mmkRkwACSc4x1GP1qvc30Y8ncjCYyBY44/mPI6H1pDfpcXUsccDq38ZbptPb/PPWnoJkyfJC7pI0keCwVCOR2HuKsxzSiKJIEbLAsQI8bRngY/z0rPmnsZESAsscbDadnCqgI4J7Z6dOmamlunnuJYbFsx7Vczg4UDJwq+pz1NF7EJannbQf29dRXUZ+y72OwKMg7CANw6dWz+HetOK0GqgtJHEsqoN+SSAxHVW4PbiiiqRfQ5mS+n0q+gt3/wBJglYwBJGOVA5PI6jjjjitSW4gm06XVdP82HySVZGA+YfxZ6g/jRRULqaRWqLWhO9zaQXMW1HbDbMfI3GACPp6VBNeE3EYwd4lHBO4A55+o4ooqi1uyC/EZkB8sNJkK5PAbJzg46is+N7e9uWnmtkJDLEFIBAHAH8unvRRUvcbREJLeK9uTHCUDBYkUdMgsST+famC3M4LTEEYPHXIzzn36c0UUkjO9jHk8i2uZbURAofnxj7xOfvHuaqzF4NxAA5y+1scDsOKKKyYtyvdrGZF7M4G07ecd8nPXpx+tUjGsQEkpLFsnI6nnA/pRRTehlui7bMBDcy3A3JGpYRjuevP4Vx97O8/kNJgLLHuUKMYG4/rxRRTSKmrQdjFupWkj8xjxtVFHGAAOOPpVKiit4nGxKKKKYgooooAKKKKACiiigAooooAXPrU8DAOOoBIX1788UUUmBq27zeTCE8seYCykgkgZx1zWnHKk1gJ4II4lhKkDqW5x17UUVky0b8N0tmrXMcY/cyCJV46cg8+vvVOa4e4Rrwfuo1+YBCQzhg33j+Haiik97FEtvqtxdWkktsViRWDq+BuQFQMKo+UHGORW5pssdvEt8RJLOww7Stu39xnv3/CiipvqdNL+GdTELi4hH2vY8KuGaEO20gZyPX9at20bi6isZJGVlCu8iHBZD0Xtj09gOPWiit46kM07vcb2LTbG3t0luLYy5yURRu5baAfnz3/AFqnaO0N8bhHLXQBh3nhVIPJVeR16E54zRRSF0NREksTFHbOf3p3EPtwvqRhRzz0qTTreATz3KRhppMohk+bkH7x9+v6UUULcnqWbPMl9LKFTzmlEIL5by1x29zySfpV9rANf7S4MaQ7thUbWYkAZHoOvXniiin0LloJpfmvaEuweSV2k3HjGMBR+WKfqlsrwZlYlGZYWUDru475yMlfyoopFR3GCO3sdMSZEk3ogkUb+A2SOPbkj6VNaH7LfSx53BkGAVBC4wBj6g80UUAyaNjIPMO0SkklggHzbto/rU1xZQNLCkymRHzgEYxgdeO9FFNonZn/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atypical (inverse) pityriasis rosea in an inguinal distribution. The herald patch is present in the left inguinal area.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_44_22214=[""].join("\n");
var outline_f21_44_22214=null;
var title_f21_44_22215="Mesalamine (mesalazine): Drug information";
var content_f21_44_22215=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mesalamine (mesalazine): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/34/33317?source=see_link\">",
"    see \"Mesalamine (mesalazine): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/5/27734?source=see_link\">",
"    see \"Mesalamine (mesalazine): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F193412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Apriso&trade;;",
"     </li>",
"     <li>",
"      Asacol&reg; HD;",
"     </li>",
"     <li>",
"      Asacol&reg; [DSC];",
"     </li>",
"     <li>",
"      Canasa&reg;;",
"     </li>",
"     <li>",
"      Delzicol&trade;;",
"     </li>",
"     <li>",
"      Lialda&reg;;",
"     </li>",
"     <li>",
"      Pentasa&reg;;",
"     </li>",
"     <li>",
"      Rowasa&reg;;",
"     </li>",
"     <li>",
"      sfRowasa&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F193413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      5-ASA;",
"     </li>",
"     <li>",
"      Asacol&reg;;",
"     </li>",
"     <li>",
"      Asacol&reg; 800;",
"     </li>",
"     <li>",
"      Mesasal&reg;;",
"     </li>",
"     <li>",
"      Mezavant&reg;;",
"     </li>",
"     <li>",
"      Novo-5 ASA;",
"     </li>",
"     <li>",
"      Novo-5 ASA-ECT;",
"     </li>",
"     <li>",
"      Pentasa&reg;;",
"     </li>",
"     <li>",
"      Salofalk&reg;;",
"     </li>",
"     <li>",
"      Salofalk&reg; 5-ASA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F193456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      5-Aminosalicylic Acid Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F193417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of ulcerative colitis:",
"     </b>",
"     Oral: Usual course of therapy is 3-8 weeks:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Delzicol&trade;: 800 mg 3 times daily for 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pentasa&reg;: 1 g 4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Asacol&reg;: 800 mg 3 times daily for 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Asacol&reg; HD: 1.6 g 3 times daily for 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lialda&reg;, Mezavant&reg;: 2.4-4.8 g once daily for up to 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Maintenance of remission of ulcerative colitis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Apriso&trade;: 1.5 g once daily in the morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Delzicol&trade;: 400 mg 4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pentasa&reg;: 1 g 4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Asacol&reg;: 1.6 g daily in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Lialda&reg;, Mezavant&reg;: 2.4 g once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Asacol&reg; HD is approved for treatment only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Active mild-to-moderate distal ulcerative colitis, proctosigmoiditis, or proctitis:",
"     </b>",
"     Retention enema: 60 mL (4 g) at bedtime, retained overnight, approximately 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Active ulcerative proctitis:",
"     </b>",
"     Rectal suppository (Canasa&reg;): Insert one 1000 mg suppository in rectum daily at bedtime; retained for at least 1-3 hours to achieve maximum benefit",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Duration of rectal therapy is 3-6 weeks; some patients may require rectal and oral therapy concurrently.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F193418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14637225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14637226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F193391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, controlled release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pentasa&reg;: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, delayed and extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Apriso&trade;: 0.375 g [contains phenylalanine 0.56 mg/capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, delayed release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delzicol&trade;: 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canasa&reg;: 1000 mg (30s, 42s) [contains saturated vegetable fatty esters]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, rectal: 4 g/60 mL (7s, 28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rowasa&reg;: 4 g/60 mL (7s) [contains potassium metabisulfite, sodium benzoate; packaged  with wipes]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rowasa&reg;: 4 g/60 mL (28s) [contains potassium metabisulfite, sodium benzoate; packaged with wipes]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     sfRowasa&trade;: 4 g/60 mL (7s, 28s) [contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, enteric coated, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Asacol&reg;: 400 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Asacol&reg; HD: 800 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lialda&reg;: 1.2 g",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5940153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed and extended release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mezavant&reg;: 1.2 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F193376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Rectal suspension",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F193394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsules:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Apriso&trade;: Administer with or without food; do not administer with antacids. The capsule should be swallowed whole per the manufacturer&rsquo;s labeling; however, opening the capsule and placing the contents (delayed release granules) on food with a pH &lt;6 is not expected to affect the release of mesalamine once ingested (data on file, Salix Pharmaceuticals Medical Information). There is no safety/efficacy information regarding this practice. The contents of the capsules should not be chewed or crushed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delzicol&trade;: Administer 1 hour before or 2 hours after a meal. The capsule should be swallowed whole per the manufacturer&rsquo;s labeling; do not break, chew, or crush.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pentasa&reg;: Administer with or without food. Although the manufacturer recommends swallowing the capsule whole, if a patient is unable to swallow the capsule, some clinicians support opening the capsules and placing the contents (controlled-release beads) on yogurt or peanut butter (Crohn&rsquo;s &amp; Colitis Foundation of America). There are currently no published data evaluating the safety/efficacy of this practice. The contents of the capsules should not be chewed or crushed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablets: Swallow whole; do not break, chew, or crush.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Asacol&reg;: Do not break outer coating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Asacol&reg; HD: Do not break outer coating; administer with or without food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lialda&reg;: Do not break outer coating; should be administered once daily with a meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mezavant&reg;: Do not break outer coating; should be administered once daily with a meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal enema: Shake bottle well. Retain enemas for 8 hours or as long as practical.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository: Remove foil wrapper; avoid excessive handling. Should be retained for at least 1-3 hours to achieve maximum benefit.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F193393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Asacol&reg;, Delzicol&trade;, Lialda&reg;, Mezavant&reg;, Pentasa&reg;: Treatment and maintenance of remission of mildly- to moderately-active ulcerative colitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Apriso&trade;: Maintenance of remission of ulcerative colitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Asacol&reg; HD: Treatment of moderately-active ulcerative colitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal: Treatment of active mild-to-moderate distal ulcerative colitis, proctosigmoiditis, or proctitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F193463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Mesalamine may be confused with mecamylamine, megestrol, memantine, metaxalone, methenamine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Apriso&trade; may be confused with Apri&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Asacol&reg; may be confused with Ansaid&reg;, Os-Cal&reg;, Visicol&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lialda&reg; may be confused with Aldara&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pentasa&reg; may be confused with Pancrease&reg;, Pangestyme&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F193454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects vary depending upon dosage form. Incidence usually on lower end with enema and suppository dosage forms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (2% to 35%), pain (&le;14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (1% to 18%), eructation (16%), nausea (3% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (3%), peripheral edema (3%), vasodilation (&ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (2% to 8%), fever (1% to 6%), chills (3%), malaise (2% to 3%), fatigue (&lt;3%), vertigo (&lt;3%), anxiety (&ge;2%), migraine (&ge;2%), nervousness (&ge;2%), paresthesia (&ge;2%), insomnia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Skin rash (1% to 6%), pruritus (1% to 3%), alopecia (&lt;3%), acne vulgaris (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Increased serum triglycerides (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (2% to 8%), dyspepsia (1% to 6%), flatulence (1% to 6%), constipation (5%), vomiting (1% to 5%), exacerbation of ulcerative colitis (1% to 3%), rectal hemorrhage (&lt;3%), abdominal distention (&ge;2%), gastroenteritis (&ge;2%), gastrointestinal hemorrhage (&ge;2%), abnormal stools (&ge;2%), tenesmus (&ge;2%), rectal pain (1% to 2%), hemorrhoids (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Polyuria (&ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic &amp; oncologic: Hematocrit/hemoglobin decreased (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Cholestatic hepatitis (&lt;3%), increased serum transaminases (&lt;3%), increased serum ALT (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infection: Infection (&ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Pain on insertion of enema tip (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Musculoskeletal: Back pain (1% to 7%), hypertonia (5%), arthralgia (&le;5%), myalgia (3%), weakness (&ge;2%), arthritis (2%), leg/joint pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ophthalmic: Visual disturbance (&ge;2%), conjunctivitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (&lt;3%), ear pain (&ge;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Decreased creatinine clearance (&lt;3%), hematuria (&lt;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasopharyngitis (1% to 4%), dyspnea (&lt;3%), bronchitis (&ge;2%), sinusitis (&ge;2%), cough (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like symptoms (1% to 5%), diaphoresis (3%), intolerance syndrome (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports (Limited to important or life-threatening): Abnormal T waves on ECG, agranulocytosis, albuminuria, anxiety, anemia, angioedema, aplastic anemia, bloody diarrhea, cholestatic jaundice, cholecystitis, drug fever, dysuria, edema, eosinophilia, eosinophilic pneumonitis, erythema nodosum, exacerbation of asthma, facial edema, fibrosing alveolitis, gastrointestinal bleeding, granulocytopenia, Guillain-Barre syndrome, hepatic failure, hepatic necrosis, hepatitis, hepatocellular damage, hepatotoxicity, hypersensitivity pneumonitis, hypertension, hypotension, increased blood urea nitrogen, increased gamma-glutamyl transferase, increased lactate dehydrogenase, increased serum alkaline phosphatase, increased serum bilirubin, increased serum creatinine, interstitial nephritis, interstitial pneumonitis, irregular menses, jaundice, Kawasaki-like syndrome, leukopenia, lupus-like syndrome, lymphadenopathy, minimal change nephrotic syndrome, myocarditis, nephrotoxicity, neutropenia, oligospermia, palpitations, pancreatitis, pancytopenia, paresthesia, perforated peptic ulcer, pericardial effusion, pericarditis, peripheral neuropathy, pharyngolaryngeal pain, pleurisy, pneumonitis, pyoderma gangrenosum, rectal polyp, renal disease, renal failure, skin photosensitivity, systemic lupus erythematosus, tachycardia, tenesmus, thrombocythemia, thrombocytopenia, transverse myelitis, vasodilation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F193397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mesalamine, aminosalicylates, salicylates, or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling (Mezavant&reg;): Additional contraindications: Severe renal impairment (GFR &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ); severe hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F193380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal discomfort: Pancreatitis should be considered in patients with new abdominal discomfort.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac effects: Pericarditis or myocarditis have been reported with use and should be considered in patients with chest pain. Use with caution in patients predisposed to these conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Colitis: Symptomatic worsening of colitis/IBD may occur following initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intolerance syndrome: May cause an acute intolerance syndrome (cramping, acute abdominal pain, bloody diarrhea; sometimes fever, headache, rash); discontinue if this occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oligospermia: In males, oligospermia (rare, reversible) has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfasalazine hypersensitivity: Patients with hypersensitivity to sulfasalazine may react to mesalamine; although usually well-tolerated in this population, use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal obstructive disorders: Patients with pyloric stenosis or other gastrointestinal obstructive disorders may have prolonged gastric retention of tablets, delaying the release of mesalamine in the colon.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution in patients with hepatic dysfunction; hepatic failure has been reported. Use of Mezavant&reg; (Canadian availability; not available in the U.S.) in severe impairment is contraindicated; use other mesalamine products with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peptic ulcer: Use with caution in patients with active peptic ulcers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment or a history of renal disease. Renal disease (including minimal change nephropathy, acute/chronic interstitial nephritis, nephrotic syndrome, and rarely renal failure) has been reported; use caution with other medications converted to mesalamine. An evaluation of renal function is recommended prior to initiation of mesalamine products and periodically during treatment. Use of Mezavant&reg; (Canadian availability; not available in the U.S.) in severe impairment is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; postmarketing reports suggest an increased incidence of blood dyscrasias in patients &gt;65 years of age. In addition, elderly may have difficulty administering and retaining rectal suppositories or may have decreased renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Apriso&trade;: Contains phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Canasa&reg; suppositories: Contain saturated vegetable fatty acid esters (contraindicated in patients with allergy to these components).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rowasa&reg; enema: Contains potassium metabisulfite; may cause severe hypersensitivity reactions (ie, anaphylaxis) in patients with sulfite allergies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bioequivalence: The Asacol&reg; HD 800 mg tablet has not been shown to be bioequivalent to 2 Asacol&reg; 400 mg tablets or 2 Delzicol&trade; 400 mg capsules.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F193385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products. Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: 5-ASA Derivatives may decrease the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May diminish the therapeutic effect of Mesalamine. Histamine H2-Antagonist-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products. Management: Consider avoiding concurrent administration of high-dose histamine H2-receptor antagonists with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin: 5-ASA Derivatives may enhance the adverse/toxic effect of Heparin. Specifically, the risk for bleeding/bruising may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin (Low Molecular Weight): 5-ASA Derivatives may enhance the adverse/toxic effect of Heparin (Low Molecular Weight). Specifically, the risk for bleeding/bruising may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products. Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiopurine Analogs: 5-ASA Derivatives may decrease the metabolism of Thiopurine Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varicella Virus-Containing Vaccines: 5-ASA Derivatives may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. The primary concern is the potential development of Reye's Syndrome, a condition that has been associated with the use of salicylates in children with varicella infections.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F193387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B/C (product specific)  (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5304690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies with mesalamine have not demonstrated teratogenicity or fertility impairment. Dibutyl phthalate (DBP) is an inactive ingredient in the enteric coating of Asacol&reg; and Asacol&reg; HD; adverse effects in male rats were noted at doses greater than the recommended human dose. Mesalamine is known to cross the placenta. An increased rate of congenital malformations has not been observed in human studies. Preterm birth, still birth and decreased birth weight have been observed; however, these events may also be due to maternal disease.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F193422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F193400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects (diarrhea) in a nursing infant have been reported while the mother received rectal administration of mesalamine within 12 hours after the first dose. Low concentrations of the parent drug and higher concentrations of the N-acetyl metabolite of the parent drug have been detected in human breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F193401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apriso&trade;: Take with or without food; do not administer with antacids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Asacol&reg; HD: Take with or without food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canasa&reg; rectal suppository contains saturated vegetable fatty acid esters.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F193399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Apriso Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.375 g (120): $357.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, controlled release",
"     </b>",
"     (Pentasa Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (240): $454.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (120): $454.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, delayed release",
"     </b>",
"     (Delzicol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (180): $454.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Enema",
"     </b>",
"     (Mesalamine Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 g (60 mL): $24.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Enema",
"     </b>",
"     (SfRowasa Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 g/60 mL (60 mL): $42.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Mesalamine-Cleanser Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 g (1): $171.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Rowasa Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 g (1): $343.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (Canasa Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (30): $704.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Asacol HD Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800 mg (180): $908.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, EC",
"     </b>",
"     (Lialda Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.2 g (120): $909.04",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F193389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function (prior to and periodically during therapy); CBC (particularly in elderly patients)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F193402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      5-ASA 400 (AR, PY);",
"     </li>",
"     <li>",
"      Asacol (BE, CH, DK, FI, GB, GR, IL, IT, LU, MX, NL, NO, NZ, PK, PT, SE, SG, TW);",
"     </li>",
"     <li>",
"      Asacol DR (KP);",
"     </li>",
"     <li>",
"      Asacol Enema (KP);",
"     </li>",
"     <li>",
"      Asacolon (CO, IE);",
"     </li>",
"     <li>",
"      Asalit (BR);",
"     </li>",
"     <li>",
"      Canasa (CO);",
"     </li>",
"     <li>",
"      Claversal (AT, BE, DE, ES, IT, LU, PT);",
"     </li>",
"     <li>",
"      Colitofalk (BE, LU);",
"     </li>",
"     <li>",
"      Coloncure (TW);",
"     </li>",
"     <li>",
"      Huma-Col-Asa (HU);",
"     </li>",
"     <li>",
"      Mesacol (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Mesalin (KP);",
"     </li>",
"     <li>",
"      Mesasal (AU, DK, NO, ZA);",
"     </li>",
"     <li>",
"      Mesren MR (GB);",
"     </li>",
"     <li>",
"      Mezavant XL (GB);",
"     </li>",
"     <li>",
"      Octasa (GB);",
"     </li>",
"     <li>",
"      Pentasa (AE, AU, BE, BH, CH, CL, CY, DK, EG, FR, GB, HK, HU, IQ, IR, JO, KW, LB, LU, LY, MY, NL, NO, OM, PH, QA, RU, SA, SE, SY, TH, TW, YE);",
"     </li>",
"     <li>",
"      Pentasa Enema (NZ);",
"     </li>",
"     <li>",
"      Pentasa SR (AE, BH, CY, EG, IL, IQ, IR, JO, KP, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Pentasa Tab (NZ);",
"     </li>",
"     <li>",
"      Salofalk (AT, AU, BG, CH, CL, CN, CO, CR, CZ, DE, EE, GB, GT, HK, HN, HR, HU, ID, IE, KP, MY, NL, PA, PE, PH, PL, SG, SV, TH, TR, UY);",
"     </li>",
"     <li>",
"      Salofalk Foam Enema (AU);",
"     </li>",
"     <li>",
"      Suprimal (EC)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F193379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Mesalamine (5-aminosalicylic acid) is the active component of sulfasalazine; the specific mechanism of action of mesalamine is unknown; however, it is thought that it modulates local chemical mediators of the inflammatory response, especially leukotrienes, and is also postulated to be a free radical scavenger or an inhibitor of tumor necrosis factor (TNF); action appears topical rather than systemic",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F193396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rectal: Variable and dependent upon retention time, underlying GI disease, and colonic pH; Oral: Tablet: ~20% to 28%, Capsule: ~20% to 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: ~18 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Mesalamine (5-ASA): ~43%; N-acetyl-5-ASA: ~78%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic and via GI tract to N-acetyl-5-aminosalicylic acid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 5-ASA: 0.5-10 hours; N-acetyl-5-ASA: 2-15 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule: Apriso&trade;: ~4 hours; Delzicol&trade;: 4-16 hours; Pentasa&reg;: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal: 4-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet: Asacol&reg;: 4-12 hours; Asacol&reg; HD: 10-16 hours; Lialda&reg;: 9-12 hours; Mezavant&reg;: 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily as metabolites, &lt;8% as unchanged drug); feces (&lt;2%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/44/22215/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crohn&rsquo;s &amp; Colitis Foundation of America (CCFA). Available at  file://www.ccfa.org/info/treatment/kidsmeds",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grand RJ, Ramakrishna J, and Calenda KA, &ldquo;Inflammatory Bowel Disease in the Pediatric Patient,&rdquo;",
"      <i>",
"       Gastroenterol Clin North Am",
"      </i>",
"      , 1995, 24(3):613-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/44/22215/abstract-text/8809239/pubmed\" id=\"8809239\" target=\"_blank\">",
"        8809239",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kamm MA, Sandborn WJ, Gassull M, et al, &ldquo;Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2007, 132(1):66-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/44/22215/abstract-text/17241860/pubmed\" id=\"17241860\" target=\"_blank\">",
"        17241860",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kornbluth A and Sachar DB, &ldquo;Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2010, 105(3):501-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/44/22215/abstract-text/20068560/pubmed\" id=\"20068560\" target=\"_blank\">",
"        20068560",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lichtenstein GR, Hanauer SB, and Sandborn WJ, &ldquo;Management of Crohn's Disease in Adults,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 104(2):465-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/44/22215/abstract-text/19174807/pubmed\" id=\"19174807\" target=\"_blank\">",
"        19174807",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9614 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-869C284B9E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_44_22215=[""].join("\n");
var outline_f21_44_22215=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193412\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193413\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193456\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193417\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193418\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14637225\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14637226\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193391\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5940153\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193376\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193394\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193393\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193463\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193454\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193397\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193380\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299675\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193385\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193387\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5304690\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193422\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193400\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193401\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193399\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193389\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193402\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193379\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F193396\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9614\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9614|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/34/33317?source=related_link\">",
"      Mesalamine (mesalazine): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/5/27734?source=related_link\">",
"      Mesalamine (mesalazine): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_44_22216="Treatment of recurrent virus-induced wheezing in young children";
var content_f21_44_22216=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of recurrent virus-induced wheezing in young children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/44/22216/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/44/22216/contributors\">",
"     Sujani Kakumanu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/44/22216/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/44/22216/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/44/22216/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/44/22216/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/44/22216/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/44/22216/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wheezing episodes in early childhood are common, heterogeneous disorders with significant morbidity. Viruses are widely recognized as common triggers of early childhood wheezing, both in children with recurrent wheezing with multiple triggers as well as those with episodic exacerbations whose predominant trigger of wheezing is viral infections. In fact, a viral cause was detected in 90 percent of wheezing illnesses in a birth cohort of children at increased risk of developing asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/1\">",
"     1",
"    </a>",
"    ]. Early childhood wheezing encompasses many clinical phenotypes and responses to treatment are variable. Instituting or escalating current asthma therapies are effective in controlling viral-induced wheezing symptoms in some patients. However, the evidence for this approach is not definitive in controlled studies, particularly in patients with intermittent symptoms.",
"   </p>",
"   <p>",
"    The optimal management for acute episodes of virus-induced wheezing in infants and preschool children has yet to be determined [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/2\">",
"     2",
"    </a>",
"    ]. Therapeutic trials in this young population are hampered by the inability to predict clinical phenotypes, such as children who will outgrow their symptoms, children who will later develop asthma, and children who have bronchiolitis, a condition for which glucocorticoids generally are not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/19/27962?source=see_link\">",
"     \"Bronchiolitis in infants and children: Treatment; outcome; and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic reviews the treatment of young children with recurrent virus-induced wheezing, defined as a minimum of three to four wheezing exacerbations a year [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/3\">",
"     3",
"    </a>",
"    ]. Treatment of bronchiolitis in infants and virus-induced asthma exacerbations in children and adults are discussed separately. The mechanisms by which viral respiratory infections cause wheezing and asthma exacerbations, and the influence of viral infection on both the development and perpetuation of asthma are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/19/27962?source=see_link\">",
"     \"Bronchiolitis in infants and children: Treatment; outcome; and prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2298?source=see_link\">",
"     \"Virus-induced wheezing and asthma: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPISODIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virus-induced wheezing is a heterogeneous disorder and response to treatment may differ among individuals. Inhaled short-acting beta 2 agonists are commonly used for symptomatic relief. Combination therapy with hypertonic saline and a bronchodilator are under investigation for treatment of acute symptoms. Inhaled and systemic glucocorticoids and leukotriene receptor antagonists have been studied for the treatment and prevention of acute episodes of virus-induced wheezing in young children who require additional therapy. Treatment of asthma, both for acute exacerbations and prevention of symptoms, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39670?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Quick-relief agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Controller medications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link\">",
"     \"Acute asthma exacerbations in children: Outpatient management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/23/11642?source=see_link\">",
"     \"Acute asthma exacerbations in children: Inpatient management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=see_link\">",
"     \"Acute severe asthma exacerbations in children: Intensive care unit management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Inhaled short-acting beta agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled bronchodilators are often first-line therapy for treatment of virus-induced wheezing and are an effective rescue treatment in symptomatic patients, especially in children with established asthma (",
"    <a class=\"graphic graphic_table graphicRef53629 \" href=\"UTD.htm?43/21/44379\">",
"     table 1",
"    </a>",
"    ). However, inhaled short-acting bronchodilators have not been shown to improve clinical outcomes, decrease the rate of hospital admission, or decrease the duration of hospitalization in children with bronchiolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39670?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Quick-relief agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link&amp;anchor=H22#H22\">",
"     \"Acute asthma exacerbations in children: Outpatient management\", section on 'Dosing and administration'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute asthma exacerbations in children: Outpatient management\", section on 'Overview of treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/19/27962?source=see_link&amp;anchor=H14#H14\">",
"     \"Bronchiolitis in infants and children: Treatment; outcome; and prevention\", section on 'Inhaled bronchodilators'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2255738\">",
"    <span class=\"h3\">",
"     Inhaled hypertonic saline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that hypertonic saline in combination with a short-acting beta agonist may be effective in treating young children with acute episodes of virus-induced wheezing. Similar limited findings have been reported for the treatment of bronchiolitis. Further study is needed before this treatment can be recommended for clinical use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/19/27962?source=see_link&amp;anchor=H403690771#H403690771\">",
"     \"Bronchiolitis in infants and children: Treatment; outcome; and prevention\", section on 'Hypertonic saline'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of inhaled hypertonic saline for the treatment of lower respiratory tract disease is based upon the hypothesis that viral infection, particularly with rhinovirus, leads to dehydration of the airway surface liquid and impaired mucus clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. In one small trial, 41 children aged one to six years (mean age 31.9 months) who presented to the emergency department with wheezing were randomly assigned to treatment with nebulized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    in 5% hypertonic saline (HS) or in 0.9% normal saline (NS) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/8\">",
"     8",
"    </a>",
"    ]. The majority of the children tested positive for at least one respiratory virus, most commonly rhinovirus. Length of stay and the rate of hospitalization were significantly lower in the HS group than the NS group. However, the small number of subjects and events limit the ability to draw conclusions about the efficacy of this therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intermittent inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of intermittent inhaled glucocorticoids on the prevention or attenuation of virus-induced wheezing in young children has been examined in several randomized trials and a systematic review [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/3,9-16\">",
"     3,9-16",
"    </a>",
"    ]. These studies are difficult to compare because of differences in dose of inhaled glucocorticoid used, timing of when the medication is started in relation to the upper respiratory tract infection (URI), and primary outcome measured [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall these studies suggest that",
"    <strong>",
"     intermittent",
"    </strong>",
"    <strong>",
"     high",
"    </strong>",
"    -dose inhaled glucocorticoids (",
"    <a class=\"graphic graphic_table graphicRef68517 \" href=\"UTD.htm?26/18/26925\">",
"     table 2",
"    </a>",
"    ), started at the onset of a URI and continued for up to 10 days, may decrease asthma-type symptoms and rescue oral glucocorticoid use in preschool children with viral-associated wheezing. This approach may be particularly effective in patients with asthma risk factors. However, there may be slight deficits in growth in some children, although the data are limited. It is unclear if intermittent high-dose inhaled glucocorticoids are effective if started after the onset of wheezing in the setting of a URI.",
"    <strong>",
"     Intermittent",
"    </strong>",
"    use of",
"    <strong>",
"     standard",
"    </strong>",
"    (low to medium) doses of inhaled glucocorticoids (",
"    <a class=\"graphic graphic_table graphicRef68517 \" href=\"UTD.htm?26/18/26925\">",
"     table 2",
"    </a>",
"    ) does not appear to be effective in this population, particularly when started after the onset of lower respiratory tract symptoms. Standard daily doses of inhaled glucocorticoids are effective in preventing episodic virus-induced wheezing in young children, as discussed below. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Daily inhaled glucocorticoids'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following randomized trials of intermittent therapy are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      propionate (750 mcg twice daily), administered as three inhalations of a 250 mcg Flovent HFA inhaler (GlaxoSmithKline), was started at the onset of an upper respiratory tract infection (URI) and continued for up to ten days in a trial of 129 children aged one to six years with recurrent virus-induced wheezing [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/13\">",
"       13",
"      </a>",
"      ]. Treatment with high-dose fluticasone decreased the use of rescue oral glucocorticoids compared with placebo (8 versus 18 percent of URIs required such rescue treatment, respectively). However, smaller gains in height and weight were seen in the treatment group (-0.33 cm and -0.64 kg) compared with placebo over the 6 to 12 month study period. Further study is needed to investigate the long term effects of this treatment. The only formulation available in the United that delivers this exact dose is a dry powder inhaler, Flovent Diskus 250 mcg (GlaxoSmithKline), but a 250 mcg HFA inhaler is available in other countries.",
"     </li>",
"     <li>",
"      Episodic use of high-dose inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      (1 mg twice daily for seven days, started early in the course of an upper respiratory tract infection at the onset of a set of symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      signs individual to each child that typically preceded the onset of wheezing) was as effective as chronic daily budesonide (0.5 mg nightly) with respect to frequency of exacerbations requiring oral glucocorticoid therapy in a trial of 278 children aged 12 to 53 months with recurrent wheezing and a positive asthma predictive index [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/3\">",
"       3",
"      </a>",
"      ]. There were also no significant differences between the two groups in bronchodilator use, episode-free days, or severity of symptoms during respiratory tract illnesses. Furthermore, treatment with intermittent high-dose budesonide resulted in a lower cumulative exposure to budesonide as compared to daily budesonide therapy.",
"     </li>",
"     <li>",
"      An earlier systematic review identified three trials of preschool children with recurrent wheeze given episodic high-dose inhaled glucocorticoids for 5 to 10 days for exacerbations in the setting of viral illnesses [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/9-11,16\">",
"       9-11,16",
"      </a>",
"      ]. Two of these studies showed a reduced requirement for oral glucocorticoids (RR = 0.53, 95% CI 0.27-1.04), and all showed modest decreases in symptom scores.",
"     </li>",
"     <li>",
"      In contrast, another trial using high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      (1 mg twice daily) at the start of a URI did not find any difference in rescue oral glucocorticoid use compared with intermittent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      or placebo in 238 children one to six years of age with moderate-to-severe intermittent wheezing [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/15\">",
"       15",
"      </a>",
"      ]. There was also no difference in the proportion of episode-free days. Symptom scores for trouble breathing and interference with activity were moderately decreased in the treatment groups compared with placebo, particularly during the first few days of treatment.",
"     </li>",
"     <li>",
"      There was no difference in the percentage of symptom-free days in a trial of 276 children one to four years of age with frequent wheezing (defined as requiring rescue medication on at least seven days in a two week period) treated with a high-dose inhaled",
"      <span class=\"nowrap\">",
"       glucocorticoid/short-acting",
"      </span>",
"      beta agonist (SABA) combination as needed for respiratory symptoms compared with a SABA alone [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There was also no difference in the proportion of symptom-free days, percentage of children with persistent wheezing, or mean duration of acute episodes in a trial of 411 one-month old infants randomized to two-week courses of standard dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      (400 mcg per day, delivered by pressurized metered dose inhaler with a spacer and mask) or placebo that were started after a three-day episode of wheezing [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/14\">",
"       14",
"      </a>",
"      ]. Formulations that can deliver this exact dose of budesonide are not available in the United States (budesonide is available as a dry powder inhaler, the Pulmicort Flexhaler [Astra-Zeneca], at 90 and 180 mcg doses and as Pulmicort respules for nebulization at 0.25, 0.5, and 1 mg doses).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data are mixed regarding the use of oral glucocorticoids to treat virus-induced wheezing in preschoolers, although overall this approach does not appear to be effective in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. However, an alternative strategy of initiating oral glucocorticoids at the earliest signs of a viral URI, rather than waiting until the onset of wheezing, in preschool children with recurrent wheezing may be effective in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following studies are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter trial, 700 preschool children (10 to 60 months of age) with acute virus-induced wheezing were randomly assigned to five days of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/20\">",
"       20",
"      </a>",
"      ]. Thirty-eight percent of the study population had no previous episodes of wheezing, 34 percent had one to three episodes, and 28 percent had four or more. Treatment with prednisolone did not shorten hospital stay, reduce",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      use, or improve symptom scores (although the baseline assessment was performed after initial albuterol administration). A seven-day post-hospitalization symptom score and readmission rate for both treatment groups was also the same. The lack of benefit of prednisolone was also noted in a subgroup analysis of 124 children at high risk for atopic asthma (history of &ge;4 wheezing episodes and a parent with asthma, or clinician diagnosed eczema).",
"     </li>",
"     <li>",
"      One open, unblinded study examined the effect of preventive intervention with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      for virus-induced wheezing episodes of asthma in preschool children [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/23\">",
"       23",
"      </a>",
"      ]. In this study, 32 children were identified early in life for wheezing with viral respiratory infections. There were two observation periods. During the first period, conventional therapy was given and the characteristics of the patient's response to a viral infection defined. During the second year, one group of patients received conventional therapy for wheezing episodes associated with a respiratory infection and one received prednisone (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) at the first sign of a URI, prior to any signs of wheezing, in addition to conventional therapy. The prednisone-treated children had significantly fewer days with wheezing, emergency department visits, and hospitalizations. These observations suggest that early intervention with systemic glucocorticoids can reduce the symptoms of virus-induced exacerbations, although confirmation of these findings in randomized trials is needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The question of whether glucocorticoids are beneficial in subgroups of patients (eg, those with recurrent episodes of virus-induced wheezing, atopic features, family history of asthma) remains unanswered. Results from one subgroup analysis suggest that the response to systemic glucocorticoids during wheezing episodes requiring hospitalization may differ based upon the type of virus detected [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/19\">",
"     19",
"    </a>",
"    ]. Additional studies are necessary to better define the characteristics of children who wheeze severely, but intermittently, and do or do not respond to oral glucocorticoid therapy. How glucocorticoid responsiveness relates to preschool children who will outgrow their asthma-like symptoms and those who will have asthma diagnosed later also needs to be studied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7383?source=see_link&amp;anchor=H3#H3\">",
"     \"Natural history of asthma\", section on 'Wheezing during the first six years'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/23/11642?source=see_link\">",
"     \"Acute asthma exacerbations in children: Inpatient management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link\">",
"     \"Acute asthma exacerbations in children: Outpatient management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of systemic glucocorticoids in the treatment of bronchiolitis is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=see_link\">",
"     \"Bronchiolitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/19/27962?source=see_link&amp;anchor=H19511330#H19511330\">",
"     \"Bronchiolitis in infants and children: Treatment; outcome; and prevention\", section on 'Systemic glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Intermittent leukotriene receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few studies have examined the intermittent use of leukotriene receptor antagonists (LTRAs) in preschool children with recurrent wheezing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/15,24\">",
"     15,24",
"    </a>",
"    ]. The results are mixed and further study is needed.",
"   </p>",
"   <p>",
"    In one of the studies previously discussed, 238 children one to five years of age with a history of recurrent wheezing with URIs were randomized to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    (1 mg twice daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    (4 mg daily), or placebo for seven days, started at the first sign of a respiratory tract infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/15\">",
"     15",
"    </a>",
"    ]. Measures of severity of acute illness were decreased in the treatment groups compared with placebo, but there was no difference in the proportion of episode-free days or rescue oral glucocorticoid use over the 12-month study period. A similar randomized trial that included older children as well (2 to 14 years of age) found a modest reduction in unscheduled visits, symptoms, days off from",
"    <span class=\"nowrap\">",
"     school/child",
"    </span>",
"    care, and parental time off from work in the montelukast group compared with placebo, but did not show a significant difference in rescue medication use or hospitalizations. Another randomized trial found no change in the number of asthma episodes in children ages six months to five years who were treated with intermittent montelukast begun at the onset of viral symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other intermittent interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts to develop antiviral agents for rhinoviruses are of obvious interest. However, because of the many serologic types of these viruses, a single \"vaccine\" is impractical.",
"   </p>",
"   <p>",
"    Novel approaches to therapy have arisen as knowledge of the mechanisms by which rhinovirus attaches to cells has become apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. As an example, capsid-binding agents and soluble ICAM-1 (intercellular adhesion molecule 1) can prevent viral binding, or encoating. Whether this approach is effective in preventing the production of symptomatic asthma by colds requires further study.",
"   </p>",
"   <p>",
"    An alternative approach to preventing viral URIs is treatment with an immunostimulant derived from eight bacterial upper respiratory tract pathogens called OM-85 BV. In a randomized trial of 75 children one to six years of age with recurrent wheezing, there was a decrease in the rate (38 percent reduction) and duration (two days shorter) of wheezing episodes in the group treated with OM-85 BV (one capsule daily for ten days each month for three months) compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/31\">",
"     31",
"    </a>",
"    ]. However, this study did not evaluate the efficacy of OM-85BV compared with traditional asthma therapies or inhalers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DAILY THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative approach to prevention of virus-induced wheezing is continuous, rather than episodic, therapy. Indications for chronic controller therapy in children with asthma, including children under four years of age, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Controller medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Daily inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard doses of inhaled glucocorticoids given daily are effective in preventing episodic virus-induced wheezing in young children, particularly in patients with a clinical diagnosis of asthma or asthma risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. This has been demonstrated in a number of randomized trials and a meta-analysis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis examined the efficacy of inhaled glucocorticoids in infants and preschoolers with recurrent wheezing and asthma symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/32\">",
"       32",
"      </a>",
"      ]. Patients who received daily inhaled glucocorticoid therapy had significantly fewer",
"      <span class=\"nowrap\">",
"       wheezing/asthma",
"      </span>",
"      exacerbations compared with placebo (18 versus 32 percent, RR 0.59, 95% CI 0.52-0.67), based upon data from 16 randomized trials. The effect of inhaled glucocorticoids on reducing wheezing exacerbations was most pronounced in patients with a diagnosis of asthma, but was independent of atopy and age (infants versus preschoolers). Patients on daily therapy also did better in all secondary outcomes measured, including a lower rate of study withdrawal because of exacerbations, and decreased symptom scores and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      use.",
"     </li>",
"     <li>",
"      In a subsequently published randomized trial discussed previously, 276 children one to four years of age with frequent wheeze were randomized to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"       beclomethasone",
"      </a>",
"      400 mcg twice daily for three months plus salbutamol as needed, placebo twice daily plus",
"      <span class=\"nowrap\">",
"       beclomethasone/salbutamol",
"      </span>",
"      combination as needed, or placebo twice daily plus salbutamol as needed [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/12\">",
"       12",
"      </a>",
"      ]. There was a modest increase in the percentage of symptom-free days in the group on daily inhaled glucocorticoid therapy compared with",
"      <span class=\"nowrap\">",
"       placebo/prn",
"      </span>",
"      salbutamol. Time to first exacerbation was also longer in the regular beclomethasone group compared with the other groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data on the effect of daily inhaled glucocorticoid therapy on linear growth velocity in this age group are mixed, although the majority of studies show minimal to no effect [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/33-40\">",
"     33-40",
"    </a>",
"    ]. Results from one study suggest that younger (&lt;3 years old), smaller preschoolers are at greater risk for growth effects [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/34\">",
"     34",
"    </a>",
"    ]. Further studies are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Daily leukotriene receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukotriene receptor antagonists, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    may be helpful in preventing virus-induced asthma exacerbations. Montelukast was studied in a randomized trial of 549 children aged two to five years of age with intermittent asthma symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/41\">",
"     41",
"    </a>",
"    ]. Over 12 months of treatment, montelukast decreased the average rate of exacerbations by 32 percent and the time to first exacerbations by two months compared with placebo. However, the need for systemic corticosteroids was not significantly different between treatment groups and the exacerbations studied were not exclusively limited to virus-induced asthma exacerbations.",
"   </p>",
"   <p>",
"    Another study investigated the effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    4 or 5 mg orally versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    inhalation 0.5 mg once daily in children two to eight years old with mild asthma or recurrent wheezing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/42\">",
"     42",
"    </a>",
"    ]. Subjects were given additional asthma medications, either twice daily inhaled budesonide or oral glucocorticoids, for increased asthma symptoms. No significant difference was found between groups for time to first supplemental asthma medication use over a 52 week period, the primary outcome of the study. However exacerbations rates were lower in the budesonide group versus the montelukast group. This study was not limited to children who suffered from intermittent wheezing episodes or virus-induced asthma exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22216/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The optimal management for acute episodes of virus-induced wheezing in infants and preschool children has yet to be determined, in part because of the heterogeneity of wheezing phenotypes. The specific therapy for each patient needs to be individualized based upon the severity of symptoms and prior responses to available treatments. Treatment of young infants and children with their first episode of wheezing (eg, bronchiolitis) and therapy for children with established asthma are discussed separately. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/19/27962?source=see_link\">",
"       \"Bronchiolitis in infants and children: Treatment; outcome; and prevention\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39670?source=see_link\">",
"       \"Chronic asthma in children younger than 12 years: Quick-relief agents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"       \"Chronic asthma in children younger than 12 years: Controller medications\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link\">",
"       \"Acute asthma exacerbations in children: Outpatient management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inhaled short-acting beta agonists are effective for rescue treatment of acute asthma symptoms in patients with recurrent episodes of virus-induced wheezing. However, these agents do not appear to be effective treatment for bronchiolitis. There is insufficient evidence to suggest that nebulized beta agonists be given in hypertonic (5%) saline rather than normal saline. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Inhaled short-acting beta agonists'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2255738\">",
"       'Inhaled hypertonic saline'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intermittent high-dose inhaled glucocorticoids started at the onset of an upper respiratory tract infection (URI) and continued for 7 to 10 days may decrease asthma-type symptoms and oral glucocorticoid use in preschool children with viral-associated wheezing. However, this therapy may result in slight deficits in growth in some children. It is unclear if intermittent high-dose inhaled glucocorticoids are effective if started after the onset of wheezing in the setting of a URI. Intermittent use of standard doses of inhaled glucocorticoids does not appear to be effective in this population, particularly when started after the onset of lower respiratory tract symptoms. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Intermittent inhaled glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The data are mixed regarding use of intermittent, systemic glucocorticoids to treat virus-induced wheezing in preschoolers, although overall this approach does not appear to be effective in most patients. However, an alternative strategy of initiating systemic glucocorticoids at the earliest signs of a viral URI, rather than waiting until the onset of wheezing, in preschool children with recurrent wheezing may be effective in some children. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Limited data suggest that either intermittent or daily treatment with leukotriene receptor antagonists, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      may be helpful in reducing symptoms associated with virus-induced wheezing. Further studies are needed. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Intermittent leukotriene receptor antagonists'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Daily leukotriene receptor antagonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For",
"      <strong>",
"       treatment",
"      </strong>",
"      of acute virus-induced wheezing symptoms in young children with recurrent episodes (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Episodic therapy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest an inhaled short-acting beta agonist (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      via nebulizer (in normal saline) or metered dose inhaler with spacer (",
"      <a class=\"graphic graphic_table graphicRef53629 \" href=\"UTD.htm?43/21/44379\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest",
"      <strong>",
"       not",
"      </strong>",
"      using inhaled glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest",
"      <strong>",
"       not",
"      </strong>",
"      using an oral glucocorticoid (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). One exception is patients with severe acute wheezing symptoms and risk factors for persistent asthma (assessed by positive modified asthma predictive indices), particularly in those who have responded to oral glucocorticoids for prior wheezing exacerbations or those who are already on daily inhaled glucocorticoids for persistent symptoms or frequent exacerbations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the",
"      <strong>",
"       prevention",
"      </strong>",
"      of virus-induced wheezing in preschool children who suffer from recurrent virus-induced wheezing episodes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest intermittent high-dose inhaled glucocorticoids (",
"      <a class=\"graphic graphic_table graphicRef68517 \" href=\"UTD.htm?26/18/26925\">",
"       table 2",
"      </a>",
"      ), begun at the onset of a URI, before wheezing has occurred, and continued for up to 10 days (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"       Fluticasone",
"      </a>",
"      propionate 750 mcg inhaled twice daily and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      1 mg nebulized twice daily have both been studied in the prevention of virus-inducing wheezing in preschool children. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Episodic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <strong>",
"       not",
"      </strong>",
"      using an oral glucocorticoid at the onset of a URI before wheezing has occurred (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Exceptions include patients with a prior history of a severe virus-induced wheezing exacerbation requiring hospitalization, patients with asthma risk factors who are currently on daily inhaled glucocorticoids for frequent exacerbations, or those who have not responded to high-dose intermittent inhaled glucocorticoids in the past. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend daily inhaled glucocorticoids at standard doses in children who continue to experience severe or recurrent episodes of wheezing despite intermittent high-dose inhaled glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). This approach may also be considered prior to a trial of intermittent high-dose glucocorticoids in patients with a history of severe wheezing exacerbations requiring hospitalizations or those requiring frequent courses of oral systemic glucocorticoids. This therapy may result in modest declines of growth velocity. Intermittent or daily",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      is an alternative, especially for patients who do not tolerate daily inhaled glucocorticoids. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Daily therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Intermittent leukotriene receptor antagonists'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"       \"Chronic asthma in children younger than 12 years: Controller medications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/1\">",
"      Jackson DJ, Gangnon RE, Evans MD, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med 2008; 178:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/2\">",
"      Brand PL, Baraldi E, Bisgaard H, et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J 2008; 32:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/3\">",
"      Zeiger RS, Mauger D, Bacharier LB, et al. Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med 2011; 365:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/4\">",
"      Gadomski AM, Bhasale AL. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev 2006; :CD001266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/5\">",
"      Daviskas E, Anderson SD. Hyperosmolar agents and clearance of mucus in the diseased airway. J Aerosol Med 2006; 19:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/6\">",
"      Randell SH, Boucher RC, University of North Carolina Virtual Lung Group. Effective mucus clearance is essential for respiratory health. Am J Respir Cell Mol Biol 2006; 35:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/7\">",
"      Mandelberg A, Amirav I. Hypertonic saline or high volume normal saline for viral bronchiolitis: mechanisms and rationale. Pediatr Pulmonol 2010; 45:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/8\">",
"      Ater D, Shai H, Bar BE, et al. Hypertonic saline and acute wheezing in preschool children. Pediatrics 2012; 129:e1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/9\">",
"      Connett G, Lenney W. Prevention of viral induced asthma attacks using inhaled budesonide. Arch Dis Child 1993; 68:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/10\">",
"      Wilson NM, Silverman M. Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroids at home. Arch Dis Child 1990; 65:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/11\">",
"      McKean M, Ducharme F. Inhaled steroids for episodic viral wheeze of childhood. Cochrane Database Syst Rev 2000; :CD001107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/12\">",
"      Papi A, Nicolini G, Baraldi E, et al. Regular vs prn nebulized treatment in wheeze preschool children. Allergy 2009; 64:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/13\">",
"      Ducharme FM, Lemire C, Noya FJ, et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. N Engl J Med 2009; 360:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/14\">",
"      Bisgaard H, Hermansen MN, Loland L, et al. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 2006; 354:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/15\">",
"      Bacharier LB, Phillips BR, Zeiger RS, et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J Allergy Clin Immunol 2008; 122:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/16\">",
"      Svedmyr J, Nyberg E, Thunqvist P, et al. Prophylactic intermittent treatment with inhaled corticosteroids of asthma exacerbations due to airway infections in toddlers. Acta Paediatr 1999; 88:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/17\">",
"      Bacharier LB. Viral-induced wheezing episodes in preschool children: approaches to therapy. Curr Opin Pulm Med 2010; 16:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/18\">",
"      Vuillermin P, South M, Robertson C. Parent-initiated oral corticosteroid therapy for intermittent wheezing illnesses in children. Cochrane Database Syst Rev 2006; :CD005311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/19\">",
"      Jartti T, Lehtinen P, Vanto T, et al. Efficacy of prednisolone in children hospitalized for recurrent wheezing. Pediatr Allergy Immunol 2007; 18:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/20\">",
"      Panickar J, Lakhanpaul M, Lambert PC, et al. Oral prednisolone for preschool children with acute virus-induced wheezing. N Engl J Med 2009; 360:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/21\">",
"      Csonka P, Kaila M, Laippala P, et al. Oral prednisolone in the acute management of children age 6 to 35 months with viral respiratory infection-induced lower airway disease: a randomized, placebo-controlled trial. J Pediatr 2003; 143:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/22\">",
"      Oommen A, Lambert PC, Grigg J. Efficacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial. Lancet 2003; 362:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/23\">",
"      Brunette MG, Lands L, Thibodeau LP. Childhood asthma: prevention of attacks with short-term corticosteroid treatment of upper respiratory tract infection. Pediatrics 1988; 81:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/24\">",
"      Robertson CF, Price D, Henry R, et al. Short-course montelukast for intermittent asthma in children: a randomized controlled trial. Am J Respir Crit Care Med 2007; 175:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/25\">",
"      Valovirta E, Boza ML, Robertson CF, et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Ann Allergy Asthma Immunol 2011; 106:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/26\">",
"      Hayden FG, Albrecht JK, Kaiser DL, Gwaltney JM Jr. Prevention of natural colds by contact prophylaxis with intranasal alpha 2-interferon. N Engl J Med 1986; 314:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/27\">",
"      Huguenel ED, Cohn D, Dockum DP, et al. Prevention of rhinovirus infection in chimpanzees by soluble intercellular adhesion molecule-1. Am J Respir Crit Care Med 1997; 155:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/28\">",
"      Turner RB, Dutko FJ, Goldstein NH, et al. Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection. Antimicrob Agents Chemother 1993; 37:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/29\">",
"      Hayden FG, Hipskind GJ, Woerner DH, et al. Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob Agents Chemother 1995; 39:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/30\">",
"      Rosenwirth B, Kis ZL, Eggers HJ. In vivo efficacy of SDZ 35-682, a new picornavirus capsid-binding agent. Antiviral Res 1995; 26:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/31\">",
"      Razi CH, Harmanc K, Abac A, et al. The immunostimulant OM-85 BV prevents wheezing attacks in preschool children. J Allergy Clin Immunol 2010; 126:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/32\">",
"      Castro-Rodriguez JA, Rodrigo GJ. Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysis. Pediatrics 2009; 123:e519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/33\">",
"      Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006; 354:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/34\">",
"      Guilbert TW, Mauger DT, Allen DB, et al. Growth of preschool children at high risk for asthma 2 years after discontinuation of fluticasone. J Allergy Clin Immunol 2011; 128:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/35\">",
"      Brand PL, Luz Garc&iacute;a-Garc&iacute;a M, Morison A, et al. Ciclesonide in wheezy preschool children with a positive asthma predictive index or atopy. Respir Med 2011; 105:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/36\">",
"      Stefanovic IM, Verona E, Cicak B, Vrsalovic R. No effect of fluticasone propionate on linear growth in preschool children with asthma. Pediatr Int 2011; 53:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/37\">",
"      Iles R, Williams RM, Williams RW, et al. A longitudinal assessment of the effect of inhaled fluticasone propionate therapy on adrenal function and growth in young children with asthma. Pediatr Pulmonol 2008; 43:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/38\">",
"      Wasserman RL, Baker JW, Kim KT, et al. Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study. Ann Allergy Asthma Immunol 2006; 96:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/39\">",
"      Bisgaard H, Allen D, Milanowski J, et al. Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing. Pediatrics 2004; 113:e87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/40\">",
"      Teper AM, Colom AJ, Kofman CD, et al. Effects of inhaled fluticasone propionate in children less than 2 years old with recurrent wheezing. Pediatr Pulmonol 2004; 37:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/41\">",
"      Bisgaard H, Zielen S, Garcia-Garcia ML, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22216/abstract/42\">",
"      Szefler SJ, Baker JW, Uryniak T, et al. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. J Allergy Clin Immunol 2007; 120:1043.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 546 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-D7E3B57AC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_44_22216=[""].join("\n");
var outline_f21_44_22216=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPISODIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Inhaled short-acting beta agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2255738\">",
"      - Inhaled hypertonic saline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intermittent inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Intermittent leukotriene receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other intermittent interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DAILY THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Daily inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Daily leukotriene receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/546\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/546|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/21/44379\" title=\"table 1\">",
"      Medication doses for pediatric acute asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/18/26925\" title=\"table 2\">",
"      Doses inhaled glucocorticoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/23/11642?source=related_link\">",
"      Acute asthma exacerbations in children: Inpatient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=related_link\">",
"      Acute asthma exacerbations in children: Outpatient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/44/22218?source=related_link\">",
"      Acute severe asthma exacerbations in children: Intensive care unit management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24247?source=related_link\">",
"      Bronchiolitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/19/27962?source=related_link\">",
"      Bronchiolitis in infants and children: Treatment; outcome; and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Controller medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39670?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Quick-relief agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7383?source=related_link\">",
"      Natural history of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2298?source=related_link\">",
"      Virus-induced wheezing and asthma: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_44_22217="RA PIP soft tissue swelling x-ray";
var content_f21_44_22217=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83905%7ERADIOL%2F85825%7ERADIOL%2F85829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83905%7ERADIOL%2F85825%7ERADIOL%2F85829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Soft tissue swelling and periarticular osteopenia of proximal interphalangeal joints in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The plain radiographs of the hand are magnified at the proximal interphalangeal joints of the third and fourth fingers showing soft tissue swelling (yellow arrows) and periarticular osteopenia (white arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Waite, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Plain radiograph of osteopenia of metacarpophalangeal joints in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 228px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The plain x-ray of the left hand in the AP projection shows a normal patient (A) and a patient with radiologically mild rheumatoid arthritis (B). The patient with rheumatoid arthritis demonstrates osteopenia around the metacarpophalangeal joints (white arrows) and mild soft tissue swelling (yellow arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image B courtesy of Richard Waite, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Plain radiograph of osteopenia of the wrist in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 235px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal radiograph of the left wrist in the AP projection (A) is compared with the left wrist of a patient with rheumatoid arthritis (B). The subtle diffuse osteopenia of the carpal bones is typified by an overall decrease in the density of the bones and by a relative paucity of trabecular markings. Less subtle is the prominent soft tissue nodule overlying the styloid process (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image B courtesy of Richard Waite, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_44_22217=[""].join("\n");
var outline_f21_44_22217=null;
var title_f21_44_22218="Acute severe asthma exacerbations in children: Intensive care unit management";
var content_f21_44_22218=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute severe asthma exacerbations in children: Intensive care unit management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/44/22218/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/44/22218/contributors\">",
"     Joy D Howell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/44/22218/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/44/22218/contributors\">",
"     Robert A Wood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/44/22218/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/44/22218/contributors\">",
"     Adrienne G Randolph, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/44/22218/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/44/22218/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/44/22218/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asthma is the most frequent cause of hospitalization among children in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/1\">",
"     1",
"    </a>",
"    ]. Asthma mortality rates in children and adults have remained fairly constant since 1996, before which there had been a steady increase [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intensive care unit (ICU) management of children with acute severe asthma exacerbation (ie, status asthmaticus), including mechanical ventilation, will be discussed here. Mechanical ventilation for adults with severe asthma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10535?source=see_link\">",
"     \"Invasive mechanical ventilation in adults with acute exacerbations of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pharmacologic management of acute asthma exacerbations and management of chronic childhood asthma also are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link\">",
"     \"Acute asthma exacerbations in children: Outpatient management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Evaluation and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Controller medications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39670?source=see_link\">",
"     \"Chronic asthma in children younger than 12 years: Quick-relief agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic hallmarks of asthma are airway inflammation, excessive mucous production, mucous plugging, and airway bronchospasm, all of which may lead to severe airflow obstruction. Airflow obstruction produces varying degrees of respiratory insufficiency and can progress to respiratory failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are at risk for requiring ICU management for asthma include those who have a history of [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/3-12\">",
"     3-12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ICU admissions, mechanical ventilation, or rapidly progressive and sudden respiratory deterioration",
"     </li>",
"     <li>",
"      Seizures or syncope during an asthma exacerbation",
"     </li>",
"     <li>",
"      Exacerbations precipitated by food",
"     </li>",
"     <li>",
"      Use of more than two beta-agonist metered dose inhaler (MDI) canisters per month",
"     </li>",
"     <li>",
"      Insufficient controller therapy or poor adherence to controller therapy",
"     </li>",
"     <li>",
"      Denial of or failure to perceive the severity of illness",
"     </li>",
"     <li>",
"      Associated depression or other psychiatric disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these factors are frequently present in patients who require ICU management, they fail to prospectively identify a significant number of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/3,7\">",
"     3,7",
"    </a>",
"    ] and should not be interpreted as absolute indications for admission to an ICU. As many as one-third of children who die from asthma were not previously classified as being at risk for fatal asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Severity assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of severity of acute asthma exacerbations is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link&amp;anchor=H2#H2\">",
"     \"Acute asthma exacerbations in children: Outpatient management\", section on 'Assessment of severity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For children who can comprehend and properly perform a forced exhalation, peak expiratory flow measurement is a reliable means of assessing severity of asthma. A moderate attack is defined by a peak flow measurement that is 40 to 69 percent of their \"personal best\" measurement or the predicted value for age, sex, and height (",
"    <a class=\"graphic graphic_table graphicRef76344 \" href=\"UTD.htm?8/32/8718\">",
"     table 1",
"    </a>",
"    ). A severe attack is defined by a peak flow that is &lt;40 percent of their personal best measurement or the predicted value for age, sex, and height.",
"   </p>",
"   <p>",
"    In addition, there are several scoring systems to help assess asthma severity in children. Examples include the Pulmonary Index Score (",
"    <a class=\"graphic graphic_table graphicRef53797 \" href=\"UTD.htm?37/43/38587\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/13\">",
"     13",
"    </a>",
"    ] and the Pulmonary Score, which is similar to the Pulmonary Index Score except that it scores only respiratory rate, wheezing, and accessory muscle use [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with acute severe asthma who fail to improve with initial treatment in the emergency department exacerbation should be admitted to the pediatric intensive care unit (ICU). ICU level management of these children entails the administration of corticosteroids, aggressive bronchodilator therapy, and close monitoring.",
"   </p>",
"   <p>",
"    Mechanical ventilation is reserved for patients with continued progression toward respiratory failure despite maximal medical therapy. The use of mechanical ventilation during an asthma exacerbation is associated with significant morbidity and increased risk of death [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Mechanical ventilation rates for children with asthma vary from center to center, with published rates ranging from 1 percent to 10 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/4,17\">",
"     4,17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The need for mechanical ventilation should be considered early in the course of illness. The decision to intubate a patient should not be delayed until respiratory failure is imminent. In select patients who are progressing toward respiratory muscle fatigue, noninvasive positive pressure ventilation (NPPV) may avoid the need for intubation by easing the work of breathing while awaiting the maximal therapeutic effects of pharmacotherapy.",
"   </p>",
"   <p>",
"    For children who do not improve despite aggressive pharmacologic therapy and mechanical ventilation, adjunctive therapies may be necessary. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Adjunctive therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREINTUBATION THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of pharmacologic therapy for acute severe asthma exacerbations is to ensure adequate oxygenation and ventilation, and ease the work of breathing. Pharmacologic therapy of children who are admitted to the intensive care unit with acute severe asthma exacerbation entails the administration of corticosteroids and aggressive bronchodilator therapy. We recommend the administration of intravenous (IV) corticosteroids, inhaled",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    , and inhaled",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/12/35008?source=see_link\">",
"     ipratropium",
"    </a>",
"    , and suggest the administration of IV",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    For those who fail to respond to these interventions, we suggest the administration of parenteral beta 2-agonists. The efficacy of these interventions has been documented in meta-analyses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    randomized controlled trials, which are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link&amp;anchor=H17#H17\">",
"     \"Acute asthma exacerbations in children: Outpatient management\", section on 'Pharmacotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Corticosteroids in children who are admitted to the ICU with acute asthma exacerbation are usually administered intravenously (IV):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"       Methylprednisolone",
"      </a>",
"      (2 to 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, with a maximum dose of 60",
"      <span class=\"nowrap\">",
"       mg/day;",
"      </span>",
"      in adults the maximum dose may be as high as 125",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link&amp;anchor=H23#H23\">",
"       \"Acute asthma exacerbations in children: Outpatient management\", section on 'Glucocorticoids'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Aggressive bronchodilator therapy consists of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hourly or continuously delivered",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       albuterol",
"      </a>",
"      via nebulizer:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For hourly administration,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       albuterol",
"      </a>",
"      (0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every hour, minimum 2.5 mg; maximum 5 mg), or",
"     </li>",
"     <li>",
"      For continuous administration,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       albuterol",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/hour",
"      </span>",
"      for children who weigh 5 to 10 kg; 15",
"      <span class=\"nowrap\">",
"       mg/hour",
"      </span>",
"      for children who weigh 10 to 20 kg; and 20",
"      <span class=\"nowrap\">",
"       mg/hour",
"      </span>",
"      for children who weigh &gt;20 kg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/12/35008?source=see_link\">",
"       Ipratropium",
"      </a>",
"      bromide (250 microgram per dose for children who weigh &lt;20 kg or are younger than six years of age; 500 microgram per dose for children who weigh &gt;20 kg or are older than six years of age) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/18\">",
"       18",
"      </a>",
"      ]. The optimal duration of therapy with ipratropium bromide has not been established. However, we suggest a duration of 24 hours following admission.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"       Magnesium sulfate",
"      </a>",
"      (25 to 75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV; maximum 2 grams) is administered upon arrival to the ICU if it has not been administered earlier.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients who fail to respond to aggressive inhaled bronchodilator therapy, we suggest the administration of intravenous bronchodilators [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/19,20\">",
"     19,20",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link&amp;anchor=H28#H28\">",
"     \"Acute asthma exacerbations in children: Outpatient management\", section on 'Parenteral beta 2-agonists'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/51/25397?source=see_link\">",
"       Terbutaline",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       microgram/kg",
"      </span>",
"      IV loading dose administered over 10 minutes, followed by an infusion of 0.1 to 10",
"      <span class=\"nowrap\">",
"       microgram/kg",
"      </span>",
"      per minute),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/47/9975?source=see_link\">",
"       Aminophylline",
"      </a>",
"      (6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV loading dose, followed by infusion of 0.6 to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per hour)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/51/25397?source=see_link\">",
"     Terbutaline",
"    </a>",
"    is usually started at 0.1",
"    <span class=\"nowrap\">",
"     microgram/kg",
"    </span>",
"    per minute and increased in 0.1 to 1",
"    <span class=\"nowrap\">",
"     microgram/kg",
"    </span>",
"    per minute increments every 30 minutes often to a maximum dose of 10",
"    <span class=\"nowrap\">",
"     microgram/kg",
"    </span>",
"    per minute until aeration and work of breathing improve.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/47/9975?source=see_link\">",
"     Aminophylline",
"    </a>",
"    is usually started at 0.8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour and titrated based on levels. Aminophylline has a mean volume of distribution of 0.5",
"    <span class=\"nowrap\">",
"     L/kg.",
"    </span>",
"    Thus, a loading dose of 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    should generate a serum level of approximately 12",
"    <span class=\"nowrap\">",
"     microgram/mL.",
"    </span>",
"    Therapeutic levels range between 10 and 20",
"    <span class=\"nowrap\">",
"     microgram/mL.",
"    </span>",
"    We suggest target levels of 12 to 15",
"    <span class=\"nowrap\">",
"     microgram/mL,",
"    </span>",
"    particularly upon initiation of therapy. Steady state levels are checked six hours following the",
"    <span class=\"nowrap\">",
"     bolus/initiation",
"    </span>",
"    of the infusion. If the patient's respiratory insufficiency fails to respond to the initiation of an aminophylline infusion, and the six-hour level is below 15",
"    <span class=\"nowrap\">",
"     microgram/mL,",
"    </span>",
"    then the infusion is increased proportionately to a target level of 15",
"    <span class=\"nowrap\">",
"     microgram/mL.",
"    </span>",
"    Serum levels of aminophylline should be measured once daily (after desired level or response to therapy achieved) and as needed when toxicity is suspected (severe tachycardia, anxiety, persistent emesis, dysrhythmias, and seizures).",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    is not available in the United States. However, in countries where it is available, efficacy in patients with acute severe asthma has been demonstrated in randomized and observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The dose is 0.5 to 5",
"    <span class=\"nowrap\">",
"     microgram/kg",
"    </span>",
"    per minute [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extreme caution should be employed in the patient with risk factors for myocardial ischemia since tachycardia increases myocardial oxygen demand. In addition, children who present with status asthmaticus are predisposed to",
"    <span class=\"nowrap\">",
"     dehydration/intravascular",
"    </span>",
"    depletion. Thus, fluid loading may be necessary to blunt some of the tachycardia associated with use of these agents. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Fluid support'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For select patients who continue to have severe or unabated increased work of breathing after intravenous bronchodilators, or while awaiting the maximum therapeutic benefit of pharmacotherapy, NPPV may help to avoid endotracheal intubation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Noninvasive positive pressure ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninvasive positive pressure ventilation (NPPV) involves the delivery of positive airway pressure, either as continuous pressure (continuous positive airway pressure, CPAP) or as mechanically assisted breaths (bilevel positive airway pressure, BiPAP), without placement of an artificial airway. In most cases, ventilation is delivered via a tight fitting nasal or facial mask. Patients who receive NPPV must be awake and cooperative, have a patent airway, and have spontaneous respirations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NPPV has been used to treat children with respiratory failure from a number of causes, including neuromuscular disorders, cystic fibrosis, bronchiolitis, and status asthmaticus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/23-35\">",
"     23-35",
"    </a>",
"    ]. However, the benefits for children with status asthmaticus are not well established.",
"   </p>",
"   <p>",
"    In a prospective study, 20 children (median age 4.8 years) admitted to the PICU with acute lower airway obstruction were randomly assigned to two hours of NPPV followed by two hours of standard therapy or to two hours of standard therapy followed by two hours of NPPV [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/31\">",
"     31",
"    </a>",
"    ]. Compared to standard therapy, NPPV decreased respiratory rate, accessory muscle use, and dyspnea; no serious morbidity was noted, but five patients were unable to tolerate NPPV for the duration of the study.",
"   </p>",
"   <p>",
"    In small case series, treatment with NPPV has been associated with improved clinical and ventilatory parameters in children with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/29,30,32,35\">",
"     29,30,32,35",
"    </a>",
"    ]. However, four of five patients in one of these case series were morbidly obese (body mass index &ge;30); the improvement in their respiratory status with NPPV may have been related to underlying obesity hypoventilation syndrome, although none of them reported a previous history [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Possible indications for NPPV &mdash; In children with acute severe asthma exacerbation, NPPV may be useful as a temporizing measure while awaiting the maximal therapeutic benefit of pharmacotherapy, or may avoid the need for intubation by easing the work of breathing in patients who are progressing toward respiratory muscle fatigue.",
"      <br/>",
"      <br/>",
"      The use of NPPV in children with status asthmaticus varies from center to center. We suggest a trial of NPPV in the following situations, provided that the child is alert, cooperative, and without increased airway secretions:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The child remains hypoxemic despite high flow oxygen",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      has documented hypercarbia",
"     </li>",
"     <li>",
"      To ease the child's work of breathing while awaiting maximal therapeutic effects of corticosteroids and bronchodilators",
"     </li>",
"     <li>",
"      The child is progressing toward respiratory muscle fatigue",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limitations of NPPV &mdash; Limitations of NPPV include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Requires patient cooperation",
"     </li>",
"     <li>",
"      Impairs ability to clear secretions from the respiratory tract",
"     </li>",
"     <li>",
"      Impairs ability to deliver medications to the respiratory tract",
"     </li>",
"     <li>",
"      Does not provide definitive control of the airway",
"     </li>",
"     <li>",
"      May cause gastric distension with increased risk of aspiration",
"     </li>",
"     <li>",
"      May cause heightened sense of air hunger upon initiation",
"     </li>",
"     <li>",
"      Patients may feel claustrophobic",
"      <br/>",
"      <br/>",
"      An experienced nurse or respiratory therapist who can coach the patient through the initiation of NPPV is invaluable. Some authors have recommended the use of mild sedatives to facilitate the patient's tolerance of NPPV [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/30\">",
"       30",
"      </a>",
"      ]. If sedation is used, great care must be taken to avoid diminishing airway protective reflexes and respiratory drive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NPPV settings &mdash; For patients with moderately increased work of breathing or relatively mild-moderate degrees of hypoxemia (those who can maintain oxygen saturation greater than 92 percent with the provision of simple face mask oxygen at fraction of inspired oxygen (FiO2) of 0.25 to 0.7) or hypercarbia (PaCO2 of 45 to 50 torr mmHg), NPPV can begin as CPAP with a pressure of 5 cm H2O.",
"      <br/>",
"      <br/>",
"      For patients with increased work of breathing and moderate or severe hypoxemia (patients requiring FiO2 &gt;70 percent by simple face mask or non-rebreather mask) and hypercarbia (PaCO2 &gt;50 mmHg), BiPAP provides a greater level of support and decreases the work of breathing more efficiently.",
"      <br/>",
"      <br/>",
"      The initial BiPAP settings should be relatively low and should be titrated to patient comfort, oxygenation, and ventilation. The inspiratory pressure may start at 8 to 10 cm H2O and the expiratory pressure at 5 cm H2O. These settings may be titrated up to an inspiratory pressure of 10 to 12 cm H2O and the expiratory pressure may be carefully titrated up to 7 to 8 cm H2O.",
"      <br/>",
"      <br/>",
"      Indications for endotracheal intubation and mechanical ventilation in patients who receive a trial of NPPV include:",
"      <br/>",
"      <br/>",
"      Lack of improvement or worsening of increased work of breathing",
"      <br/>",
"      Persistent hypercarbia (PaCO2 &gt;50 mmHg)",
"      <br/>",
"      Need for supplemental oxygen in excess of 60 percent",
"      <br/>",
"      Altered mental status",
"      <br/>",
"      <br/>",
"      (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Endotracheal intubation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Discontinuing NPPV &mdash; BiPAP can be weaned to CPAP when the patient's work of breathing and respiratory rate are minimally elevated (compared to what is normal for the patient's age) and the oxygen requirement is &lt;50 percent. CPAP can be withdrawn when the work of breathing and respiratory rate have normalized and the oxygen requirement is &le;40 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ENDOTRACHEAL INTUBATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intubation should be approached cautiously in patients with status asthmaticus because manipulation of the airway can cause increased airflow obstruction due to exaggerated bronchial responsiveness. Adequate venous access, noninvasive monitoring, and sedation should be optimized before intubation. The clinician most experienced with airway management should perform the intubation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians must be prepared to manage acute deterioration due to tube malposition, tube obstruction, pneumothorax, equipment failure, hypotension,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to intubate a patient with status asthmaticus is made clinically based upon clinical findings (eg, rapid, shallow breathing, somnolence) and physiologic changes (eg, hypercapnia). Care must be taken to control the airway before the patient suffers a respiratory arrest or a hypoxic insult. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indications for intubation in patients with acute severe asthma include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypoxemia despite provision of high concentrations of oxygen or NPPV",
"     </li>",
"     <li>",
"      Severe and unremitting work of breathing (eg, inability to speak)",
"     </li>",
"     <li>",
"      Altered mental status",
"     </li>",
"     <li>",
"      Respiratory or cardiac arrest",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypercarbia alone is not an indication for intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/17,37,38\">",
"     17,37,38",
"    </a>",
"    ]. However, if a patient demonstrates a progressively rising PaCO2 despite maximal medical therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    NPPV, then intubation is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of endotracheal intubation and mechanical ventilation for children with status asthmaticus and respiratory failure are [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      To take over the work of breathing from the exhausted patient and allow respiratory muscle rest.",
"     </li>",
"     <li>",
"      To insure adequate oxygenation.",
"     </li>",
"     <li>",
"      To insure sufficient (not necessarily \"normal\") gas exchange until airway obstruction can be reversed. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Ventilation strategy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These goals should be accomplished with the fewest adverse effects. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oxygenation &mdash; Adequate oxygenation is usually achieved without difficulty in most asthmatic patients since the airways, not the alveoli, are the primary targets of inflammation and bronchospasm. However, mucous plugging, atelectasis, hyperinflation, and",
"      <span class=\"nowrap\">",
"       ventilation/perfusion",
"      </span>",
"      <span class=\"nowrap\">",
"       (V/Q)",
"      </span>",
"      mismatch may contribute to hypoxemia. Oxygenation is affected primarily by the fraction of inspired oxygen (FiO2). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Ventilator settings'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Atelectasis that results from mucous plugging can usually be treated with percussion and drainage, and regular removal of secretions from the endotracheal tube [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/40\">",
"       40",
"      </a>",
"      ]. In addition, positioning of the patient so that collapsed lung segments are nondependent helps to improve atelectasis.",
"      <br/>",
"      <br/>",
"      If these measures prove insufficient, extrinsic positive end expiratory pressure (PEEP) above initial PEEP (3 cm H2O is suggested) may be carefully applied. The titration of PEEP also may be helpful in recruiting atelectatic lung units. Hyperinflation, however, by generating more Zone I physiology (where alveolar pressure exceeds pulmonary arterial pressure), may produce",
"      <span class=\"nowrap\">",
"       V/Q",
"      </span>",
"      mismatch and therefore worsen hypoxemia. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Ventilator settings'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Ventilation &mdash; In children with severe asthma, ventilation is compromised by obstruction of small airways. This obstruction can be difficult to manage, even in patients who have been intubated. Ventilation is affected by tidal volume, inspiratory and expiratory times (I:E ratio), inspiratory flow rates, and respiratory rate. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Ventilation strategy'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H19\">",
"       'Ventilator settings'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ventilatory modes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of ventilatory modes have been successfully employed in the management of asthma patients who require intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/3,4,41\">",
"     3,4,41",
"    </a>",
"    ]. These include: pressure control ventilation, pressure support ventilation, PSV, volume control ventilation (eg, pressure regulated volume control, PRVC), and synchronized intermittent mandatory ventilation (SIMV), which delivered with pressure control",
"    <span class=\"nowrap\">",
"     (SIMV/PC)",
"    </span>",
"    or volume control",
"    <span class=\"nowrap\">",
"     (SIMV/VC).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Pressure control",
"    </span>",
"    &nbsp;&mdash;&nbsp;In",
"    pressure control ventilation",
"    <span class=\"nowrap\">",
"     (SIMV/PC),",
"    </span>",
"    inspiration ceases when a preset maximum pressure is reached; the delivered volume varies depending upon lung mechanics (eg, airway resistance, lung compliance, hyperinflation), and minute ventilation (respiratory rate [RR] x tidal volume [TV]) is not assured.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pressure support",
"    </span>",
"    &nbsp;&mdash;&nbsp;PSV is flow-cycled in that once triggered by a demand valve, the preset pressure is sustained until the inspiratory flow tapers, usually to 25 percent of its maximal value [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/42\">",
"     42",
"    </a>",
"    ]. With PSV, the clinician determines the final airway pressure. TV and RR (ie, minute volume) are a consequence of patient-related variables plus ventilator settings. PSV decreases patient-ventilatory dyssynchrony and is useful when weaning from ventilatory support [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/17\">",
"     17",
"    </a>",
"    ]. Functionally, PSV (invasive) is equivalent to BiPAP (noninvasive). As with pressure control ventilation, minute ventilation is not assured.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Volume control",
"    </span>",
"    &nbsp;&mdash;&nbsp;In volume control ventilation (PRVC or",
"    <span class=\"nowrap\">",
"     SIMV/VC),",
"    </span>",
"    inspiration is terminated after delivery of a preset tidal volume. An advantage to volume control ventilation is that it permits comparison of peak inspiratory pressure and plateau pressure measurements (peak-to-plateau measurements), which provides an indication of airway resistance and response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/3\">",
"     3",
"    </a>",
"    ]. Depending on airway resistance, mucous plugging, and the degree of atelectasis, a disadvantage is that peak pressures may be elevated. Volume control is the preferred mode of mechanical ventilation at our institution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18086632\">",
"    <span class=\"h4\">",
"     Pressure regulated volume control",
"    </span>",
"    &nbsp;&mdash;&nbsp;PRVC is a mode specific to the Servo 300 ventilator that assures the patient receives the",
"    <span class=\"nowrap\">",
"     desired/set",
"    </span>",
"    tidal volume, but at the lowest peak pressure possible. PRVC offers advantages of both volume and pressure control ventilation. These include optimal inspiratory flow, assured tidal volumes, and minimized airway pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     SIMV",
"    </span>",
"    &nbsp;&mdash;&nbsp;In synchronized intermittent mandatory ventilation (SIMV), the ventilator delivers breaths based upon a preset TV or peak pressure and RR that are synchronized with the patient's inspiratory effort. However, if the patient fails to initiate a breath, a full tidal volume breath will be delivered at the appropriate interval (ie, one breath every five seconds if the RR is set at 12 breaths per minute). SIMV can be delivered with volume control",
"    <span class=\"nowrap\">",
"     (SIMV/VC)",
"    </span>",
"    or pressure control",
"    <span class=\"nowrap\">",
"     (SIMV/PC).",
"    </span>",
"    At the author's institution, volume control is preferred. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Weaning from mechanical ventilation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Choice of mode",
"    </span>",
"    &nbsp;&mdash;&nbsp;We prefer volume control ventilation (eg, PRVC or",
"    <span class=\"nowrap\">",
"     SIMV/VC)",
"    </span>",
"    over pressure control ventilation for intubated children with asthma since volume control ventilation allows for consistent minute ventilation in the face of changing airway resistance and lung compliance. If PRVC is an available mode, it may be the best option since it assures that the patient receives the",
"    <span class=\"nowrap\">",
"     desired/set",
"    </span>",
"    tidal volume at the lowest peak pressure possible [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Ventilation strategy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful mechanical ventilation in patients with asthma depends upon limiting the risk of hyperinflation and barotrauma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/44\">",
"     44",
"    </a>",
"    ]. The risk of hyperinflation is reduced by decreasing the minute volume and permitting adequate time for complete exhalation before the next inhalation is initiated. This is accomplished by slowing the RR and increasing the expiratory time, thereby decreasing the ratio of inspiratory to expiratory time (I:E ratio) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/3\">",
"     3",
"    </a>",
"    ]. The risk of barotrauma is decreased by minimizing hyperinflation and peak inspiratory pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Ventilator settings'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Diminishing the risk of hyperinflation and barotrauma requires acceptance of PaCO2 that is higher than normal and a pH that is lower than normal (&gt;7.2), a strategy that is called \"permissive hypercapnia\" or \"controlled hypoventilation\" [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/46-49\">",
"     46-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This strategy is widely used in patients with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/46,47,50-54\">",
"     46,47,50-54",
"    </a>",
"    ]. Although hypercapnic acidosis can be associated with serious morbidity, PaCO2 near 70 mmHg (torr) and a pH near 7.25 can be safely and comfortably tolerated in most children so long as levels do not increase rapidly [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/46,55\">",
"     46,55",
"    </a>",
"    ]. A slow increase in PaC02 (approximately 10",
"    <span class=\"nowrap\">",
"     mmHg/hr)",
"    </span>",
"    permits intracellular buffering mechanisms to accommodate the decreasing serum pH [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential contraindications to permissive hypercapnic ventilation include increased intracranial pressure, poor myocardial function, and coexistent metabolic acidosis (eg, with renal disease).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Ventilator settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of mechanical ventilator settings must take into account the physiologic derangements of acute severe asthma, including airflow obstruction and atelectasis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/3\">",
"     3",
"    </a>",
"    ], as well as the objectives of minimizing hyperinflation and barotrauma.",
"   </p>",
"   <p>",
"    Initial ventilator settings should be adjusted as necessary to maintain adequate ventilation, assessed by chest auscultation and measurement of arterial blood gases (",
"    <a class=\"graphic graphic_table graphicRef77503 \" href=\"UTD.htm?18/5/18523\">",
"     table 3",
"    </a>",
"    ), and to prevent complications [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/44\">",
"     44",
"    </a>",
"    ]. The placement of an indwelling arterial catheter facilitates obtaining frequent arterial blood samples and continuous arterial pressure monitoring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2009?source=see_link\">",
"     \"Arterial puncture and cannulation in children\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H28\">",
"     'Monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      FiO2 &mdash; Upon intubation, FiO2 should be set at 1.0. FiO2, then decreased as tolerated to concentrations of 0.5 or lower to maintain oxygen saturation &gt;92 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Respiratory rate &mdash; The respiratory rate (RR) should be set near or below physiologic rates (8 to 12 breaths per minute) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/4,46\">",
"       4,46",
"      </a>",
"      ], keeping the minute ventilation under 115",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per minute. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10535?source=see_link\">",
"       \"Invasive mechanical ventilation in adults with acute exacerbations of asthma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tidal volume &mdash; The delivered tidal volume (TV) should initially be 8 to 10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/4,43\">",
"       4,43",
"      </a>",
"      ]. The peak and plateau pressures attained with these volumes should be noted and kept under 40 cm H2O and 30 to 35 cm H2O, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/4\">",
"       4",
"      </a>",
"      ]; maintaining these limits helps to minimize dynamic hyperinflation and barotrauma [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/43\">",
"       43",
"      </a>",
"      ]. The TV may need to be reduced if the peak pressure limit exceeds 40 cm H2O [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/3\">",
"       3",
"      </a>",
"      ]; reducing the tidal volume will result in increased PaCO2 [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/47\">",
"       47",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Dynamic hyperinflation'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H22\">",
"       'Barotrauma'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H18\">",
"       'Ventilation strategy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inspiratory time, I:E, and inspiratory flow &mdash; Inspiratory times should be appropriately low (0.75 to 1.5 seconds) to keep the I:E ratio between 1:3 and 1:5.",
"      <br/>",
"      <br/>",
"      Expiratory time should be maximized to allow complete exhalation, avoid hypercarbia, and prevent dynamic hyperinflation and intrinsic PEEP (elevation of alveolar pressure above atmospheric pressure at the end of exhalation, also called auto-PEEP).",
"      <br/>",
"      <br/>",
"      To this end, inspiratory flow should be set at the highest rate the patient can tolerate without generating excessively high peak pressures; in adults, flow rates of 80 to 100",
"      <span class=\"nowrap\">",
"       L/minute",
"      </span>",
"      are recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/56\">",
"       56",
"      </a>",
"      ]. In children, flow rates of 4 to 10",
"      <span class=\"nowrap\">",
"       L/kg",
"      </span>",
"      per minute, with a maximum of 80 to 100",
"      <span class=\"nowrap\">",
"       L/minute",
"      </span>",
"      are appropriate, since these rates are typically employed in children during pressure control ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      PEEP &mdash; The use of extrinsic PEEP in the ventilated asthmatic patient is controversial [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/3\">",
"       3",
"      </a>",
"      ]. Some experts advocate that it not be used, whereas many others suggest that with proper precautions, it can be a helpful intervention, particularly in patients with atelectasis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/43,58,59\">",
"       43,58,59",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      PEEP can effectively open collapsed airways, improve ventilation, and potentially reduce air trapping [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/58\">",
"       58",
"      </a>",
"      ]. Application of low levels of PEEP also may relieve dyspnea by facilitation of ventilator triggering and synchronization for intubated patients capable of taking spontaneous breaths [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/3,58,59\">",
"       3,58,59",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Some degree of PEEP (eg, 3 cm H20) is necessary to compensate for the external resistance added to the respiratory tract by the endotracheal tube. Higher levels of PEEP (5 to 8 cm H20) may be beneficial for children demonstrating persistent and severe hypercarbia despite appropriate tidal volumes (10",
"      <span class=\"nowrap\">",
"       mL/kg)",
"      </span>",
"      and expiratory times that permit complete exhalation.",
"      <br/>",
"      <br/>",
"      We suggest that PEEP initially be set at at least 3 cm H2O; PEEP may be increased in increments of 1 cm H2O to determine whether additional PEEP improves ventilation. Most patients with asthma can be successfully managed with PEEP in the range of 3 to 8 cm H2O. Care must be taken to ensure that extrinsic PEEP does not exceed intrinsic or auto-PEEP [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/4\">",
"       4",
"      </a>",
"      ]. PEEP should be adjusted or diminished if adverse effects occur (eg, dynamic hyperinflation).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Dynamic hyperinflation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute severe asthma exacerbation are at risk for progressive air trapping and alveolar hyperinflation, which may lead to alveolar rupture and hemodynamic compromise. Airflow obstruction during expiration slows lung emptying and inspiration may be initiated before exhalation is complete. The phenomenon that occurs when a new breath begins before the lung has reached the static equilibrium volume is called dynamic hyperinflation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dynamic hyperinflation can occur in patients with asthma who are breathing spontaneously. It is a physiologic response to airflow obstruction and exists, to an extent, because increasing lung volume tends to increase airway caliber and can reduce the resistive work of breathing. However, in patients with severe asthma it becomes maladaptive, occurring at the expense of increased mechanical load and elastic work of breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/4,61,62\">",
"     4,61,62",
"    </a>",
"    ]. Dynamic hyperinflation can cause alveolar overdistention resulting in hypoxemia, hypotension, or alveolar rupture. Dynamic hyperinflation increases the magnitude of the drop in airway pressure that the patient must generate to trigger a breath, thereby increasing the patient's workload (",
"    <a class=\"graphic graphic_figure graphicRef64640 \" href=\"UTD.htm?17/34/17966\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are several ways to assess for the presence of dynamic hyperinflation. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of the end-inspired volume above apneic FRC (VEI). This measurement consists of collecting all the exhaled gas from paralyzed, ventilated patients after 40 to 60 seconds of apnea. This volume is termed \"end-inspiratory lung volume above FRC\" (VEI). Most pulmonary and circulatory complications of ventilation are avoided when VEI is maintained below 20",
"      <span class=\"nowrap\">",
"       mL/kg.",
"      </span>",
"      The ventilator settings are adjusted to achieve this goal, primarily by keeping minute ventilation below 115",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per minute. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Ventilator settings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measurement of the end-inspiratory plateau pressure (Pplat). This measure is obtained by pausing ventilation briefly (0.4 seconds) at end-inspiration and measuring the airway pressure. Keeping Pplat below 30 cm H2O can decrease complications [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/63\">",
"       63",
"      </a>",
"      ]. Whether this measure is valid in children is unknown. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10535?source=see_link\">",
"       \"Invasive mechanical ventilation in adults with acute exacerbations of asthma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Measurement of intrinsic or auto-PEEP. Auto-PEEP is measured during an expiratory pause maneuver; it is the difference between delivered PEEP and actual or measured PEEP. It is the easiest of the three ways of assessing dynamic hyperinflation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interventions to correct air-trapping include decreasing the respiratory rate (functionally increasing expiratory time), increasing inspiratory flow rates (functionally decreasing the inspiratory time) and lowering the tidal volume. In adults, it has been demonstrated that limiting minute ventilation is the key to avoiding dynamic hyperinflation; keeping the minute ventilation under",
"    <span class=\"nowrap\">",
"     115/mL/kg",
"    </span>",
"    is a recommended goal (",
"    <a class=\"graphic graphic_table graphicRef77503 \" href=\"UTD.htm?18/5/18523\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Ventilator settings'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10535?source=see_link\">",
"     \"Invasive mechanical ventilation in adults with acute exacerbations of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endotracheal intubation with mechanical ventilation in the child with asthma can be associated with significant morbidity including hypotension, barotrauma (including pneumothorax), and myopathy. These complications occur in 10 to 26 percent of children who are ventilated for asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/46,52,64-66\">",
"     46,52,64-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For asthmatic patients receiving mechanical ventilation, more than one-half of complications occur during or immediately after intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/67\">",
"     67",
"    </a>",
"    ]. Common causes of acute deterioration in intubated patients include tube displacement or malposition, tube obstruction, pneumothorax, and equipment failure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Barotrauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary barotrauma in the mechanically ventilated patient is the result of alveolar rupture and is characterized by the development of extra-alveolar air. Barotrauma occurs when the transalveolar pressure increases to a degree that disrupts the structural integrity of the alveolus. This leads to alveolar rupture and interstitial emphysema.",
"   </p>",
"   <p>",
"    Once present, interstitial emphysema may dissect along perivascular sheaths into the mediastinum [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/68\">",
"     68",
"    </a>",
"    ]. If the mediastinal parietal pleura then ruptures, a pneumothorax results. Dissection of air elsewhere along fascial planes can also result in pneumomediastinum, pneumoperitoneum, or subcutaneous emphysema [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/69\">",
"     69",
"    </a>",
"    ]. Other clinical manifestations of pulmonary barotrauma include bronchopleural fistula, tension pneumothorax, tension lung cysts, hyperinflation of the left lower lobe, systemic gas embolism, and subpleural air cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32934?source=see_link\">",
"     \"Pulmonary barotrauma during mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pneumothorax should be suspected if the patient becomes hypoxemic and hypotensive following intubation and the hypoxemia and hypotension do not respond to fluid administration and alteration in ventilatory pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/17\">",
"     17",
"    </a>",
"    ]. Imaging should be performed promptly so that treatment can be provided expeditiously. The most experienced clinician should perform needle decompression or insertion of a chest tube for pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39113?source=see_link&amp;anchor=H13169123#H13169123\">",
"     \"Causes of acute respiratory compromise in children\", section on 'Tension pneumothorax'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypotension is a risk in any patient who is transitioned from negative to positive pressure ventilation. This risk is increased in patients with asthma who are mechanically ventilated. The hyperinflation that is intrinsic to asthma and the increased intrathoracic pressure associated with positive pressure ventilation impede venous return to the heart. This effect may be compounded by the administration of sedatives and paralytics, which act as vasodilators and myocardial depressants [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Sedation and paralysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Several steps can be taken to minimize the risk of hypotension in asthmatic patients who require mechanical ventilation. These include measures to limit peak pressure and avoid hyperinflation, as described above. Patients also may benefit from the administration of intravenous fluids to improve and optimize intravascular volume. Optimization of intravascular volume may help to blunt the tachycardia that results from vasodilation associated with systemic absorption of bronchodilators. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Fluid support'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Clinicians caring for children with acute severe asthma exacerbation who require mechanical ventilation should be prepared to provide volume resuscitation if necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=see_link&amp;anchor=H13#H13\">",
"     \"Hypovolemic shock in children: Initial evaluation and management\", section on 'Fluid resuscitation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An extreme measure that can be taken if blood pressure fails to respond to volume resuscitation is to transiently disconnect the patient from the ventilator or ambu bag. This permits complete evacuation of the lung and in turn, appropriate filling of the heart.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other complications of mechanical ventilation in children with asthma include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nosocomial infection (eg, pneumonitis, sinusitis, tracheobronchitis)",
"     </li>",
"     <li>",
"      Gastrointestinal bleeding (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=see_link\">",
"       \"Stress ulcer prophylaxis in the intensive care unit\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Prolonged weakness, the risk increases with neuromuscular blockade and corticosteroid use [",
"      <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/71-76\">",
"       71-76",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Sedation and paralysis'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Subglottic stenosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive measures for children with asthma who require mechanical ventilation include analgesia, sedation, and muscle relaxation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/3,43,44\">",
"     3,43,44",
"    </a>",
"    ]. These measures help to prevent tachypnea, breath stacking, and ventilator dyssynchrony, particularly in the setting of hypercapnia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Fluid support",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fluid status of children with acute severe asthma exacerbation who are admitted to the ICU must be carefully monitored. Many patients are hypovolemic on presentation (related to poor intake and increased insensible fluid loss from the respiratory tract) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The risk of hypotension is increased in patients who are mechanically ventilated and who receive sedatives and paralytics. Intravenous fluids should be administered to replace losses and optimize intravascular volume. However, overhydration should be avoided since it may result in pulmonary edema. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Hypotension'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Sedation and paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sedation is used to promote",
"    <span class=\"nowrap\">",
"     patient/ventilator",
"    </span>",
"    synchrony and blunt tachypnea to reduce the risk of barotrauma. A variety of agents can be used for sedation.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     Ketamine",
"    </a>",
"    , a synthetic derivative of phencyclidine, is often recommended as the induction agent of choice for the asthma patient requiring intubation because it has bronchodilatory as well as sedative effects. Ketamine also has been administered as a continuous infusion in patients receiving invasive or noninvasive positive pressure ventilation for asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/4,30\">",
"     4,30",
"    </a>",
"    ]. Alternative agents that can be used for sedation in ventilated patients with asthma include narcotics and benzodiazepines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link&amp;anchor=H17#H17\">",
"     \"Rapid sequence intubation (RSI) in children\", section on 'Sedative and induction agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neuromuscular blockade may be employed as an adjunct to intubation and to blunt tachypnea and ventilator dyssynchrony sedated patients receiving assisted ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/3,44\">",
"     3,44",
"    </a>",
"    ]. However, efforts should be made to discontinue the use of neuromuscular blocking agents as soon as is feasible since their use in combination with corticosteroids is associated with an increased risk of myopathy of critical illness [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/4,17,61,71-76\">",
"     4,17,61,71-76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link&amp;anchor=H24#H24\">",
"     \"Rapid sequence intubation (RSI) in children\", section on 'Paralysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who require mechanical ventilation for asthma require close monitoring, including frequent auscultation. Auscultation provides important information regarding aeration, optimal duration of exhalation (wheezing should terminate before the onset of the next inhalation), and the presence of pneumothorax or mucus plugging (indicated by asymmetric breath sounds) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children who are admitted to the ICU for management of acute severe asthma are usually monitored with a cardiorespiratory monitor that displays a continuous electrocardiogram tracing, respiratory rate, noninvasive blood pressure, and oxygen saturation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, those who require mechanical ventilation also may require arterial and central venous access for hemodynamic monitoring and a bladder catheter to monitor urine output.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     WEANING FROM MECHANICAL VENTILATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the goals for mechanical ventilation is to ease the patient's work of breathing and allow the muscles of respiration to rest. Once initiated, mechanical ventilation should be continued for at least 24 to 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/77\">",
"     77",
"    </a>",
"    ]. Beyond that, the duration of mechanical ventilation varies from patient to patient [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/77\">",
"     77",
"    </a>",
"    ]. Most patients can be extubated within four to five days [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Positive response to therapy is indicated by [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Improvement in and normalization of arterial blood gas measurements",
"     </li>",
"     <li>",
"      Decreased wheezing in the expiratory phase of respiration",
"     </li>",
"     <li>",
"      Decreased need for supplemental oxygen (indicating improvement in ventilation-perfusion",
"      <span class=\"nowrap\">",
"       [V/Q]",
"      </span>",
"      mismatch)",
"     </li>",
"     <li>",
"      Decrease in the amount of peak inspiratory pressure necessary to deliver the desired tidal volume",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Weaning from mechanical ventilation should be considered as the patient's hypercarbia improves (eg, when a normal PaCO2 is maintained despite decreases in the minute ventilation).",
"   </p>",
"   <p>",
"    As the clinical status improves, the patient can be permitted to breathe spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/43\">",
"     43",
"    </a>",
"    ]. If PRVC is used as the initial mode, the patient should be transitioned to",
"    <span class=\"nowrap\">",
"     SIMV/VC",
"    </span>",
"    with pressure support.",
"    <span class=\"nowrap\">",
"     SIMV/VC",
"    </span>",
"    and pressure support ventilation can facilitate synchronization and support of ventilation during the weaning process. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Ventilatory modes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients receiving SIMV with pressure support, the proportion of the patient's minute ventilation that is supported should be steadily decreased by lowering the set respiratory rate. Paralysis should be withdrawn before attempts to lower the respiratory rate.",
"   </p>",
"   <p>",
"    Once the patient demonstrates readiness for extubation, sedation should be held until the patient demonstrates appropriate strength and wakefulness.",
"   </p>",
"   <p>",
"    A trial of extubation can be performed when the patient is comfortably achieving adequate oxygenation and effective ventilation. This is indicated by a normal PaCO2 or normal pH with minimal settings (PEEP and pressure support of 5 cm H2O each) and a PaO2 of 90 mmHg with an FiO2 of &le;0.4 or less. Once extubated, patients should be observed in the ICU for at least 24 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In extreme cases, airflow obstruction is so severe that sufficient ventilation cannot be achieved despite intensive bronchodilator therapy, intravenous corticosteroids, ventilatory support, sedation, and paralysis. In such cases, adjunctive therapies, such as inhalational anesthetics or extracorporeal life support, may be successful as rescue measures. However, the routine use of these therapies cannot be recommended on the basis of existing clinical studies. They remain heroic rescue maneuvers for the extremely refractory patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Inhalational anesthetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inhalational anesthetics, halothane,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/63/17397?source=see_link\">",
"     isoflurane",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/47/23286?source=see_link\">",
"     sevoflurane",
"    </a>",
"    are potent bronchodilators; the mechanism of action is unknown. Nonetheless, in animal models and case reports of patients with respiratory acidosis, the use of inhalational anesthetics has resulted in improved ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/4,78\">",
"     4,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Practical limitations to the use of inhalational anesthetics include the abrupt return of bronchoconstriction after discontinuation and the need for delivery via anesthesia machine with proper scavenging of anesthetic gas (to avoid the second-hand inhalation of aerosolized anesthetic by healthcare personnel or other patients). This usually requires the bedside presence of an anesthesiologist, who can provide guidance regarding the dose, duration, and discontinuation of inhalational anesthetic.",
"   </p>",
"   <p>",
"    The use of inhalational anesthetics may be tried as a rescue maneuver in children with acute severe asthma exacerbations who have continued ventilatory failure despite appropriate mechanical ventilation and aggressive medical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Extracorporeal membrane oxygenation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In case reports, extracorporeal membrane oxygenation (ECMO) has been used to successfully treat acute severe asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/4,79-83\">",
"     4,79-83",
"    </a>",
"    ]. However, the use of ECMO in such patients is a heroic measure that requires the availability of an ECMO center. The use of ECMO is precluded in all but the most desperate situations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with status asthmaticus who require mechanical ventilation have increased in-hospital mortality compared to patients who do not require mechanical ventilation (7 versus 0.2 percent in the Nationwide Inpatient Sample for the year 2000) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/84\">",
"     84",
"    </a>",
"    ]. In one review of asthma management in 1528 children who were treated in 11 pediatric ICUs, the mortality rate for ventilated asthmatic children was 2 to 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/44/22218/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute severe asthma exacerbation may be defined by a Pulmonary Index Score of &ge;12 (",
"      <a class=\"graphic graphic_table graphicRef53797 \" href=\"UTD.htm?37/43/38587\">",
"       table 2",
"      </a>",
"      ) or peak flow rate &lt;40 percent of the predicted value for age, sex, and height or personal best (",
"      <a class=\"graphic graphic_table graphicRef76344 \" href=\"UTD.htm?8/32/8718\">",
"       table 1",
"      </a>",
"      ). Children with acute severe asthma exacerbation who fail to improve with initial treatment in the emergency department should be admitted to the pediatric intensive care unit (ICU). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ICU management of children with acute severe asthma entails aggressive pharmacotherapy. We recommend the administration of intravenous (IV) corticosteroids, inhaled",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"       albuterol",
"      </a>",
"      , and inhaled",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/12/35008?source=see_link\">",
"       ipratropium",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ) and we suggest the administration of IV",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34262?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). For patients who fail to respond to these measures we suggest the administration of parenteral beta 2-agonists (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pharmacotherapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=see_link&amp;anchor=H17#H17\">",
"       \"Acute asthma exacerbations in children: Outpatient management\", section on 'Pharmacotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In select patients, noninvasive positive pressure ventilation (NPPV) may avoid the need for intubation. Provided that the child is alert, cooperative, and without increased airway secretions, and the ICU personnel are experienced in the administration of NPPV, we suggest a trial of NPPV in the following situations (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Noninvasive positive pressure ventilation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The child remains hypoxemic despite high flow oxygen",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      has documented hypercarbia",
"     </li>",
"     <li>",
"      To ease the child's work of breathing while awaiting maximal therapeutic effects of corticosteroids and bronchodilators",
"     </li>",
"     <li>",
"      The child is progressing toward respiratory muscle fatigue",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The decision to intubate a patient with status asthmaticus is made clinically based upon clinical findings and physiologic changes. Care must be taken to control the airway before the patient suffers a respiratory arrest or a hypoxic insult. The clinician most experienced with airway management should perform the intubation. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"       \"Emergent endotracheal intubation in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"       \"Rapid sequence intubation (RSI) in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Successful mechanical ventilation in patients with asthma depends upon limiting the risk of hyperinflation and barotrauma. This requires acceptance of PaCO2 that is higher, and a pH that is lower than normal, a strategy called \"permissive hypercapnia\" or \"controlled hypoventilation.\" (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Ventilation strategy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ventilator settings should be adjusted as necessary to maintain adequate ventilation, assessed by chest auscultation and measurement of arterial blood gases, and to prevent complications (",
"      <a class=\"graphic graphic_table graphicRef77503 \" href=\"UTD.htm?18/5/18523\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Ventilator settings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of mechanical ventilation in patients with asthma include hyperinflation, barotrauma, pneumothorax, myopathy, nosocomial infection, gastrointestinal bleeding, and subglottic stenosis. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supportive measures that help to prevent tachypnea, breath stacking, and ventilator dyssynchrony include analgesia, sedation, and paralysis. To minimize the risk of myopathy, neuromuscular blocking agents should be discontinued as soon as is feasible. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adjunctive therapies, such as general anesthesia or extracorporeal life support, may be warranted for patients who do not respond to aggressive pharmacologic therapy and mechanical ventilation. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Adjunctive therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mortality rate for ventilated asthmatic children is 2 to 3 percent. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/1\">",
"      Mannino DM, Homa DM, Akinbami LJ, et al. Surveillance for asthma--United States, 1980-1999. MMWR Surveill Summ 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/2\">",
"      Pirie J, Cox P, Johnson D, Schuh S. Changes in treatment and outcomes of children receiving care in the intensive care unit for severe acute asthma. Pediatr Emerg Care 1998; 14:104.",
"     </a>",
"    </li>",
"    <li>",
"     Rotta AT. Asthma. In: Pediatric critical care, 3rd ed, Fuhrman BP, Zimmerman JJ (Eds), Mosby, Philadelphia 2006. p.589.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/4\">",
"      Werner HA. Status asthmaticus in children: a review. Chest 2001; 119:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/5\">",
"      Chipps BE, Murphy KR. Assessment and treatment of acute asthma in children. J Pediatr 2005; 147:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/6\">",
"      Mountain RD, Sahn SA. Clinical features and outcome in patients with acute asthma presenting with hypercapnia. Am Rev Respir Dis 1988; 138:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/7\">",
"      Robertson CF, Rubinfeld AR, Bowes G. Pediatric asthma deaths in Victoria: the mild are at risk. Pediatr Pulmonol 1992; 13:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/8\">",
"      Strunk RC, Mrazek DA, Fuhrmann GS, LaBrecque JF. Physiologic and psychological characteristics associated with deaths due to asthma in childhood. A case-controlled study. JAMA 1985; 254:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/9\">",
"      Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/10\">",
"      Kolbe J, Vamos M, Fergusson W, Elkind G. Determinants of management errors in acute severe asthma. Thorax 1998; 53:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/11\">",
"      Ordo&ntilde;ez GA, Phelan PD, Olinsky A, Robertson CF. Preventable factors in hospital admissions for asthma. Arch Dis Child 1998; 78:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/12\">",
"      Carr W, Zeitel L, Weiss K. Variations in asthma hospitalizations and deaths in New York City. Am J Public Health 1992; 82:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/13\">",
"      Scarfone RJ, Fuchs SM, Nager AL, Shane SA. Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. Pediatrics 1993; 92:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/14\">",
"      Smith SR, Strunk RC. Acute asthma in the pediatric emergency department. Pediatr Clin North Am 1999; 46:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/15\">",
"      Mansel JK, Stogner SW, Petrini MF, Norman JR. Mechanical ventilation in patients with acute severe asthma. Am J Med 1990; 89:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/16\">",
"      Dales RE, Munt PW. Use of mechanical ventilation in adults with severe asthma. Can Med Assoc J 1984; 130:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/17\">",
"      Roberts JS, Bratton SL, Brogan TV. Acute severe asthma: differences in therapies and outcomes among pediatric intensive care units. Crit Care Med 2002; 30:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/18\">",
"      Beakes DE. The use of anticholinergics in asthma. J Asthma 1997; 34:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/19\">",
"      Stephanopoulos DE, Monge R, Schell KH, et al. Continuous intravenous terbutaline for pediatric status asthmaticus. Crit Care Med 1998; 26:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/20\">",
"      Wheeler DS, Jacobs BR, Kenreigh CA, et al. Theophylline versus terbutaline in treating critically ill children with status asthmaticus: a prospective, randomized, controlled trial. Pediatr Crit Care Med 2005; 6:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/21\">",
"      Browne GJ, Penna AS, Phung X, Soo M. Randomised trial of intravenous salbutamol in early management of acute severe asthma in children. Lancet 1997; 349:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/22\">",
"      Bohn D, Kalloghlian A, Jenkins J, et al. Intravenous salbutamol in the treatment of status asthmaticus in children. Crit Care Med 1984; 12:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/23\">",
"      Fortenberry JD, Del Toro J, Jefferson LS, et al. Management of pediatric acute hypoxemic respiratory insufficiency with bilevel positive pressure (BiPAP) nasal mask ventilation. Chest 1995; 108:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/24\">",
"      Padman R, Lawless ST, Kettrick RG. Noninvasive ventilation via bilevel positive airway pressure support in pediatric practice. Crit Care Med 1998; 26:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/25\">",
"      Bernet V, Hug MI, Frey B. Predictive factors for the success of noninvasive mask ventilation in infants and children with acute respiratory failure. Pediatr Crit Care Med 2005; 6:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/26\">",
"      Essouri S, Chevret L, Durand P, et al. Noninvasive positive pressure ventilation: five years of experience in a pediatric intensive care unit. Pediatr Crit Care Med 2006; 7:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/27\">",
"      Piastra M, Conti G, Caresta E, et al. Noninvasive ventilation options in pediatric myasthenia gravis. Paediatr Anaesth 2005; 15:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/28\">",
"      Sprague K, Graff G, Tobias DJ. Noninvasive ventilation in respiratory failure due to cystic fibrosis. South Med J 2000; 93:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/29\">",
"      Carroll CL, Schramm CM. Noninvasive positive pressure ventilation for the treatment of status asthmaticus in children. Ann Allergy Asthma Immunol 2006; 96:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/30\">",
"      Akingbola OA, Simakajornboon N, Hadley Jr EF, Hopkins RL. Noninvasive positive-pressure ventilation in pediatric status asthmaticus. Pediatr Crit Care Med 2002; 3:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/31\">",
"      Thill PJ, McGuire JK, Baden HP, et al. Noninvasive positive-pressure ventilation in children with lower airway obstruction. Pediatr Crit Care Med 2004; 5:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/32\">",
"      Beers SL, Abramo TJ, Bracken A, Wiebe RA. Bilevel positive airway pressure in the treatment of status asthmaticus in pediatrics. Am J Emerg Med 2007; 25:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/33\">",
"      Javouhey E, Barats A, Richard N, et al. Non-invasive ventilation as primary ventilatory support for infants with severe bronchiolitis. Intensive Care Med 2008; 34:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/34\">",
"      Cambonie G, Mil&eacute;si C, Jaber S, et al. Nasal continuous positive airway pressure decreases respiratory muscles overload in young infants with severe acute viral bronchiolitis. Intensive Care Med 2008; 34:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/35\">",
"      Mayordomo-Colunga J, Medina A, Rey C, et al. Non-invasive ventilation in pediatric status asthmaticus: a prospective observational study. Pediatr Pulmonol 2011; 46:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/36\">",
"      2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Part 10.5 Near-fatal asthma. Circulation 2005; 112 (Suppl 24):139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/37\">",
"      Asthma: a follow up statement from an international paediatric asthma consensus group. Arch Dis Child 1992; 67:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/38\">",
"      Qureshi F. Management of children with acute asthma in the emergency department. Pediatr Emerg Care 1999; 15:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/39\">",
"      Bohn D, Kissoon N. Acute asthma. Pediatr Crit Care Med 2001; 2:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/40\">",
"      Maxwell GM. The problem of mucus plugging in children with asthma. J Asthma 1985; 22:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/41\">",
"      Sarnaik AP, Daphtary KM, Meert KL, et al. Pressure-controlled ventilation in children with severe status asthmaticus. Pediatr Crit Care Med 2004; 5:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/42\">",
"      MacIntyre NR. Respiratory function during pressure support ventilation. Chest 1986; 89:677.",
"     </a>",
"    </li>",
"    <li>",
"     Schwarz AJ, Lubinsky PS. Acute severe asthma. In: Essentials of pediatric intensive care, 2nd ed, Levin DL, Morriss FC (Eds), Churchill Livingstone, Inc, New York 1997. p.130.",
"    </li>",
"    <li>",
"     Helfaer MA, Nichols DG, Rogers MC. Lower airway disease: Bronchiolitis and asthma. In: Textbook of pediatric intensive care, Rogers MC, Nichols DG (Eds), Williams &amp; Wilkins, Baltimore 1996. p.133.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/45\">",
"      Hickling KG, Walsh J, Henderson S, Jackson R. Low mortality rate in adult respiratory distress syndrome using low-volume, pressure-limited ventilation with permissive hypercapnia: a prospective study. Crit Care Med 1994; 22:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/46\">",
"      Cox RG, Barker GA, Bohn DJ. Efficacy, results, and complications of mechanical ventilation in children with status asthmaticus. Pediatr Pulmonol 1991; 11:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/47\">",
"      Darioli R, Perret C. Mechanical controlled hypoventilation in status asthmaticus. Am Rev Respir Dis 1984; 129:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/48\">",
"      Scoggin CH, Sahn SA, Petty TL. Status asthmaticus. A nine-year experience. JAMA 1977; 238:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/49\">",
"      Picado C, Montserrat JM, Roca J, et al. Mechanical ventilation in severe exacerbation of asthma. Study of 26 cases with six deaths. Eur J Respir Dis 1983; 64:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/50\">",
"      Bellomo R, McLaughlin P, Tai E, Parkin G. Asthma requiring mechanical ventilation. A low morbidity approach. Chest 1994; 105:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/51\">",
"      Menitove SM, Goldring RM. Combined ventilator and bicarbonate strategy in the management of status asthmaticus. Am J Med 1983; 74:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/52\">",
"      Dworkin G, Kattan M. Mechanical ventilation for status asthmaticus in children. J Pediatr 1989; 114:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/53\">",
"      DeNicola LK, Monem GF, Gayle MO, Kissoon N. Treatment of critical status asthmaticus in children. Pediatr Clin North Am 1994; 41:1293.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). Full text available at: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on September 1, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/55\">",
"      Tuxen DV. Permissive hypercapnic ventilation. Am J Respir Crit Care Med 1994; 150:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/56\">",
"      ECC Committee, Subcommittees and Task Forces of the American Heart Association. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2005; 112:IV1.",
"     </a>",
"    </li>",
"    <li>",
"     Venkataraman ST. Mechanical ventilation and respiratory care. In: Pediatric critical care, Fuhrman BP, Zimmerman JJ (Eds), Mosby, Philadelphia 2006. p.692.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/58\">",
"      Marini JJ. Should PEEP be used in airflow obstruction? Am Rev Respir Dis 1989; 140:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/59\">",
"      Stewart TE, Slutsky AS. Occult, occult auto-PEEP in status asthmaticus. Crit Care Med 1996; 24:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/60\">",
"      Blanch L, Bernab&eacute; F, Lucangelo U. Measurement of air trapping, intrinsic positive end-expiratory pressure, and dynamic hyperinflation in mechanically ventilated patients. Respir Care 2005; 50:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/61\">",
"      Papiris S, Kotanidou A, Malagari K, Roussos C. Clinical review: severe asthma. Crit Care 2002; 6:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/62\">",
"      Tuxen DV, Williams TJ, Scheinkestel CD, et al. Use of a measurement of pulmonary hyperinflation to control the level of mechanical ventilation in patients with acute severe asthma. Am Rev Respir Dis 1992; 146:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/63\">",
"      Leatherman J. Life-threatening asthma. Clin Chest Med 1994; 15:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/64\">",
"      Stein R, Canny GJ, Bohn DJ, et al. Severe acute asthma in a pediatric intensive care unit: six years' experience. Pediatrics 1989; 83:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/65\">",
"      Shugg AW, Kerr S, Butt WW. Mechanical ventilation of paediatric patients with asthma: short and long term outcome. J Paediatr Child Health 1990; 26:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/66\">",
"      Newth CJ, Meert KL, Clark AE, et al. Fatal and near-fatal asthma in children: the critical care perspective. J Pediatr 2012; 161:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/67\">",
"      Zimmerman JL, Dellinger RP, Shah AN, Taylor RW. Endotracheal intubation and mechanical ventilation in severe asthma. Crit Care Med 1993; 21:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/68\">",
"      Pingleton SK. Barotrauma in acute lung injury: is it important? Crit Care Med 1995; 23:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/69\">",
"      Maunder RJ, Pierson DJ, Hudson LD. Subcutaneous and mediastinal emphysema. Pathophysiology, diagnosis, and management. Arch Intern Med 1984; 144:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/70\">",
"      Morris WP, Butler BD, Tonnesen AS, Allen SJ. Continuous venous air embolism in patients receiving positive end-expiratory pressure. Am Rev Respir Dis 1993; 147:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/71\">",
"      Road J, Mackie G, Jiang TX, et al. Reversible paralysis with status asthmaticus, steroids, and pancuronium: clinical electrophysiological correlates. Muscle Nerve 1997; 20:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/72\">",
"      Lacomis D, Smith TW, Chad DA. Acute myopathy and neuropathy in status asthmaticus: case report and literature review. Muscle Nerve 1993; 16:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/73\">",
"      Douglass JA, Tuxen DV, Horne M, et al. Myopathy in severe asthma. Am Rev Respir Dis 1992; 146:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/74\">",
"      Barohn RJ, Jackson CE, Rogers SJ, et al. Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids. Muscle Nerve 1994; 17:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/75\">",
"      Leatherman JW, Fluegel WL, David WS, et al. Muscle weakness in mechanically ventilated patients with severe asthma. Am J Respir Crit Care Med 1996; 153:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/76\">",
"      Tousignant CP, Bevan DR, Eisen AA, et al. Acute quadriparesis in an asthmatic treated with atracurium. Can J Anaesth 1995; 42:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/77\">",
"      Maffei FA, van der Jagt EW, Powers KS, et al. Duration of mechanical ventilation in life-threatening pediatric asthma: description of an acute asphyxial subgroup. Pediatrics 2004; 114:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/78\">",
"      Shankar V, Churchwell KB, Deshpande JK. Isoflurane therapy for severe refractory status asthmaticus in children. Intensive Care Med 2006; 32:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/79\">",
"      Shapiro MB, Kleaveland AC, Bartlett RH. Extracorporeal life support for status asthmaticus. Chest 1993; 103:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/80\">",
"      King D, Smales C, Arnold AG, Jones OG. Extracorporeal membrane oxygenation as emergency treatment for life-threatening acute severe asthma. Postgrad Med J 1986; 62:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/81\">",
"      Tajimi K, Kasai T, Nakatani T, Kobayashi K. Extracorporeal lung assist for patient with hypercapnia due to status asthmaticus. Intensive Care Med 1988; 14:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/82\">",
"      Mabuchi N, Takasu H, Ito S, et al. Successful extracorporeal lung assist (ECLA) for a patient with severe asthma and cardiac arrest. Clin Intensive Care 1991; 2:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/83\">",
"      Conrad SA, Green R, Scott LK. Near-fatal pediatric asthma managed with pumpless arteriovenous carbon dioxide removal. Crit Care Med 2007; 35:2624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/44/22218/abstract/84\">",
"      Krishnan V, Diette GB, Rand CS, et al. Mortality in patients hospitalized for asthma exacerbations in the United States. Am J Respir Crit Care Med 2006; 174:633.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5747 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_44_22218=[""].join("\n");
var outline_f21_44_22218=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Severity assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREINTUBATION THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Noninvasive positive pressure ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ENDOTRACHEAL INTUBATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ventilatory modes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Pressure control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pressure support",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Volume control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18086632\">",
"      Pressure regulated volume control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - SIMV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Choice of mode",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Ventilation strategy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Ventilator settings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Dynamic hyperinflation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Barotrauma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Hypotension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Fluid support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Sedation and paralysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      WEANING FROM MECHANICAL VENTILATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      ADJUNCTIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Inhalational anesthetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Extracorporeal membrane oxygenation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/5747\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5747|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/34/17966\" title=\"figure 1\">",
"      Auto PEEP trigger threshold",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/5747|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/32/8718\" title=\"table 1\">",
"      Eval acute asthma attack",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/43/38587\" title=\"table 2\">",
"      Pulmonary index score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/5/18523\" title=\"table 3\">",
"      Initial ventilator settings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/16/33034?source=related_link\">",
"      Acute asthma exacerbations in children: Outpatient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2009?source=related_link\">",
"      Arterial puncture and cannulation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39113?source=related_link\">",
"      Causes of acute respiratory compromise in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37354?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Controller medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26010?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39670?source=related_link\">",
"      Chronic asthma in children younger than 12 years: Quick-relief agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=related_link\">",
"      Hypovolemic shock in children: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10535?source=related_link\">",
"      Invasive mechanical ventilation in adults with acute exacerbations of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32934?source=related_link\">",
"      Pulmonary barotrauma during mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/21/18776?source=related_link\">",
"      Stress ulcer prophylaxis in the intensive care unit",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_44_22219="Thrombopoietic factors";
var content_f21_44_22219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F55953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F55953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Thrombopoietic growth factors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        First generation thrombopoietic growth factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        rHuTPO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        PEG-rHuMGDF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Second generation thrombopoietic growth factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Peptide TPO receptor agonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Romiplostim (AMG 531, Nplate)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Non-peptide TPO receptor&nbsp;agonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Eltrombopag (SB497115, Promacta/Revolade)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        E5501 (AKR-501, YM-477)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        LGA-4665",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        NIP-004, NIP-022",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Butyzamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        TPO receptor agonist antibodies (anti-Mpl antibody)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Minibodies (VB22 sc(Fv)2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Domain subclass-converted TPO agonist antibodies (MA01G4G344)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TPO: thrombopoietin.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_44_22219=[""].join("\n");
var outline_f21_44_22219=null;
var title_f21_44_22220="Causes neuropsychiatric lupus";
var content_f21_44_22220=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F81577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F81577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic possibilities to be considered in patients with lupus who have neuropsychiatric symptoms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Active CNS lupus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Sequelae of lupus that is now inactive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ischemia due to healed vascular lesions with luminal narrowing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent neurologic deficits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Complications of chronic illness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Functional disorders:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anxiety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Conversion reactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schizophrenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Manic-depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dementia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obsessive compulsive disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Complications of other organ system involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metabolic imbalance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Complications of treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Steroid psychosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug induced meningitis - NSAIDs, azathioprine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posterior leukoencephalopathy - cyclophosphamide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychoactive medications - tranquilizers, antidepressants,",
"narcotics, analgesics, beta blockers, cimetidine,",
"trimethoprim-sulfamethoxazole, antimalarials, anticonvulsants, alcohol,",
"street drugs, alpha-adrenergic agents, antiarrhythmics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CNS tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head trauma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_44_22220=[""].join("\n");
var outline_f21_44_22220=null;
var title_f21_44_22221="Classes of ERCP complications";
var content_f21_44_22221=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73512%7EGAST%2F71241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73512%7EGAST%2F71241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of site, timing, and severity of complications related to endoscopic retrograde cholangiopancreatography (ERCP)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Focal",
"       </td>",
"       <td>",
"        Occurring at the point of endoscopic contact",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonspecific",
"       </td>",
"       <td>",
"        Occurring in organs not traversed or treated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Timing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immediate",
"       </td>",
"       <td>",
"        Occurring during ERCP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early",
"       </td>",
"       <td>",
"        Evident within the recovery period",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Delayed",
"       </td>",
"       <td>",
"        Focal (occurring within 30 days)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonspecific (first symptom presenting within 3 days)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Late",
"       </td>",
"       <td>",
"        Evident after months or years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Criteria for severity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Length of stay",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mild",
"       </td>",
"       <td>",
"        &le;3 nights",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Moderate",
"       </td>",
"       <td>",
"        4 to 10 nights",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Severe",
"       </td>",
"       <td>",
"        &gt;10 nights, ICU admission, or surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fatal",
"       </td>",
"       <td>",
"        Death attributable to the procedure within 30 days (or longer if under continued in-patient treatment for the complication)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Other indices of severity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Need for blood transfusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Additional interventions (endoscopic or radiologic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Total length of stay",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        Permanent residual disability",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Cotton PB, Gastrointest Endosc 1994; 40:514 and Aliperti G, et al, Gastrointest Endosc Clin N Am 1996; 6:379.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Grading system for the major complications of endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <colgroup span=\"3\" width=\"30%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mild",
"       </td>",
"       <td class=\"subtitle1\">",
"        Moderate",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Pancreatitis",
"        </strong>",
"       </td>",
"       <td>",
"        Amylase at least three times normal at more than 24 hours after the procedure, requiring admission or prolongation of planned admission to two to three days",
"       </td>",
"       <td>",
"        Hospitalization of 4 to 10 days",
"       </td>",
"       <td>",
"        Hospitalization of more than ten days, hemorrhagic pancreatitis, phlegmon or pseudocyst, or intervention (percutaneous drainage or surgery)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Bleeding",
"        </strong>",
"       </td>",
"       <td>",
"        Clinical (not just endoscopic) evidence of bleeding, hemoglobin drop &lt;3 g, and no need for transfusion",
"       </td>",
"       <td>",
"        Transfusion (four units or less), no angiographic intervention or surgery",
"       </td>",
"       <td>",
"        Transfusion (five units or more) or intervention (angiographic or surgical)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cholangitis",
"        </strong>",
"       </td>",
"       <td>",
"        Temperature of &gt;38&deg;C for 24 to 48 hours",
"       </td>",
"       <td>",
"        Febrile or septic illness requiring more than three days of hospital treatment or endoscopic or percutaneous intervention",
"       </td>",
"       <td>",
"        Septic shock or surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Perforation",
"        </strong>",
"       </td>",
"       <td>",
"        Possible, or only very slight leak of fluid or contrast, treatable by fluids and suction for three days or less",
"       </td>",
"       <td>",
"        Any definite perforation treated medically for 4 to 10 days",
"       </td>",
"       <td>",
"        Medical treatment for more than 10 days, or intervention (percutaneous or surgical)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Cotton PB, et al. Endoscopic sphincterotomy complications and their management: An attempt at consensus. Gastrointest Endosc 1991; 37:383.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_44_22221=[""].join("\n");
var outline_f21_44_22221=null;
var title_f21_44_22222="Cardiovascular management Turner syndrome";
var content_f21_44_22222=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F69744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F69744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Turner syndrome: Cardiovascular screening and monitoring",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 409px; height: 269px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_44_22222=[""].join("\n");
var outline_f21_44_22222=null;
var title_f21_44_22223="ICP waveforms";
var content_f21_44_22223=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F61774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F61774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pathologic A waves",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 153px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Interpreting ICP waveforms: A waves. The most clinically significant ICP waveforms are A waves, which may reach elevations of 50 to 100 mm Hg, persist for 5 to 20 minutes, then drop sharply - signaling exhaustion of the brain's compliance mechanisms. A waves may come and go, spiking from temporary rises in thoracic pressure or from any condition that increases ICP beyond the brain's compliance limits. Activities, such as sustained coughing or straining during defecation, can cause temporary elevations in thoracic pressure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nursing Procedures, 4th Ed. Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_44_22223=[""].join("\n");
var outline_f21_44_22223=null;
